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Abstract: 
Asymmetric transfer hydrogenation (ATH) represents a powerful methodology for the 
synthesis of chiral secondary alcohols. The synthesis of chiral propargylic alcohols by 
asymmetric transfer hydrogenation of acetylenic ketones has been applied to a number of 
applications including target oriented synthesis. 
In this thesis, the asymmetric transfer hydrogenation of a large number of functionalized 
alkyones and dialkyones has been fully investigated. Basic principles as well as detailed 
reaction conditions for the ATH of acetylenic ketones have been established. Chiral 
propargylic alcohols have been successfully prepared by a new method that was 
developed during this project and some of the products and strategies were used for the 
total synthesis of (-)-yashabushidiol B and panaxjapyne A. 
Moreover a group of aromatic ketones functionalized with the 1,3-dioxin-4-one scaffold 
were prepared and used as substrates for asymmetric transfer hydrogenation. Detailed 
reaction conditions such as catalyst loading, temperature, substitution effects and stability 
of substrates were fully investigated. Reduced products were prepared in a highly 
stereoselective manner and the utility of this method and the resulting chiral alcohols have 
been illustrated by the total synthesis of yashabushitriol. 
The application of ATH to the preparation of a highly optically pure ester for scanning 
tunnelling microscopy (SCM) dissociation and hierarchical assembly was also undertaken.  
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1. Introduction: 
1.1. Asymmetric Synthesis 
Asymmetric synthesis is a process that directly produces an optically active compound 
from symmetrically constituted molecules without requiring resolution of a racemic 
mixture. It involves the creation of a new stereocentre by stereoselective reactions on a 
starting molecule that may be symmetric or asymmetric. Asymmetric synthesis can 
broadly be divided into three types depending on the strategies used. 1. Asymmetric 
induction through diastereoisomer formation. 2. Asymmetric catalysis. 3. Chiral pool 
synthesis. 
 
1.1.1. Asymmetric Induction through Diastereoisomer Formation. 
Asymmetric induction can be achieved by the preferential formation of one 
diastereoisomer over the other as a result of the influence of a chiral feature present in the 
substrate, reagent or environment. It can be further divided into internal asymmetric 
induction and external asymmetric induction (chiral auxiliary approach).  
 
1.1.1.1. Internal Asymmetric Induction. 
The presence of a stereocentre in a substrate can influence the formation of a new chiral 
centre in order to form a more complex enantiomerically enriched product. The effects of 
internal asymmetric induction have been studied extensively and a number of rules and 
models have been discovered. To understand how the stereogenic centre controls the 
formation of the new stereogenic centre during the course of a reaction, several models 
and transition states have been proposed. For example, Cram’s1 rule was proposed by 
Cram in 1952 and has been widely used to explain how the adjacent stereocentre affects 
the addition direction of nucleophilic reagents by steric hindrance. For example (Figure 1) 
      2 
 
if using a Grignard reagent to attack aldehyde 1 which bears a chiral centre at the α 
position the products are unlikely to be generated in 1/1 ratio; instead the direction of the 
Grignard reagent addition is influenced by the chirality of compound 1 which results in 
unequal formation of products 2 and 3. The major conformation is assumed to be that in 
which the C=O group is trans to the large group on the adjacent C atom. The nucleophile 
approaches from the face obstructed by the smaller group. 
 
Figure 1. Example and favoured transition state of Cram’s rule. 
Subsequent Felkin model2 and Felkin-Anh model3 further extended the substrate scope 
and added orbital factors into the asymmetric induction system. Other rules such as the 
Cram-chelation model,4 chelation model5 and non-chelation model6 for 1,3-induction have 
also been proposed to explain the different stereoselective experimental results. 
 
1.1.1.2. External Asymmetric Induction-The Use of Chiral Auxiliaries. 
In order to control the stereochemistry, an external chiral source (chiral auxiliary) can be 
incorporated temporarily into the substrate and this can be removed and recycled after 
reaction is complete. One well known and most widely used chiral auxiliary is the Evans 
oxazolidinone auxiliary 4. The Evans auxiliary7can be coupled with an acid chloride to 
form a chiral N-acyloxazolidinone 5 which induces syn diastereoselectivity via Bu2BOTf 
or tetrachlorotitanium promoted aldol reactions and also controls the absolute 
configuration of the aldol product 6 at the same time (Figure 2). 
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Figure 2. Example of Evans auxiliary facilitated aldol reaction 
Other chiral auxiliaries such as (S,S)-psuedoephedrine8 and tert-butanesulfinamide9 have 
received considerable attention  since they were originally developed. 
Chiral auxiliary approaches, because of their generally reliability and versatility have been 
widely utilized in synthesis of enantiomerically pure compounds and natural products.  
 
1.1.2. Asymmetric Catalysis. 
Asymmetric catalysis, in which each molecule of catalyst, by virtue of being continually 
regenerated, can yield many molecules of chiral product, has significant potential 
advantages over other means.10 Several processes involving asymmetric catalysis have 
been commercialized due to their molecular efficiency. Asymmetric catalysis has long 
been accepted by scientists for laboratory scale synthesis and its impact in the field of 
organic chemistry is growing. Extensive amounts of work involving asymmetric catalysts 
and asymmetric catalysts promoted reactions have been published, and how the 
enantioselective catalysts work, i.e. detailed mechanistic studies, has been widely 
investigated. 
Asymmetric catalysis, due to the chiral environment created during transformation, 
operates by decreasing the transition state energy of one configuration relative to the other. 
This imbalance between the energy of the two transition states causes the enantiomer 
derived from the lower transition state energy to be synthesised more rapidly than the 
other.11 
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1.1.2.1 Transition Metal Based Asymmetric Catalysts. 
To date, transition metal promoted asymmetric catalysis has made a wide selection of 
organic reactions possible.12 Transition metal catalysis has been broadly developed and has 
become increasingly important in laboratory scale synthesis as well as industrial 
production. 
A broad range of ligand types as well as catalyst complexes have been developed; whilst it 
is not possible to classify the types of catalysts in detail within this introduction, by 
function they include hydrogenation/transfer hydrogenation,13 cross coupling,14 
metathesis,15 oxidation16 and many other applications of different types.   
 
1.1.2.2 Asymmetric Organocatalysis. 
Asymmetric organocatalysis17 refers to asymmetric reactions that can be catalysed by 
organocatalysts. Organocatalysis was recognized as an environmentally-friendly 
alternative to transition-metal based catalysts especially in the pharmaceutical industry as 
toxic metals are eliminated from products. Organocatalysts can be inexpensive to prepare, 
stable and the reactions could be performed under aerobic environment. It is also 
recognized as a bridge between metal catalysis and enzyme catalysis. More interestingly, 
activation pattern of organocatalysts are different from metal catalysis. The scope of 
asymmetric reactions has been extended tremendously thanks to the development of new 
activation methods.  
An example at the beginning of 21st century, a proline-(8)-catalyzed direct asymmetric 
aldol reaction18 was first published by the Barbas III group (Figure 3). This example 
perfectly demonstrates how simple the organocatalyst and the reaction can be.  
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Figure 3. L-Proline catalyzed asymmetric aldol reaction. 
 
1.1.2.3 Enzyme Catalysis. 
Enzymes are biological macromolecules that can be used as biocatalysts for 
stereoselective chemical reactions.19 Enzyme catalysis is characterized by high catalytic 
activities and selectivities, achieved under mild conditions. However, compared to 
synthetic catalysts, the catalytic pool of enzymes is limited. There are many features of 
enzyme catalysis: firstly, enzymes show high specificities toward their physiological 
substrates; compounds that differ only slightly from the natural substrate are often not 
acted upon. Secondly, the activity of many enzymes can be tuned, allowing the 
metabolism to proceed at a rate optimal for the well-being of the organism. Thirdly, 
enzymes can bring about enormous rate accelerations.  
Enzyme catalysed reactions have been investigated and applied to natural product 
biosynthesis. Even small chiral molecules can be obtained by enzyme catalysis as an 
alternative to traditional organic reactions. For example, one of the most widely studied 
enzymes in organic chemistry is carbonyl reductase20 which can reduce ketones to the 
corresponding alcohols stereoselectively (Figure 4). 
 
Figure 4. Asymmetric ketone reduction by carbonyl reductase. 
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1.1.3. Chiral Pool Synthesis. 
Enantiomerically enriched compounds may be obtained by chemical transformations from 
enantiomerically enriched precursors, often derived from Nature’s chiral pool. Chiral 
compounds derived from nature such as tartaric acid, D-mannitol and ascorbic acid have 
been applied abundantly in the total synthesis of natural products. An example of the 
synthesis of the natural product (S)-minquartynoic acid 12 in enantio-pure manner from L-
(+)-tartaric acid 10 is illustrated in Figure 5.21 
 
Figure 5. Asymmetric synthesis from natural chiral pool. 
 
1.2 Transition Metal Catalysed Asymmetric Transfer Hydrogenation of 
Ketones. 
1.2.1. A Short History of Asymmetric Transfer Hydrogenation. 
The asymmetric transfer hydrogenation (ATH) of ketones is one of the most convenient 
and extensively studied transformations in organic chemistry. The benefits, including 
excellent selectivity, operationally simplicity and wide substrate scopes, have led to their 
broad applications to the synthesis of secondary chiral alcohols and related natural 
products. 
To date, several categories of substrate, including aromatic/aliphatic ketones, imines and 
compounds with activated C=C bonds such as α,β-unsaturated ketones, cyanoolefins and 
dicyanoolefins have all been found to be active substrates for ATH reactions.22 
Different types of catalyst complexes have been prepared and screened (Figure 6). At first, 
chiral diphosphine ligands, and bipyridine based ligands, were developed and applied to 
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transfer hydrogenation in 2-propanol at elevated temperatures. However, only poor 
enantioselectivities and reactivities were found.  
When complex 15-[HRu(CO)2] was used the reaction had to be carried out at 120 °C; after 
111 h the resulting (S)-1-phenylethanol (S)-14 was obtained with only 35% yield and 4% 
ee.23 When 16-[RuBr2] complex was applied the same product chiral 1-phenylethanol 14 
was formed in 80% yield and 52% ee.24 
No success was achieved when a bipyridine based ligand 17 was used in ATH of 
acetophenone 13.25 Instead of bipyridine ligand, improvement was achieved by using a 
chiral bioxazole ligand. Plaftz reported by using 18-[Ir(cod)Cl2] complex, in which case 
the enantioselectivity of formation of chiral 1-phenylethanol reached 58% ee and it was 
isolated in good yield (89%).26 
Diphosphine-diamine 19 and diphosphine-diimine 20 ligands were combined with the 
same metal core; [Ru(DMSO)Cl2], to form catalytic complexes by the Noyori group. 
Interestingly, when the two complexes were tested under the same reaction conditions the 
results were totally different. The enantioselectivity and reactivity of the diphosphine-
diamine-[Ru(DMSO)Cl2] (19-[Ru(DMSO)Cl2]) complex was remarkable. The reduction 
of acetophenone 13 proceeded from room temperature to 45 °C with only 0.5 mol% of 
[Ru(DMSO)Cl2] and both excellent yield (80%) and ee (52%) were achieved. When a 20-
[Ru(DMSO)Cl2] catalyst was tested there was almost no conversion and also the ee was 
poor (18%). The authors claimed that catalyst 20-[Ru(DMSO)Cl2] is less effective 
because of the lack of NH functionality.22c, 27 
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Figure 6. ATH with different ligands. 
 
1.2.2. Ligands with NH Functionality. 
Ligands that incorporate NH functionality have attracted significant attention. In 1995, 
Noyori’s group reported a ruthenium catalyst [RuCl2(mesitylene)]-(S,S)-TsDPEN 21 for 
asymmetric transfer hydrogenation of prochiral aromatic ketones at low catalyst loadings 
(S/C=200-500). This reduction could be carried out at room temperature in 2-propanol in a 
very efficient manner. Excellent ee values (up to 98%) and yields (up to 98%) were 
obtained by this catalyst. The authors also elaborated the reason why they used 
[RuCl2(arene)]2 to form the catalyst complex. The special function of the arene which is 
coordinated with Ru are as follows: (1) arene ligands automatically occupy three adjacent 
coordination sites of Ru in an octahedral coordination environment, leaving three sites 
with a fac relationship for other functions; (2) arene ligands are relatively weak electron 
donors which may provide a unique reactivity on the metallic centre; (3) ready 
modification of the substitutions of the arene is possible. 
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Figure 7. ATH by TsDPEN ligand. 
After extensive investigation the conclusions were: (1) high enantioselectivity was 
obtained only when an appropriate arene and chiral ligand were combined; (2) the 
presence of a primary or secondary amine end in the amino alcohols/diamine ligands is 
crucial for the catalytic activity.28, 22c 
In addition to TsDPEN 22, other amine ligands such as TsDACH 23 and β-amino alcohols 
24-26 (Figure 8) have been combined with [RuCl2(arene)]2 (usually the arenes are 
benzene, p-cymene, mesitylene and hexamethylbenzene) and excellent results were 
achieved in the transfer hydrogenation of aromatic ketones.29 
 
Figure 8. Different structures of ligands with NH functionality. 
 
1.2.3. Tethered Catalysts. 
The tether that links the mono-tosylated diamine ligand to the arene ring was first 
introduced by Wills’s group. Due to the linking through the tether this catalyst exhibits 
higher catalytic activity compared to the original untethered catalysts. The authors believe 
that the tether serves to prevent the rotation of the arene ring, thus offering the potential for 
the addition of functional groups at various positions in a predictable manner. Another 
benefit of the tether is it can enhance the stability of the catalyst. 
Taking the ATH of acetophenone 13 as an example (Figure 9), the tethered catalyst (R,R)-
c2 was capable of reducing of 200 molecules of 13 at 28 °C within 3 h (96% ee). The 
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(R,R)-c2 catalyst could also be used at elevated temperature; at 40 °C (R,R)-c2 could 
efficiently complete the conversion of 1000 equivalents of acetophenone within 5 h and 
the substrate loading could even reach up to 10,000/1. The enantioselectivity of 14 
remains at the same level as the Noyori catalyst but it is more applicable to ketones which 
are not so active under previous reported conditions, for example hindered ketones.30 
 
Figure 9. ATH of 13 by tethered catalyst (R,R)-c2. 
Following this initial report, catalysts containing different tethers were prepared by Wills 
et al. (Figure 10), including tethers that incorporate an aromatic group 27-29,31 dimethyl 
3032 and even a heteroatom such as oxygen 31. Several of these catalysts share the same 
reactivity whilst the tethered catalyst with an amino alcohol ligand proved to be less active 
and less stable.     
 
Figure 10. Structures of tethered catalysts. 
The Ikariya group reported the oxo-tethered catalyst 31 before the report on the same 
complex by Wills et al. Asymmetric transfer hydrogenation of acetophenone 13 using the 
oxo-tethered complex 31 in HCO2H/TEA 5/2 mixture proceeded rapidly; 1000 molecules 
of 13 can be fully reduced per catalyst molecule in 3 h at 60 °C (97% ee). From the 
experimental results catalyst 31 is more active than the four-carbon tethered catalyst 32 
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(Figure 11). Catalyst 31 could also be used for asymmetric hydrogenation of ketones. 
Hydrogenation of aromatic ketones at 60 °C in methanol afforded the corresponding 
products with excellent ee values (Figure 12).34 
 
Figure 11. Catalytic reactivity difference between catalysts 31 and 32. 
 
Figure 12. ATH of aromatic ketones of catalyst 31. 
The tether can also be linked at the sulfonamide side for example the mono-sulfonylated 
diamine tethered catalysts35 33-35 and the N-methyl-sulfamoyl-tethered catalysts36 36 and 
37 which have also been reported. These catalysts could reduce acetophenone 13 
efficiently but compared to other tethered catalysts their enantioselectivities were 
relatively low. From Wills’s report, using arene modified catalysts for acetophenone 13 
reduction the ee values only reached up to 68% (Figure 14). 
 
Figure 13. Catalysts that tether at the sulfonamide side. 
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Figure 14. ATH by tethered catalysts. 
One advantage of a tethered catalyst was discovered by Mohar et al.37 From previous 
reports, for some reason the asymmetric transfer hydrogenation of 1-naphthyl ketones 
always proceeded with low enantioselectivities. With regards to the ATH of 1-
acetonaphthone, catalyst 21 could only provide a product of 83% ee in HCO2H/TEA 5/2 
mixture but 93% ee in isopropanol, whereas both tethered TsDACH catalyst 27 and O- 
linked catalyst 31 could provide 84% ee in HCO2H/TEA 5/2 mixture.
31, 33 Catalyst 37 
demonstrated exceptionally high enantioselectivities in the ATH of 1-naphthyl ketones 
(Figure 15); products with up to 99.9% ee values could be prepared without any further 
processing/purification. 
 
Figure 15. Advantageous effect of catalyst 37 in reduction of 1-naphthyl ketones. 
 
1.2.4. Mechanism of ATH of Bifunctional Ruthenium Catalysts. 
In the mechanism of asymmetric transfer hydrogenation, it has been proposed that a 
hydride from the ruthenium and a proton from the amine of the 18e ruthenium hydride 
amine intermediate are delivered to ketone through a rate-determining six-membered 
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pericyclic transition state (Figure 16). This has been supported by quantum chemical 
calculations.38 
 
Figure 16. Pericyclic transition state of hydrogen transfer. 
The six-membered pericyclic transition state was experimentally supported by the kinetic 
isotope effect measurements as reported in both Noyori and Casey’s publications.39 In 
reality, a sufficiently fast non-concerted reaction that is rapid compared to the applied 
detection method may be occasionally taken as a concerted reaction. In addition, a 
significant acceleration of reaction rates in the ATH of acetophenone with 
Ru[TsDPEN](η6-p-cymene) c1 catalyst in a binary water/co-solvent mixture has been 
discovered. The authors claim that reaction rates were observed to increase with the 
increasing polarity of co-solvent in a manner that is not characteristic of pericyclic 
reactions.40 
Meijer also reported that the interaction of acetophenone with the hydrido complex 
RuH[N-(p-X-phenyl)-N′-(p-toluenesulfonyl)-1,2-ethylenediamine](η6-p-cymene) in 
HCO2H/NEt3 mixture via a pericyclic transition state is not plausible, and that CO2 
interacts with the same complex (reverse reaction) possibly via an ion-pair intermediate. 
Evidence from computational calculations which involve solvents suggest: (1) the 
activation barriers are lowered and the concerted mechanism predicted in the gas phase is 
converted into a sequential mechanism in methanol solution with the substrate appearing 
as a methoxide-like intermediate, which exists for a short but finite time in the reactive 
trajectory. (2) a concerted transition state was observed in aqueous solution, however, only 
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the hydride was transferred at that point, whereas the proton was transferred later by a 
water molecule.41 
In 2012, the Ikariya group published a mechanistic study of asymmetric transfer 
hydrogenation of ketones catalyzed by the bifunctional ruthenium complex (S)-
[RuH[(R,R)-OCH(Ph)CH(Ph)NH2](η6-benzene)] and (S)-[RuH[(R,R)-p-TsNCH(Ph)CH 
(Ph)NH2](η6-mesitylene)].  
The reaction of [(S)-RuH[(R,R)-OCH(Ph)CH(Ph)NH2](η6-benzene)] with acetone was 
studied in the gas phase as well as in the continuum solvent reaction field of isopropanol 
using the SMD solvation model. The gas phase modelling is in agreement with previously 
reported data. The optimized concerted transition state (Ts1-2 in Figure 17) ∆E is 15.1 
kcal/mol which is much higher than the highest energy transition state (Ts2 in Figure 18) 
of ∆E=11.5 kcal/mol calculated in continuum solvent reaction field. The major barrier to 
the hydride transfer (Ts1 in Figure 18) in solvent is ∆E=9.8 kcal/mol which suggests that 
hydride transfer can only break the Ru-H and form the new C-H bond at this point. The 
calculated barrier for the proton transfer (Ts2 in Figure 18) is ∼2 kcal/mol higher than the 
barrier of the hydride transfer on both electronic and free energy scales. 
 
Figure 17. ATH of acetone gas phase modelling.1 
1. ∆E(∆G°298K)kcal/mol 
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Figure 18. ATH of acetone continuum solvent reaction field solvation modelling.1 
1. ∆E(∆G°298K)kcal/mol 
Introduction of explicit solvent molecules into the calculations further stabilizes the proton 
transfer step. Compared to the gas phase and non-solvent solvation modelling, the 
incorporation of one molecule of isopropanol will decrease the energy barrier of each step. 
This is especially the case in the transition states of proton transfer (Ts2a and Ts2b in 
Figure 19); the incorporation of one or two molecules of isopropanol will significantly 
decrease the energy of Ts2a and Ts2b which makes the hydride transfer the highest energy 
step. 
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Figure 19. ATH of acetone continuum solvent reaction field solvation modelling + 
explicit solvent.1, 2 
1. ∆E(∆G°298K)kcal/mol. 
2. R=isopropyl 
 
Figure 20. Revised catalytic cycle of asymmetric transfer hydrogenation. 
Based on the present work and the overall experimental and theoretical data accumulated 
so far, Ikariya and co-workers proposed a revised catalytic cycle of asymmetric transfer 
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hydrogenation. The first step is the enantio-determining hydride transfer from the neutral 
amine which is also rate-determining. The second step is the formation of the ion pair by 
reaction with the solvent molecule and then the product is released. The sixteen electron 
amido-Ru complex becomes coordinated to isopropanol and forms the isopropyloxo-Ru 
complex through a metal-ligand O-H bond cleavage. Through ionization and anion 
reorientation the ion pair intermediate is then formed. The hydride regeneration from 
isopropanol can be recognized as the reverse reaction of hydride transfer. After release of 
acetone the catalytic cycle is closed.42 
 
1.2.5. Iridium, Osmium and Iron Based Catalysts in ATH of Ketones. 
Although the majority of reported ATH reactions require the use of ruthenium, 
enantioselective transfer hydrogenation based on iridium, osmium and iron catalysts has 
also been investigated. Novel ligands that have been found to not be efficient in ruthenium 
catalysed transfer hydrogenation have demonstrated immense power in iridium and other 
metal-catalysed transfer hydrogenation.43 
A range of ligands were used in the Ir catalysed ATH of ketones. Before the development 
of 1,2-diamine ligands, bidentate ligands such as imine-pyridine,25 bi(2-oxazoline)26 and 
diphosphine44 were used for ATH of ketones. Although those catalysts could offer high 
catalytic reactivity at elevated temperature (≥ 80 °C) the lack of applications at room 
temperature and the relatively low and variable enantioselectivity are still problems that 
chemists have to face. Tosylated 1,2-diamine ligand was first intruded by Lemaire45 in the 
ATH reaction of acetophenone 13 at room temperature (Figure 21). This catalyst could be 
formed in situ and used at room temperature with a slight increase of enantioselectivity 
compared to the pyridine, bi(2-oxazoline) and diphosphine ligands mentioned earlier. 
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Figure 21. Ir catalysed ATH of ketones using TsDPEN as ligand. 
By following these ideas, more chiral 1,2-diamine based ligands were discovered and 
applied to the field of ketone transfer hydrogenation. These include complex 38 (up to 93% 
ee for aryl ketone ATH),46 39 [IrCl(Cp*){(R,R)-TsCYDN }] (94-96% ee for aryl ketone 
ATH)47 and 40 [IrCl(Cp*){(R,R,R)-CsDPEN}] (85-98% ee for aryl ketone ATH)48 which 
are very active as well as enantioselective. With regard to the non-functionalized aromatic 
ketone reduction, more catalysts have been reported, including polymer-supported 
IrCl(Cp*)-diamine catalyst,49 proline-based hydroxamic acid-[IrCl2(Cp*)]2 complex,
50 
quinine and cinchonine derivatives-[IrCl(cod)]2
51 and diamino[bis(thiophene)][Ir(cod) 
(PPh3)],
52 all of which work very well. Like Ru catalysts, isopropanol, formic acid and 
sodium formate are suitable as the hydrogen donor when Ir catalysts were used although 
triethylamine was not commonly involved.  
 
Figure 22. Different iridium catalysts for ATH. 
Notably, iridium catalysts could also be used in the ATH of functionalized aromatic 
ketones. The catalyst 45 in Figure 23 was employed by Carreira and co-workers53 for the 
reduction of α-cyano and α-nitro ketones. From the experimental results α-cyano and α-
nitro ketone could not only tolerate the reaction conditions but also were reduced with 
excellent enantioselectivity. In particular, it was found that the use of electron-poor ligands 
enhanced enantioselectivity and catalytic activity. 
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Figure 23. ATH of functionalized aromatic ketones by Ir catalyst. 
Less widely used osmium catalysts are also able to catalyze transfer hydrogenation of 
carbonyl compounds in an enantioselective manner. For example, Os-pybox-phosphite 
complexes (Figure 24) were reported to be active as well as stereoselective for transfer 
hydrogenation. Good to excellent ee values (55-94%) were achieved but this catalytic 
system is less efficient than Ru catalysts and needs to be carried out at 82 °C.54 
 
Figure 24. Osmium catalyzed ATH reaction. 
Fe complex trans-[Fe(CO)(NCMe)-(PPh2CH2CHNCHPhCHPhNCHCH2PPh2)](BPh4)2 
46 was found to be extremely active as well as stereoselective in transfer hydrogenation of 
aromatic ketones (Figure 25).55 This transfer hydrogenation catalyst could reach average 
TOFs of 2000-3000/h in isopropanol at 22 °C compared to the most efficient asymmetric 
hydrogenation catalyst (TOF 4000/h) in the same solvent. Good to excellent 
enantioselectivities were achieved when the substrates were aromatic ketones. The catalyst 
was equally active towards aliphatic ketones but the enantioselectivities were significantly 
lower. 
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Figure 25. Iron catalyzed ATH reaction. 
 
1.2.6. Asymmetric Transfer Hydrogenation of Diketones, Keto Esters and 
Dynamic Kinetic Resolution. 
1.2.6.1. ATH of α-Keto Esters and 1,2-Diketones. 
Aromatic α-keto esters have been recognized as activated ketones and their asymmetric 
transfer hydrogenation was first reported by the Mohar group (Figure 26). An array of 
ligands has been tested and the screening suggested the more hindered RSO2N group 
could offer better enantioselectivity. This may be due to the high activity of α-keto esters 
as the enantioselectivities were lower than unactivated ketones (average 70-90% ee).56 
 
Figure 26. ATH of α-keto esters in organic solvent. 
Aromatic α-keto esters are good substrates for asymmetric transfer hydrogenation. 
Following the ATH study of α-keto esters in organic solvents by Mohar, Li’s group 
published another α-keto ester reduction under aqueous conditions and with a (R,R)-2,4,6-
triisopropyl-C6H2SO2-DPEN ligand (Figure 27).
57 ATH of α-keto esters in water with the 
cationic surfactant (DTAB, dodecyl trimethyl ammonium bromide) is faster than in 
organic solvent and by using this ligand the average ee values were around 80-90%. With 
more evidence collected for the ATH of aromatic α-keto esters, it was found that the 
general ee values were lower than other aromatic ketones. In some extreme examples, 
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even in the reduction of aromatic ketones the enantioselectivities were still low (R1=2,4,6-
trimethylphenyl, 35% ee; R1=2-methoxyphenyl, 34% ee).  
 
Figure 27. ATH of α-keto esters in water. 
In 2009, Zhang reported an asymmetric transfer hydrogenation of α-keto pantolactam, by 
using Noyori’s [Ru(p-cymene)Cl]-(R,R)-TsDPEN] catalyst [(R,R)-c1] (Figure 28). 
According to his publication, a simple, efficient, and highly enantioselective method was 
developed and more than 2 kg of this key intermediate has been synthesized in excellent 
chemical yield and optical purity.58 
 
Figure 28. ATH of α-keto pantolactam. 
 
1.2.6.2. ATH of β-Keto Esters and 1,3-Diketones. 
Asymmetric transfer hydrogenation of β-keto esters was first reported by the Carpentier 
group in 1998. By using [RuCl2(η6-arene)]2 and ephedrine or mono-tosylated diamine 
ligands the authors found that only aromatic β-keto esters could afford high 
enantioselectivities (Figure 29). According to the author if R1 equals Me or CH2OMe then 
no matter what R2 group is used the enantioselectivity will be disappointingly low (Figure 
29).59 
 
Figure 29. The first report of the ATH of β-keto esters. 
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Asymmetric transfer hydrogenation of β-keto esters can be carried out in an emulsion 
(water/CH2Cl2) system with more accelerated turnover rate than in water. The authors 
suggested that when the ketones are in solid form or have limited solubility in water, 
emulsion is the solution in which reaction reactivity was enhanced but enantioselectivity 
was maintained at the same level (Figure 30).60 
 
 Figure 30. ATH of β-keto esters in emulsion. 
Diastereoselective asymmetric transfer hydrogenation of chiral aliphatic 4-hydroxy-2-keto 
esters is ambitious. According to the paper published by Carpentier,61 substrates were 
reduced successfully but diastereoselectivities were quite unpredictable; not only were de 
values poor, but in some examples just changing the structure of the arene will turn the 
major product from syn to anti. All the efforts to improve de by changing the structure of 
ligands, arene and R groups were all in vain and the widely applied c1 catalyst has proved 
to be totally inefficient in this system (Figure 31).    
 
Figure 31. ATH of chiral β-keto esters. 
Asymmetric transfer hydrogenation of 1,3-diketones was first reported by the Cossy 
group.62 Under optimized conditions, good diastereo- and enantioselectivities could be 
achieved when R1=R2=Ar (up to 98.5/1.5 dr and 99.5% ee), if R1 or R2 equals alkyl then 
the ee and dr will decline substantially. Unlike other ketones, 1,3-diketones are not quite 
active at room temperature therefore elevated temperatures and high catalyst loadings 
were required for complete conversion. 
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Figure 32. ATH of 1,3-diketones. 
 
1.2.6.3. Asymmetric Transfer Hydrogenation Dynamic Kinetic Resolution. 
α-Substituted ketones, due to their low pKa values have been discovered to be good 
substrates for dynamic kinetic resolution. The Wills group reported the dynamic kinetic 
resolution of a group of structurally novel α-substituted ketones. In general good to 
excellent ees and des were achieved even in the case of non-aromatic ketones (Figure 
33).63 
 
Figure 33. DKR of α-substituted ketones. 
Not only restricted to β-keto esters, β-keto amides, or other substrates with only one 
ketone group, 1,3-diketones are applicable to dynamic kinetic resolution methods as well. 
Cossy et al. reported a group of novel 2-alkyl-1,3-diketones which could be used in mono-
reductive dynamic kinetic resolution (Figure 34).64 The catalyst can recognize the less 
steric hindered therefore more active carbonyl and reduce it in a both diastereo- and 
enantioselective manner. The method is only applicable to diketones in which the two 
carbonyls have different reactivity. If the two carbonyls have similar reactivity, 
enantioselectivity will decrease which also result inseparable mixed products.  
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Figure 34. DKR of 1,3-diketones. 
Racemic benzoin is a good substrate for dynamic kinetic resolution. In 1999, Ikariya 
published a very efficient route for the large scale synthesis of chiral 1,2-diols by a 
dynamic kinetic resolution. The ee value of the product chiral 1,2-diol 59 could be further 
enhanced by recrystallization. Notably compound 58 is not easily reduced by currently 
available direct hydrogenation catalysts (Figure 35).65 
 
Figure 35. DKR of α-hydroxyl ketones. 
A very efficient dynamic kinetic resolution of ethyl 2-benzamidomethyl-3-oxo-4,4,4-
trifluorobutanoate 60 was applied to access the syn-enriched chiral compound at the early 
synthetic stage of the synthesis of the anti-bacterial substances Sanfetrinem and LK-157. 
The authors claim that low concentration of substrate and small η6-arene size of the 
catalyst was detrimental for high diastereoselectivity. Using Ru(mesitylene) the 
diastereoselectivity (syn/anti 94/6) of dynamic kinetic resolution turns out to be very high 
as well as the enantioselectivity (>99% ee). After a recrystallization the de value of 61 was 
determined to be >99% (Figure 36).66 
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Figure 36. DKR of α-substituted-γ-trifloro-β-keto ester. 
Dynamic kinetic resolution of 2-methoxy-3-oxo esters has been reported by the R-Vidal 
group.67 During the screening of catalysts the authors discovered that dr values are 
determined by the arene of catalyst rather than the substituents on the diamine ligands. 
When the arene was 1,3,5-trimethylbenzene, products were formed with the maximum dr 
values. They also found that dr values were independent of temperature or solvent. In their 
substrate screen, with the exception of R1=2-bromophenyl (2.5/1 dr), all other products 
including R1=(E)-phenylvinyl were formed in drs higher than 24/1 (Figure 37). 
 
Figure 37. DKR of α-methoxyl-β-keto esters. 
Recently the Yawen group published the dynamic kinetic resolution of 2-chloro-3-oxo 
esters by using (S,S)-c1 catalyst in HCO2H/Et3N 5/2 mixture.
68 In contrast to the results 
described in Figure 37, 2-chloro-3-oxo esters as the starting material did not yield 
products in good diastereoselectivity (Figure 38). According to the authors, the dr values 
are not dependent on catalyst loading but heavily on the substitution on the aromatic ring. 
Modest to good drs and ees were obtained under optimized conditions suggesting that 2-
chloro-3-oxo esters might not be the ideal substrates for ATH dynamic kinetic resolution. 
In this paper only one catalyst was tested therefore an understanding of the nature of the 
relationship between structure of catalysts and drs or ees of products is still elusive. 
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Figure 38. DKR of α-chloro-β-keto esters. 
Dynamic kinetic resolution of β-keto sulfones with HCO2H/Et3N 5/2 was reported by the 
Zhang group in 2008. Excellent enantioselectivities and diastereoselectivites were 
achieved by using (S,S)-c1 catalyst when substrates were aromatic β-keto sulfones. The 
author demonstrated that the reaction worked equally well when performed in CH3OH, 
CH3CN and DMSO but slower when in THF and toluene. For some reason, 2-substitution 
of the aryl will jeopardize both the ee and dr values. The reduction system is extremely 
substrate dependent; for example if Ar=4-methoxyphenyl the yield will drop to <5% and 
ee were generally low when aliphatic β-keto sulfones were tested (Figure 39).69 
Figure 39. DKR of β-keto sulfones. 
Dynamic kinetic resolution of α-alkyl-β-keto amides was first published by Krska.70 The 
products, chiral α-alkyl-β-hydroxyl-amides are ideal starting materials for lactam synthesis. 
By using the catalyst shown in Figure 40 good to excellent enantioselectivities and 
diastereoselectivities could be achieved. The authors expanded the scope of substrates by 
changing the R2 group and the results demonstrate that both enantioselectivity and 
diastereoselectivity are not strictly affected by the size of the R2 group.  
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Figure 40. DKR of α-alkyl-β-keto amides. 
Transfer hydrogenation has been used in the dynamic kinetic resolution of β-aryl-α-keto 
esters and β-amino-α-keto esters by the Johnson group recently.71 The starting material can 
be obtained on a multi-gram scale therefore this offers a good opportunity for application 
to a synthetic target. In this paper the author described synthesis of chiral β-aryl-α-
hydroxy-esters and γ-butyrolactones by dynamic kinetic resolution. From ligand screening 
the results showed that TsDPEN was inefficient for the DKR of α-keto esters (57/43 er). 
Increasingly, the large size of the Ar group of the diamine and the R group of the 
sulfonamide has beneficial effects on enantioselectivity (Figure 41). 
Figure 41. DKR of β-aryl-α-keto esters and lactone formation. 
Another application of dynamic kinetic resolution of β-amino-α-keto esters was also 
published by the Johnson group recently.72 Starting material; β-amino-α-keto esters are 
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readily available from the corresponding α-diazo-β-amino-esters. This paper also proved 
that the increase of the size of Ar group of the diamine has a beneficial effect over dr 
values. Both enantio- and diastereoselectivities were highly dependent on the nature of the 
R group. If the R group was aromatic, both enantio- and diastereoselectivity were high; if 
the R group was an alkyl group then the enantio- and diastereoselectivity decreased 
dramatically (e.g for CH2Bn the dr and er drops to 3/1, 59/41 respectively) (Figure 42). 
 
Figure 42. DKR of β-amino-α-keto esters. 
 
1.2.7. Asymmetric Transfer Hydrogenation of Propargylic Ketones. 
Soon after the publications on the ATH of aromatic ketones, Noyori reported the 
asymmetric transfer hydrogenation of propargylic ketones by using the same ruthenium 
catalyst c1 and isopropanol as hydrogen donor.73 This method allows reduction of 
structurally diverse propargylic ketones to propargylic alcohols with high enantiomeric 
purity whilst leaving the C≡C bond intact. This reaction is characterized by high yields, 
excellent enantioselectivities and low catalyst loadings (0.5 mol%), has become a major 
and powerful pathway to access chiral propargylic alcohols and has been widely applied to 
natural product synthesis (Figure 43). 
 
Figure 43. ATH of propargylic ketones. 
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After Noyori’s publication, asymmetric transfer hydrogenation of propargylic ketones has 
proven to be a reliable method for the synthesis of chiral propargylic alcohols. More often 
than not it has been used as a key transformation in target related synthesis. However a full 
and detailed picture of the general behaviour of propargylic ketones in transfer 
hydrogenation is still elusive. 
In 2011, Cossy published a diastereoselective transfer hydrogenation of chiral α,β-epoxy 
and α,β-aziridinyl ynones. In this letter, the structures of chiral α,β-epoxy, α,β-aziridinyl 
and the absolute configuration of catalysts ((R,R)-c1 or (S,S)-c1) were demonstrated to 
have a significant effect on the diastereoselectivity, and this was discussed in detail 
(Figure 44).74 The author also elucidated how different adjacent functional groups on 
substrates could affect the stabilities and diastereoselectivities in catalytic transfer 
hydrogenation. 
 
Figure 44. ATH of α,β-epoxy and α,β-aziridinyl ynones. 
To access chiral aliphatic secondary alcohols; a one-pot catalytic asymmetric transfer 
hydrogenation-hydrogenation process was also developed by the Cossy group. Catalyst 
(R,R)-c1 and Pd/BaSO4 were introduced sequentially to first reduce the carbonyl of the 
ynone and then the triple bond (Figure 45).75 Interestingly, formic acid was used as the 
hydrogen source for both transfer hydrogenation and hydrogenation. Side reactions such 
as Pd catalysed redox reaction generated traces of saturated ketone and therefore will 
cause the erosion of ee values. Compared to other hydrogenation catalysts (Pd(OH)2/C, 
PdCl2, Pd(acac)2 and Pd/C), Pd/BaSO4 can potentially offer the highest yields and was 
therefore chosen for the stage two reduction.  
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Figure 45. One-pot ATH and hydrogenation of propargylic ketones. 
The three examples above constitute a summary of systematic asymmetric transfer 
hydrogenation studies on propargylic ketones. Although there are several applications in 
natural product synthesis, these routes generally introduced without any major change to 
the catalyst structures or reaction conditions. The method of asymmetric transfer 
hydrogenation of propargylic ketones has been widely used in natural product total 
synthesis and in most cases Noyori’s method73 has been applied without optimization. In 
the following chapter a range of functionalized propargylic ketones were reduced by ATH 
to demonstrate the efficiency and power of Noyori’s asymmetric transfer hydrogenation in 
natural product total synthesis. 
 
1.2.8. ATH of Propargylic Ketones: Applications to Total Synthesis of 
Natural Products. 
Asymmetric transfer hydrogenation of propargylic ketones to generate chiral propargylic 
alcohols serve as a convenient method which has received broad application in the total 
synthesis of natural products. Usually this is used as a key step and provides a reliable way 
to introduce a hydroxyl group into the skeleton of natural products. To date this method 
has been applied by a number of synthetic groups. For example (Figure 46) the formal 
synthesis of phoslactomycins and leustroducsins by the Cossy group from chiral 
compound 64 and 65 obtained from ATH,76  the total synthesis of fostriecin by the Trost 
group from diol 66,77 the synthesis of pentacyclic lycopodium alkaloid huperzine Q from 
starting material 6778 and the de novo total synthesis of macrolides cladospolide B-D from 
propargylic alcohol 69.79 
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Figure 46. ATH in total synthesis of natural products. 
 
1.3. Asymmetric Reduction of Propargylic Ketones. 
Before the enantioselective catalytic method discussed above, chiral Alpine borane was 
widely applied to the reduction of conjugated ynones (Figure 47).80 Yields and 
selectivities varied depending on the structural differences of the ynones. The range and 
scale of this transformation are limited due to (1) the high cost of (+)/(-)-Alpine borane  (2) 
the requirement of stoichiometric loadings (3) specific structural requirements of 
substrates;  but still important in small-scale target related synthesis. 
 
Figure 47. Asymmetric reduction of ynones by chiral Alpine borane. 
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A (L)-TarB-NO2 71 and sodium borohydride mediated asymmetric reduction of α,β-
propargylic ketones was developed by the Singaram group.81 In this publication a 
range of propargylic ketones were tested but only highly branched aliphatic ynones 
could reach up to 90% ee, whilst reduction of aromatic and linear aliphatic ynones 
led to only poor to modest enantioselectivity (6-58% ee) (Figure 48). Furthermore, 
the use of (L)-TarB-NO2 as ligand to control the enantioselectivity required its use in 
stoichiometric amounts (1 equiv). 
 
Figure 48. Asymmetric reduction of ynones by (L)-TarB-NO2 and sodium borohydride. 
The asymmetric reduction of prochiral γ-acetylenic-β-keto ester 72 to the corresponding 
alcohol 73 with bakers’ yeast was first reported by Hiyama (Figure 49).82 The selectivity 
of baker’s yeast reduction is dependent on the size difference of groups on the each side of 
the carbonyl group of the substrate. Because the enantioselectivity is only moderate in 
most cases this method has not been widely applied in target related synthesis. 
 
Figure 49. Asymmetric reduction of propargylic ketone by baker’s yeast. 
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1.4. Synthesis of 6-(2-Hydroxy-2-alkyl(aryl)ethyl)-2,2-dimethyl-4H-1,3-
dioxin-4-ones. 
Using literature methods, 6-(2-hydroxy-2-alkyl(aryl)ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-
ones (Figure 50) can be prepared both in racemic and enantio-enriched manner from a 
variety of reactions. 
To form the racemic compound the procedure is relatively simple. There are two methods: 
(1) lithium enolate attack on aldehydes (Figure 50); (2) vinylogous Mukaiyama reaction 
(Figure 51); both of which have been applied to obtain 6-(2-hydroxy-2-alkyl(aryl)ethyl)-
2,2-dimethyl-4H-1,3-dioxin-4-ones. 
The most convenient and straightforward approach is by lithium enolate attack (Figure 
50).83 Lithium enolate is first formed by LDA deprotonation of 2,2,6-trimethyl-1,3-dioxin-
4-one 74 and the in situ generated reagent is used straight away to couple with aldehydes. 
This method was also adopted in this project to form racemic samples (see later sections).  
 
Figure 50. Preparation of 6-(2-hydroxy-2-alkyl(aryl)ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-
ones by lithium enolate attack. 
The vinylogous Mukaiyama reaction has also been applied to the synthesis of 6-(2-
hydroxy-2-alkyl(aryl)ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-ones. A variety of reaction 
conditions and catalysts have been investigated. These include the TiCl4
84 and silicon 
tetrachloride85 (SiCl4) promoted Mukaiyama reactions. Those reactions generally have to 
be run under anhydrous condition although a Bi(OTf)3·4H2O
86 catalyzed Mukaiyama 
addition developed by Scettri is not so moisture sensitive (Figure 51). 
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Figure 51. Preparation of 6-(2-hydroxy-2-alkyl(aryl)ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-
ones by vinylogous Mukaiyama reaction. 
The asymmetric synthesis of chiral 6-(2-hydroxy-2-alkylethyl)-2,2-dimethyl-4H-1,3-
dioxin-4-ones was first reported by Chikara by using a Mukaiyama aldol reaction.87 A 
novel tartaric acid derived acyloxyborane complex 75 was applied as the catalyst. 
Aliphatic, aromatic and vinyl aldehydes were tested and the result shows that the ee values 
were largely independent of the substrate structure; moderate ee values (62-73% ee) and 
yields (44-84%) were achieved (Figure 52).   
Ti4+ and Cu2+((S)-Tol-BINAP/CuF2) Lewis acid complexes 77 were discovered by 
Carreira in 1995 and 1998 respectively.88 Those catalysts exhibit unprecedented high 
enantioselectivities (up to 99% ee) and catalytic reactivities (1-3 mol% loading) in the 
vinylogous Mukaiyama reaction with aldehydes. The reactions are applicable to both 
aliphatic, aromatic, vinyl aldehydes and propargylic aldehydes without erosion of 
enantioselectivity. But to get pure product, an acidic work-up was required because of silyl 
migration which will increase the complexity of manipulation. A [Cu(S,S)-Ph-
pybox](SbF6)2 catalysed asymmetric Mukaiyama reaction was developed by the Evans 
group.89 This catalyst can be generally applied to a broad range of enol silyl ethers and 
dienol silyl ethers. To the silyl ether described in Figure 52, only one example has yet 
been demonstrated to work with good yield and ee (94%, 92% ee, 5 mol% catalyst).  
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Figure 52. Catalytic entantioselective synthesis of 6-(2-hydroxy-2-alkylethyl)-2,2-
dimethyl-4H-1,3-dioxin-4-ones. 
More catalytic Mukaiyama-type reactions have been published (see Figure 52 for general 
procedure). Scettri reported a Ti(Oi-Pr)4/(R)-BINOL complex which can be applied to 
both aliphatic and aromatic aldehyde substrates. In his report, enantioselectivities for 
aromatic aldehyde substrates were higher than for aliphatic (97->99% ee versus 89-92% 
ee).90 
The Denmark’s group discovered that the combination of a catalytic amount of the chiral 
bis-phosphoramide 76 and silicon tetrachloride is able to promote a highly 
enantioselective and diastereoselective addition of silyl enol ether to aldehydes.91 This 
method is highly efficient, and good to excellent dr values and yields were achieved even 
at a loading of bis-phosphoramide catalyst as low as 1 mol% (Figure 52). 
 
1.4.1. Applications of 6-(2-Hydroxy-2-alkylethyl)-2,2-dimethyl-4H-1,3-
dioxin-4-ones. 
Katritzky92 demonstrated that the 1,3-dioxin-4-one ring can be opened under high 
temperature or UV irradiation conditions to release acylketene intermediate through a 
retro-Diels-Alder mechanism. The acylketene intermediate has a strong affinity to 
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electron-rich substrates and therefore can serve as a scavenger of nucleophilic reagents 
such as alcohols, amines and thiols to generate β-keto esters, β-keto amides or β-keto 
thioesters. The reaction in Figure 53 is the most commonly used application of 1,3-
dioxin-4-one and has been used widely in natural product total synthesis. 
 
Figure 53. Ring open of 1,3-dioxin-4-one. 
There are some applications which include the reaction shown in Figure 53. The 1,3-
dioxin-4-one scaffold was recognized as the precursor to β-keto esters and a range of 
structures can be prepared from this reaction. For example at an early stage of the 
synthesis of 3,5-deoxy amphotericin B methyl ester, the Carreira group treated compound 
78 in n-butanol at 110 °C to release the β-keto ester 79 which could be further converted to 
acetonide 3,5-diol 80 (Figure 54).93 Other applications of the thermal ring opening 
reaction to generate β-keto esters are all of  the retro-Diels-Alder type.94 
 
Figure 54. Application in total synthesis of natural products. 
The Scheidt group reported the preparation of bicyclic compounds taking advantage of the 
embedded enol ether from the 1,3-dioxin-4-one core.95 The 1,3-dioxin-4-one served as a 
nucleophilic reagent which can couple with aldehydes in a diastereoselective manner by a 
Sc(OTf)3 promoted Prins cyclization (Figure 55). According to the authors, the 
diastereoselectivities are dependent on the R2 groups of the aldehydes and during the 
cyclization no racemization was observed.  
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Figure 55.  Prins cyclization reaction of 1,3-dioxin-4-one. 
 
1.5. Chiral Diynols-Structure and Synthesis. 
1.5.1. Structure of Chiral Diynols in Natural Products. 
As a subclass of acetylenic natural product, diynols are unique structures found in many 
diacetylenic and polyacetylenic natural products.96 In addition to their intriguing structure, 
this group of natural products is known to contain examples with highly potent anti-cancer 
and anti-HIV properties. However, the enantioselective syntheses of polyyne natural 
products are relatively rare due to the high instability of the polyyne unit.97 Diynol natural 
products, their biological properties and total synthesis, will be discussed here.  
The diynol natural products, strongylodiol A-C (Figure 56) were isolated from the sponge 
genus Strongylophora.98 This group of compounds was found to contain most typically 
long-chain diacetylenic alcohols. Strongylodiols A-C possess cytotoxic activities against 
tumour cells (DLD-1 and MOLT-4), normal cells (IMR-90) and can be potentially used 
for anti-cancer treatment. Containing relatively simple structures, strongylodiols A-C are 
some of the most typical diynol compounds from nature. Several total syntheses of 
strongylodiol A and strongylodiol B have been published.98 
 
Figure 56. Structures of strongylodiol A-C. 
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Diynol natural products panaxjapyne A-C (Figure 57) were isolated as secondary 
metabolites from the roots of Panax japonicus C. A. Meyer var. major99 alongside four 
other known compounds. The roots of Panax species have long been used either in 
Chinese traditional herbal medicine or for food in Asian regions. The roots of Panax 
species were prescribed as an expectorant, hemostatic, sedative, analgesic and antitussive 
medicine. It has also been found to be a rich source of C17 polyacetylene compounds. 
Potent yeast α-glucosidase activity inhibitory effects have been reported for these three 
new compounds. To date only a total synthesis of panaxjapyne C has been reported, using 
L-ascorbic acid as the source of chirality.100 
 
Figure 57. Structures of panaxjapyne A-C. 
(S)-Minquartynoic acid (Figure 58) contains four contiguous triple bonds. This compound, 
isolated from the twigs of ochanostachysamentacea from Southeast Asia exhibits broad 
cytotoxicity against 10 different tumour cell lines. In Peru it was widely used as traditional 
medicine to cure malaria and leishmaniasis.101Although the total synthesis of (S)-
minquartynoic acid has been published, the construction of notoriously unstable chiral 
polyynol is still challenging.102 
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Figure 58. Structures of (S)-minquartynoic acid. 
 
1.5.2. Synthesis of Chiral Diynols. 
The structural diversity of diynols in nature makes access to this kind of building block of 
huge significance. The first 1,3-diyne asymmetric additions to aldehydes were reported by 
Carreira using a Zn(OTf)2/N-methylephedrine ligand (Figure 59).
103 In the context of their 
total synthesis of (R)-strongylodiol A and B, asymmetric 1,3-diyne addition was used to 
introduce the chiral diynol functionality. 
 
Figure 59. 1,3-Diyne asymmetric addition by Carreira’s method. 
The addition of 1,3-diynes to aldehydes has proved troublesome. (R)-Strongylodiol A and 
(R)-strongylodiol B were formed only in 62% yield/82% ee and 68% yield/80% ee 
respectively even when using a large excess of the ligand (4 equiv).104 The long standing 
problem of this system is that when non α or β-branched aldehydes are used, the 
enantioselectivities typically drop to 70-88% ees. If α,β-unsaturated aldehydes are used, a 
competing Cannizaro reaction resulted in product formation in low yields (as low as 35%). 
Tykwinski also reported a modified method of Carreira’s Zn(OTf)2/N-methylephedrine 
protocol for the asymmetric addition of terminal di- and triynes to aldehydes.105 Although 
the effects of reaction conditions have been fully investigated, including  temperature, 
loading of Zn(OTf)2, base and additives, this reaction is essentially still a non-catalytic one. 
To obtain good conversions and ee values, 1.6 equiv of Zn(OTf)2 and 1.2 equiv of N-
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methylephedrine are required in the general procedure. Furthermore these reaction 
conditions are still inapplicable to non α or β-branched aldehydes, for example when 
R1=4-t-butylphenyl and R2=Et, only 45% yield and 64% ee were achieved.   
Considering that Carreira’s and related methods are strictly dependent on and limited by 
the structure of the aldehydes, a catalytic system has been developed which has 
applicability to a broader array of substrates.   
In 2010 the Trost group first published the systematic study of catalytic 1,3-diyne 
asymmetric addition to aldehydes by using their (S,S)-ProPhenol ligand 82 (Figure 60).106 
Under mild reaction conditions the scope of substrates could be extended to α-branched 
aliphatic aldehydes and α,β-unsaturated aldehydes without serious erosion of yields or ee 
values. However there were still some limitations within this system. For example when 
(Z)-α,β-unsaturated aldehydes were applied, a product of only 63% ee was obtained. Other 
α-branched aldehydes (up to 83% ee) and aldehydes with a long chain (up to 82% ee) such 
as octanal are also not ideal substrates for enantioselective diynylation. Furthermore, the 
use of 2-3 equivalents of the 1,3-diyne is necessary for the full conversion of aldehydes. 
This protocol has also been applied to total synthesis of (R)-strongylodiol A and (R)-
strongylodiol B and products of 88% ee and 87% ee were obtained respectively. A similar 
system established by Wang employed a chiral 1,4-amino alcohol as the ligand in place of 
ProPhenol.107 This reaction worked very well with aromatic aldehydes but when α,β-
unsaturated aldehydes were tested the ee values dropped to 80-84% which is slightly 
lower than Trost’s system. Interestingly, this method also has been applied to the total 
synthesis of (R)-strongylodiol A and (R)-strongylodiol B. With aliphatic aldehydes the 
1,4-amino alcohol catalyst was less enantioselective; 55% ee for (R)-strongylodiol A and 
58% ee for (R)-strongylodiol B were reported by this method. Although for the first time 
the ProPhenol/Me2Zn method makes the 1,3-diyne asymmetric addition a truly catalytic 
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reaction and extended the scope of aldehyde substrates; the application of this reaction is 
still strictly restricted by the poor performance in aliphatic aldehyde substrates. 
 
Figure 60. 1,3-Diyne asymmetric addition by Trost’s method. 
Trost claims the problems they encountered in aliphatic aldehyde 1,3-diyne asymmetric 
addition were caused by substrate enolization during the course of the reaction.108 To 
overcome the challenges in the field of 1,3-diyne asymmetric addition, the 1,1’-binaphth-
2-ol (BINOL)/ZnEt2/Ti(OiPr)4 catalytic system developed previously for alkyne addition 
has been extended to asymmetric 1,3-dialkynes addition by the Pu group (Figure 61).109 
This strategy is applicable to aliphatic aldehydes (up to 95% ee), aromatic aldehydes (up 
to 94% ee) and α,β-unsaturated aldehydes (up to 92% ee). Not only has the substrate scope 
been extended, the method gives both excellent yields and good selectivities, hence filling 
the gap left previously.  
 
Figure 61. 1,3-Diyne asymmetric addition by Pu’s method. 
Although the catalytic 1,3-diyne asymmetric addition is an efficient way to access the 
chiral targets, the application is still limited by the structure of substrates. In general, there 
are two ways to prepare the 1,3-diynes (Figure 62).109 The synthesis of 1,3-diynes is not 
efficient and sometimes is even troublesome. Firstly if R is a short chain such as n-butyl, 
the corresponding 1,3-diyne will be too volatile to be separated from benzene or toluene 
(Figure 62, Reaction 1). To date, nobody has published the 1,3-diyne addition using 
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highly volatile diyne species such as 1,3-octadiyne. Also the preparation of 1,3-diyne is 
not very economic or environment friendly. To prepare 7 mmol 1,3-diyne it is necessary to 
consume 380 mL of benzene.106 Moreover, additional difficulty was caused by the low 
stability of 1,3-diynes. The publications in this area indicate that 1,3-diynes are unstable at 
room temperature therefore additional care should be taken when preparing these species. 
 
Figure 62. Synthesis of 1,3-diyne. 
The use of highly reactive and enolizable aldehydes such as acetaldehyde for 1,3-diyne 
addition is rare. Only one example of acetaldehyde 1,3-diyne asymmetric addition has 
been reported (0.2 mmol scale, 66%, 94% ee) by using 4 equivalents of acetaldehyde.108 
Reportedly, when the alkyne addition was performed the acetaldehyde was rapidly 
consumed by a competing aldol reaction rather than 1,3-dialkyne addition. Although the 
disfavoured reaction can be partially controlled by tuning the addition speed, the formation 
of large amounts of side-product is unavoidable.   
 
1.6. The Advantages and Disadvantages of Asymmetric Transfer 
Hydrogenation Compared to Asymmetric Hydrogenation.  
Both asymmetric hydrogenation193 and asymmetric transfer hydrogenation prochiral 
unsaturated compounds can be used as one of the most efficient methods to get access of 
the corresponding chiral products. 
With concern to catalyst/substrate diversity, asymmetric hydrogenation apparently has 
more choices of ligands and metal cores compared to transfer hydrogenation. Thanks to 
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the diversity the substrate scope of hydrogenation is much broader than transfer 
hydrogenation. 
The substrate scope includes ketones, imines, unfunctionalized alkenes, functionalized 
alkenes such as α,β-unsaturated esters/acids, enol esters and enamines and heterocycles. 
The substrate scope of asymmetric transfer hydrogenation is relatively limited because the 
catalysts are more reactive to electro-deficient double bonds such as ketones, imines, 
dicyanoolefins and nitroolefins. Furthermore to achieve good enantioselectivities a 
binding group such as aromatic ring and triple bond conjugations in majority of the case 
are necessary. 
In term of reactivity of catalysts, transfer hydrogenation catalysts are unable to compete 
with hydrogenation catalysts although during the past twenty years the reactivity has been 
enormously improved. In a recent publication, Ir catalyzed acetophenone asymmetric 
hydrogenation can reach 5.0 × 106 S/C loading194 (91% yield, 98% ee) which is far more 
active than present transfer hydrogenation method. 
The advantages of asymmetric transfer hydrogenation are also very distinctive. First and 
foremost is the use other hydrogen sources such as isopropanol, HCO2H and HCO2Na 
instead of H2. Transfer hydrogenation reactions can be carried out at 1 atm pressure 
therefore simple for operation while high pressure H2 (30-200 atm for laboratory use) in 
hydrogenation is unavoidable. Secondly aromatic ring and triple bond are unique binding 
groups for transfer hydrogenation which is rarely seen in asymmetric hydrogenation.   
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2. Results and Discussion: 
2.1. ATH of 2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones and 
Application to the Total Synthesis of Yashabushitriol. 
2.1.1. Synthesis of Ketone Precursors. 
Initial studies in this project were directed at the synthesis of 2,2-dimethyl-6-(2-
oxoalkylethyl)-1,3-dioxin-4-one precursors, followed by a study of their asymmetric 
transfer hydrogenation. 
As outlined in Figure 63, it was envisaged that the desired ketone precursors could be 
prepared either from N-acylbenzotriazoles or acid chlorides. Literature precedent110 
suggests that direct coupling of an acid chloride is the most convenient and 
straightforward method to access 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones 
however some disadvantages, including variable and relatively low yields, may require the 
use of alternative methods.  
 
Figure 63. Two possible routes for the synthesis of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-
dioxin-4-ones. 
The widely used precursor N-acylbenzotriazoles can be easily prepared from carboxylic 
acids or acid chlorides on large scales (more than 10 g) and in high yields. Literature 
reported92 that better yields can be achieved compared to acid chlorides therefore this 
reaction was enlisted as the secondary plan.  
 
2.1.1.1. Synthesis of N-Acylbenzotriazoles. 
The synthesis of N-acylbenzotriazoles (compounds 83-94) from carboxylic acid chlorides 
was achieved following El-Dusouqui’s method (Table 1).111 High yields (up to 99%) of 
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products and in generally good purities were achieved after a basic work-up and the 
products were desiccated to dryness before use without further purification. Katritzky’s 
method112 of preparing N-acylbenzotriazoles (compounds 95-97) directly from carboxylic 
acids (Table 2) was also adopted for the synthesis of benzotriazole amides when the acid 
chlorides were not commercially available. By using this method, products were provided 
in equally high purity as well as high yield despite the requirement for the use of four 
equivalents of benzotriazole.    
 
Table 1. Synthesis of N-acylbenzotriazoles from carboxylic acid chlorides. 
 
Entry R (No.)1 Yield2 
(%) 
Entry R (No.)1 Yield2 
(%) 
1 2-Bromophenyl (83) 96 6 4-Methoxylphenyl (88) 99 
2 2-Methylphenyl (84) 99 7 3-Methylphenyl (89) 99 
3 2-Furanyl (85) 99 8 Isobutenyl (90) 93 
4 4-Methylphenyl (86) 99 9 Benzyl (94) 99 
5 4-Fluorophenyl (87) 96    
1. Compound number. 
2. Isolated yield. 
 
Table 2. Synthesis of N-acylbenzotriazoles from carboxylic acids. 
 
Entry R (No.)1 Yield2 (%) 
1 2-Phenylethynyl (95) 93 
2 2-Thienyl (96) 79 
3 4-Nitrophenyl (97) 81 
1. Compound number. 
2. Isolated yield. 
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2.1.1.2. Synthesis of 2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones. 
2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones precursors were first synthesized by 
Katritzky’s method.92 Deprotonation of 2,2,6-trimethyl-1,3-dioxin-4-one 74 by LDA 
(LDA was prepared in situ) at -78 °C resulted in the formation of the lithium enolate. 
Claisen condensation occurred after the addition of N-acylbenzotriazole/THF solution and 
the desired ketones were obtained in low to moderate yields (15-46%) (Table 4). Attempts 
to prepare similar ketones from carbonyl acid chlorides (Table 3) however led to lower 
yields compared to the method described in Table 4. Since N-acylbenzotriazole was 
completely consumed during the course of the reaction, presumably the poor yields may 
result from decomposition of products under the basic reaction conditions overnight. 
Another drawback of this reaction is that a large amount of unreacted 2,2,6-trimethyl-1,3-
dioxin-4-one 74 remained in the solution after work-up. Since compound 74 and product 
have very similar polarity, meticulous column chromatography was needed to separate 
pure samples from starting material. Furthermore we found that benzotriazole should be 
completely removed from product. In an attempt to prepare ketone 113 by the method 
described in Table 4, benzotriazole could not be completely removed even after column 
chromatography twice. When treating the impure sample under standard transfer 
hydrogenation conditions no reaction was observed. Considering the coordination ability 
of benzotriazole it is likely that benzotriazole acting as a catalyst inhibitor. 
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Table 3. Synthesis of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones from carboxylic 
acid chlorides. 
 
Entry R(No.)1 Yield2 (%) 
1 Methyl (98) 15 
2 Phenyl (99) 26 
3 trans-Cinnamonyl (100) 13 
1. Compound number. 
2. Isolated yield. 
 
Table 4. Synthesis of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones from N-
acylbenzotriazoles. 
 
R(No.)1 Yield2 (%) R(No.)1 Yield2 (%) 
2-Bromophenyl (101) 21 4-Nitrophenyl (107) 36 
2-Methylphenyl (102) 30 Isobutenyl (108) 28 
2-Furanyl (103) 27 2-Phenylethynyl (109) 15 
4-Methylphenyl (104) 46 3-Methylphenyl (110) 46 
4-Fluorophenyl (105) 38 Benzyl (111) 15 
4-Methoxylphenyl (106) 39   
1. Compound number. 
2. Isolated yield. 
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2.1.1.3. Second Generation Synthesis of 2,2-Dimethyl-6-(2-oxoalkylethyl)-
1,3-dioxin-4-ones. 
To counteract the inefficiency found in the previous synthesis a new synthetic pathway 
was designed (Figure 64). In this approach, N-acylbenzotriazoles were replaced by 
aldehydes, which have proved to be better nucleophilic acceptors for the 2,2,6-trimethyl-
1,3-dioxin-4-one lithium enolate. The reaction was carried out under the conditions shown 
in Table 5 and alcohols (compounds 114-123) were found to be the only products after 
work-up. The products were readily separated from starting materials in improved yields 
(up to 97%). In addition, products of this step could also be used subsequently as racemic 
standards for HPLC.  
 
Figure 64. An alternative routes for the synthesis of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-
dioxin-4-ones. 
In the second step, the alcohols were oxidized by PCC in CH2Cl2 at room temperature. 
The PCC oxidation was finished in a few hours and in general no dehydration product or 
over-oxidation of the double bond was detected. Taking advantage of this clean reaction, 
the ketones in Table 6 could be separated easily (on a large scale, 7 g of ketone 99 was 
prepared) with purity that is good enough for a S/C 5000/1 reduction (see ATH part). 
Although the PCC oxidation can offer clean products effectively, the method is not 
compatible with certain R groups including trans-cinnamonyl and 2-furanyl (Table 6, 
Entries 10 and 11). PCC will inevitably oxidize the furan ring and may break the double 
bond of the trans-cinnamonyl group. Other oxidative systems such as pyridine-sulphur 
trioxide (SO3·Py)/base and Swern oxidation all failed in this transformation (Figure 65). 
When those two reactions were performed, only the dehydration product was found. Dess-
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Martin oxidation of this compound has been published by Lee;113 but considering the cost 
of the Dess-Martin reagent, PCC oxidation is more economic, equally efficient and 
achieves a sufficiently clean transformation.  
The second generation procedure was able to furnish the ketones on a multi-gram scale 
and with enough purity to pave the way for the asymmetric transfer hydrogenation and a 
target related synthesis. 
 
Table 5. Synthesis of racemic samples by Claisen-type condensation.1 
 
R(No.)2 Yield3 (%) R(No.)2 Yield3 (%) 
Phenyl (114) 66 2-Thienyl (119) 58 
4-Nitrophenyl (115) 66 2-Methylphenyl (120) 84 
4-Methylphenyl (116) 60 4-Fluorophenyl (121) 81 
3-Methylphenyl (117) 81 4-Methyoxyphenyl (122) 77 
4-Bromophenyl (118) 60 2-Furyl (123) 97 
1. Aldehydes were used directly without distillation. 
2. Compound number. 
3. Isolated yield. 
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Table 6. Synthesis of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones by PCC 
oxidation. 
 
Entry R(No.)1 Yield
2 (%) 
Entry R(No.)1 Yield2 
(%) 
1 Phenyl (99) 89 6 2-Thienyl (113) 76 
2 4-Nitrophenyl (107) 46 7 2-Methylphenyl (102) 67 
3 4-Methylphenyl (104) 73 8 4-Fluorophenyl (105) 64 
4 3-Methylphenyl (110) 81 9 4-Methyoxyphenyl (106) 93 
5 4-Bromophenyl (112) 80 10 trans-Cinnamonyl (100) 0 
   11 2-Furyl (103) 0 
1. Compound number. 
2. Isolated yield. 
 
 
Figure 65. Failed oxidations under other conditions. 
 
2.1.2 Asymmetric Transfer Hydrogenation of 2,2-Dimethyl-6-(2-
oxoalkylethyl)-1,3-dioxin-4-ones. 
2.1.2.1. Optimization of Reaction Conditions. 
The asymmetric transfer hydrogenation of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-
ones commenced from the optimization of reaction conditions by using 2,2-dimethyl-6-(2-
oxo-2-phenylethyl)-4H-1,3-dioxin-4-one 99 as starting material. This compound proved to 
be stable when treated in HCO2H/TEA 5/2 mixture at rt for a week. At elevated 
temperature (40°C and 50°C) the compound is stable for up to 3 days although literature 
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reports indicate that dioxin-4-one ring can be cleaved at high temperature through a retro-
Diels-Alder reaction.92  
From solvent screening tests (Table 7, Entries 1-5) it was found that the catalyst reactivity 
is highly solvent dependent. HCO2H/TEA 5/2 mixture, EtOAc and THF are not suitable 
solvents for this reduction presumably because of the strong interaction between solvent 
and ketone substrate. When CH2Cl2 and CH3CN were tested as solvents the reaction rates 
were substantially increased. In the ATH of acetophenone 13, when HCO2H/TEA were 
used as a hydride donor the reaction efficiency was only slightly affected by the choice of 
solvent. But in the case of compound 99, the reduction rate is highly solvent dependent. 
Subsequently, the reactivities of catalysts were tested. As expected, the tethered catalyst 
(R,R)-c2 yields the best results against catalysts (R,R)-c1, (R,R)-c4 and (R,R)-c5; it could 
fully convert compound 99 within 7 h at rt with 1 mol% catalyst loading. The reactivity of 
catalyst (R,R)-c1 is lower although 2 mol% of is enough to reach full conversion of the 
compound 99 within 24 h. The lowest catalytic reactivities were observed using catalysts 
(R,R)-c4 and (R,R)-c5 in which the N of the ligands had been modified with allyl or Bn. In 
fact, N-substituted catalysts (Table 7, Entries 6 and 7) hardly convert any substrate under 
exactly the same conditions.  
Tethered catalyst (R,R)-c2 of varied loading and different reaction temperatures were 
investigated. As demonstrated in Table 7 Entries 8-12, one molecule of (R,R)-c2 could 
reduce up to 1000 molecules of 99 at rt. More interestingly when the same reaction were 
tested at 40°C and 50°C, although the reactions were more rapid, the enantioselectivities 
were maintained at the same level (Table 7, Entries 11 and 12). When (R,R) configuration 
catalyst was used the absolute configuration of 114 was unambiguously assigned to be R 
by comparing the optical rotation with that reported.88 
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Table 7. Optimization of reaction conditions. 
 
 
Entry Catalyst Solvent1,2 S/C T 
(°C) 
Time 
(h) 
Conv 
(%)3 
ee 
(%)4 
1 (R,R)-c1 HCO2H/TEA 5/2 50/1 rt 80 <10 - 
2 (R,R)-c1 EtOAc 50/1 rt 80 33 98 (R) 
3 (R,R)-c1 THF 50/1 rt 80 63 98 (R) 
4 (R,R)-c1 CH2Cl2 50/1 rt 13 100 98 (R) 
5 (R,R)-c1 CH3CN 50/1 rt 13 100 98 (R) 
6 (R,R)-c4 CH2Cl2 50/1 rt 24 <10 - 
7 (R,R)-c5 CH2Cl2 50/1 rt 24 <10 - 
8 (R,R)-c2 CH2Cl2 100/1 rt 7 100 98 (R) 
9 (R,R)-c2 CH2Cl2 500/1 rt 29 100  98 (R) 
10 (R,R)-c2 CH2Cl2 1000/1 rt 70 >99 98 (R) 
11 (R,R)-c2 CH2Cl2 1000/1 40 17 100 98 (R) 
12 (R,R)-c2 CH2Cl2 1000/1 50 10 100 98 (R) 
1. Substrate concentration is 0.15 M. 
2. 5 Equivalent of formic acid were used when organic solvents were used. 
3. Conversions were determined by 1H NMR. 
4.  Ee values were determined by chiral HPLC, CHIRALPAK IB column. 
 
2.1.2.2. ATH of 2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones at rt. 
Under optimized conditions catalyst (R,R)-c2 was tested at room temperature with a 
selection of substrates bearing different R groups. We found the reaction time is 
substituent dependent; when R=alkyl, alkenyl, alkynyl and aryl without strong 
electron-donating groups or atoms the reactions finished within 24 h; on the contrary 
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if a strong electron-donating group or atom was attached to aryl the reactivities of the 
substrates were decreased (Table 8, Entries 12 and 13). The enantioselectivities 
however appear to have no relevance to reaction time. The relationship between ee 
values and R groups is also very clear. When R=phenyl or substituted phenyl all the 
ee values that were obtained were excellent except for 2-bromophenyl (Table 8, 
Entry 11), which may be due to the electronic/steric effect causing disruption of the 
interaction between the catalyst and the aromatic ring of the substrate.  
As expected, when R=phenylacetylenyl (Entry 2) the reaction proceeded with an 
excellent ee value (98% ee) while ee values were eroded for R=trans-Cinnamonyl 
(73% ee) (Entry 8) and isobutenyl (70% ee) (Entry 14). The poorest ee (59% ee) was 
for R=methyl (Entry 15) which suggested that methyl is not a good group for 
asymmetric induction. By comparing the optical rotation of compound 128 with the 
literature value114 the absolute configuration was determined to be (S) which was still 
consistent with other compounds. 
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Table 8. ATH of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones at rt. 
 
Entry Product1(No.)2 Time (h)3 Yield (%)4 ee (%)5 
1 Phenyl (R-114) 7 89 98  
2 Phenylacetylenyl (R-124) 8 82 98 
3 4-Nitrophenyl (R-115) 8 94 96 
4 4-Methylphenyl (R-116) 12 96 97 
5 3-Methylphenyl (R-117) 12 98 98 
6 4-Bromophenyl (R-118) 15 87 98 
7 2-Thienyl (R-119) 24 95 98 
8 trans-Cinnamonyl (R-125) 25 99 73 
9 2-Methylphenyl (R-120) 30 90 98 
10 4-Fluorophenyl (R-121) 30 98 99 
11 2-Bromophenyl (R-126) 40 88 82 
12 2-Furyl (R-123) 50 91 99 
13 4-Methoxylphenyl (R-122) 180 92 98 
14 Isobutenyl (R-127) 8 18 70 
15 Methyl (S-128) 16 89 59 
1. Absolute configurations of known compounds were determined by optical rotation and unknown 
compounds were assigned by analogy. 
2. Compound number. 
3. Reaction time was determined by following the reaction by TLC. 
4. Isolated yield. 
5.  Ee values were determined by chiral HPLC, CHIRALPAK IB column. 
 
2.1.2.3. ATH of 2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones at 
Elevated Temperature. 
Ketones prepared from the PCC oxidation were reduced at 50 °C by using catalyst (R,R)-
c2 (Table 9). It is necessary for the reactions to be completed within 72 h because of the 
relatively low thermal stability of the 1,3-dioxin-4-one ring. As shown in Table 9, under 
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these conditions, with the exception of the results shown in Table 9 Entries 7 and 10, all 
the substrates were reduced at a 0.1 mol% catalyst loading. In Entry 2, when R=phenyl, 
0.02 mol% of catalyst was used and the reaction was still completed within 72 h. Alcohol 
R-114 was obtained with excellent enantioselectivity (98% ee) without significant 
decomposition although the yield is slightly lower than Entry 1.  
 
Table 9. ATH of 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones at elevated 
temperature. 
 
Entry R(No.)1 S/C Yield2 (%) ee3 (%) 
1 Phenyl (R-114) 1000/1 98 98 
2 Phenyl (R-114) 5000/1 93 98 
3 4-Nitrophenyl (R-115) 1000/1 82 95 
4 4-Methylphenyl (R-116) 1000/1 92 98 
5 3-Methylphenyl (R-117) 1000/1 91 98 
6 4-Bromophenyl (R-118) 1000/1 95 97 
7 2-Thienyl (R-119) 500/1 98 99 
8 2-Methylphenyl (R-120) 1000/1 94 >95 
9 4-Fluorophenyl (R-121) 1000/1 85 98 
10 4-Methyoxyphenyl (R-122) 500/1 76 98 
1. Compound number. 
2. Isolated yield. 
3.  Ee values were determined by chiral HPLC, CHIRALPAK IB column. 
The concise synthesis of this type of compounds could facilitate the total synthesis of 
compounds bearing a chiral hydroxyl at the benzyl position such as yashabushitriol,115 (R)-
(+)-kavain116 and (-)-centrolobine.117 
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Figure 66. Potential targets. 
 
2.1.3. Total Synthesis of Yashabushitriol. 
Yashabushitriol 129 was isolated from the male flowers of Alnus sieboldiana (252 mg 
from 9.2 kg male flowers) and bears a 1,3,5-triol structure.115 The absolute configuration 
of this compound has been determined to be (1R), (3R), (5S) based on the reduction of the 
known yashabushiketodiol and 1H NOE analysis. To date, only one racemic synthesis118 
and one formal synthesis119 of compound 129 have been published. Because of the lack of 
full data for compound 129 as well as the attractive synthetic strategy (which includes two 
highly stereo-selective ATH and one chemo-selective hydrogenation), an asymmetric 
synthesis of yashabushitriol 129 was developed by using the method described in Figure 
67.  
 
Figure 67. Synthesis plan of yashabushitriol 129. 
As the C1 hydroxyl group is in the vicinal position of phenyl, it was envisaged that the C1 
hydroxyl could be installed through the ATH of the corresponding ketone 99 which was 
prepared on a 7 g scale and in 98% ee. The chiral C3 hydroxyl group could be introduced 
through a chelation controlled cis selective reduction after conversion to a,β-keto ester 132, 
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then by two more steps to reach the Weinreb amide 134. After conversion to a propargylic 
ketone 135 from 134, ATH provides a convenient way to introduce the C5 asymmetry. 
Finally the triple bond should be hydrogenated and acetonide removed to complete the 
synthesis of yashabushitriol 129. Other steps required for the synthesis include Weinreb 
amide formation, acetonide protection and deprotection, all of which are well established 
transformations. 
The synthesis (Scheme 1) commenced from the enantiomerically enriched alcohol R-114 
which is available through the reduction described above. The 1,3-dioxin-4-one ring-
opening reaction proved to be a convenient way to form the required β-keto ester. Under 
the n-butanol reflux conditions, this was converted in high yield to a single product 132. 
The resulting β-keto ester 132 was reduced cis selectively by applying Snider’s 
procedure120 ((C2H5)2BOMe/NaBH4) and the resulting crude 1,3-diol was protected by 
formation of an acetonide. After protection, the diastereoselectivity of the crude mixture 
was determined to be syn/anti=5/1 by 1H NMR. The well established highly syn-selective 
reduction121 did not work very well for compound 132. The Meshram group122 employed 
Zn(BH4)2 in the reduction of a similar compound and using this method the 
diastereoselectivity could reach syn/anti=10/1.  
 
Scheme 1. Synthesis toWeinreb amide 134. 
The major syn product 133 could be easily separated from the anti diastereomer by silica 
gel column chromatography. Literature precedent suggests that the syn conformation is a 
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chair while the anti product is a twisted boat. The difference between them can easily be 
determined by Rychnovsky 13C NMR analysis.123 From the 13C NMR of compound 133, 
the relative configuration was unambiguously assigned to be syn.   
At this stage, we were aware that ester 133 would not be a good electrophile for 
phenylacetylene coupling. To address this, a standard Grignard reagent promoted Weinreb 
amide formation124 was used to form compound 134 which was employed for the 
subsequent coupling step. 
As anticipated, the coupling reaction preceded well (Scheme 2) and the propargylic 
ketone 135 was isolated in 84% yield without side-products being observed. The ketone 
was reduced to alcohol 136 using 1 mol% (R,R)-c2 with excellent dr selectivity 
(5R/5S=37/1) and yield (94%). The diastereoselectivity of the reduction was fully 
investigated by using catalysts of different structures and different absolute configurations. 
When the racemic catalyst ±c3 was used (Table 10, Entry 6), the poor dr value 
(5R/5S=1/1.6) suggested the 5S product 137 was slightly favoured by the induction of 
intrinsic chirality of the acetonide ring. The 1/1.6 ratio of diastereoisomers also suggests 
that the effect of substrate control is not significant. When the chiral catalysts c1 and c2 
were employed, the chirality was controlled by the communal directing effects of both the 
substrate and the catalysts. When (S,S) catalysts were applied both catalysts and substrate 
preferentially direct the C-5 hydroxyl toward the (S) configuration. Therefore in a 
“matched” case, both (S,S)-c1 and (S,S)-c2 catalysts provided excellent dr values. When 
(R,R) catalysts were applied the situation was reversed; (R,R) catalysts tend to form (R) 
configuration products whilst the substrate directs the C-5 hydroxyl towards the (S) 
configuration. In this situation, it is expected that the catalyst control could outweigh 
substrate control; so the desired (R) configuration could still be formed. Nearly total 
catalyst control was found in the case of the (R,R)-c2 catalyst reduction (Table 10, Entries 
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1 and 2). As anticipated, the resulting alcohol has both a very high diastereoselectivity 
(dr=37/1) and the correct configuration (5R) although it is formed through a “mismatched” 
transition state. This total catalyst control suggests that the physical interaction between 
the (R,R)-c2 catalyst and the chirality of the acetonide ring is not high enough to 
jeopardize or slow down the favoured transition state formation. What is unexpected is 
that the substrate-catalyst mismatch was slightly intensified by using (R,R)-c1 catalyst; the 
relatively poor diastereoselectivity (dr=10/1 but still in favour of 5R) indicated that the 
favoured transition state was partially hindered by the substrate (Table 10, Entry 3). 
 
Scheme 2. Synthesis and ATH of compound 135 by using different catalysts. 
 
Table 10. Results for ATH of compound 135. 
 
1.  Dr values were determined by 1H NMR. 
2. Isolated yield. 
3. Structure of ±c3 catalyst 
 
Entry Catalyst Loading (mol %) dr1 (5R/5S) Yield2 (%) 
1 (R,R)-c2 1  37/1 94 
2 (R,R)-c2 5 37/1 93 
3 (R,R)-c1 5  10/1 99 
4 (S,S)-c2 5  1/30 99 
5 (S,S)-c1 5  1/29 99 
6 ±c33 5  1/1.6 73 
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With sufficient 136 in hand, the synthesis continued with a late stage triple bond reduction 
and deprotection. Compound 136 was subjected to a hydrogenation which is seemingly 
simple but proved to be problematic. A catalytic amount of Pd(OH)2/C (Pd 20% w/w) was 
used initially to reduce the triple bond. The reaction was completed within 30 min under 1 
atm H2; however by analyzing the crude 
1H NMR it was found that the H1 that should be 
present at 4.9 ppm was missing (Figure 68). Concomitant with H1, peaks which belong to 
the acetonide (two singlets at 1.70-1.50 ppm) were also not present. From TLC apart from 
one spot that was close to the place of starting material (protected yashabushitriol), another 
more polar spot (which is not yashabushitriol) was found. After separation and 1H NMR 
analysis the major product was shown to not be yashabushitriol 129 but (-)-yashabushidiol 
B (protected yashabushitriol/(-)-yashabushidiol B =1/5). This may be because Pd(OH)2/C 
is too active and can remove the OH at the benzylic position. Therefore a milder catalyst 
Pd/C(en) (Pd 20% w/w) was applied to this reaction. Literature precedents125 suggested 
that Pd/C(en) (in which Pd/C is poisoned by ethylenediamine) is unable to remove a 
benzyloxy group. Unfortunately hydrogenolysed product (-)-yashabushidiol B was still 
found in the reaction mixture when using this catalyst; probably due to incomplete 
poisoning. Another problem of Pd/C(en) catalyst is that the catalytic activity dropped 
substantially which makes it difficult to control the reaction time. After 18 h the starting 
material was still incompletely consumed using 5% of catalyst. 
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Figure 68. Hydrogenolysis (over reduction) in Pd catalysed hydrogenation. 
A slower hydrogenation may result in the formation of more yashabushidiol B, hence 
Pd/C(en) is also not the ideal hydrogenation catalyst for this reaction. To overcome this 
aforementioned over reduction, PtO2 was chosen to minimize hydrogenolysis. Taking into 
account the fact that acetonide is an electron-withdrawing group which will facilitate 
hydrogenolysis, it should be removed first. Acetonide protection was removed using PPTS 
and the crude product was used directly after passing through a short silica gel column. 
Using a catalytic amount of PtO2 (6-7 mol%), the carbon-carbon triple bond was reduced 
smoothly within 30 min under 1 atm hydrogen gas atmosphere whilst the benzyl hydroxyl 
remained intact (Scheme 3). The final product, yashabushitriol 129, was generated as the 
only product after hydrogenation in excellent yield (86% over two steps). According to the 
same principle, the 5S isomer was also used in the hydrogenation and 5-epi-
yashabushitriol 5-epi-129 was obtained with satisfactory yield (74 % over two steps). The 
absolute structure of synthetic yashabushitriol 129 was confirmed unambiguously by X-
ray crystallography (Figure 69). The absolute structure of yashabushitriol also served to 
prove that the absolute structure of the natural 129 has been assigned correctly in previous 
publications. Unfortunately 5-epi-Yashabushitriol is an amorphous solid therefore the 
Reaction mixture 
 
Isolated  
 
H1                     H2 
H3   H3 H4 
H1                         H2 
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absolute 5-epi configuration was assigned as (S) by comparing chemical shifts with 
yashabushitriol and empirical knowledge of the enantioselectivity of ATH reactions.    
 
Scheme 3. Completion of the synthesis of yashabushitriol and 5-epi-yashabushitriol. 
 
Figure 69. X-Ray crystallography of yashabushitriol. 
The NMR data, the melting point and optical rotation values of synthetic yashabushitriol 
also match the authentic natural sample. Considering it is the first asymmetric total 
synthesis of yashabushitriol and 5-epi-yashabushitriol and the original NMR data of this 
compound was not fully reported it is useful to compare the 1H and 13C NMR data of these 
two compounds with the natural one (Table 11). 
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Table11. 1H and 13C NMR assignment of natural yashabushitriol, synthetic 
yashabushitriol and 5-epi-yashabushitriol. 
 
H Natural 
yashabu
shitriol 
Synthetic 
yashabushi
triol 
5-epi-
yashabushi
triol 
C Natural 
yashabu
shitriol 
Synthetic 
yashabushi
triol 
5-epi-
yashabushi
triol 
H1 - 7.38-7.15 7.37-7.15 C1 - 127.7 127.7 
H2 - 7.38-7.15 7.37-7.15 C2 - 128.6 128.6 
H3 - 7.38-7.15 7.37-7.15 C3 - 128.4 128.4 
H5 4.92 4.98 4.94 C4 144.3 144.3 144.3 
H6 - 2.02, 1.73-
1.67 
1.95-1.52 C5 74.6 75.4 75.3 
H7 4.30 4.38-4.31 4.20 C6 45.2 45.1 46.0 
H8 - 1.73-1.67 1.95-1.52 C7 69.6 70.4 73.5 
H9 3.96 4.04-3.96 3.96-3.88 C8 43.1 42.8 43.5 
H10 - 1.93-1.83, 
1.81-1.78 
1.95-1.52 C9 68.1 68.6 72.2 
H11 - 2.80, 2.66 2.79-2.59 C10 39.1 39.2 39.7 
H13 - 7.38-7.15 7.37-7.15 C11 32.0 32.1 31.7 
H14 - 7.38-7.15 7.37-7.15 C12 142.0 142.0 141.9 
H15 - 7.38-7.15 7.37-7.15 C13 - 125.7 125.7 
    C14 - 128.5 128.5 
    C15 - 126.9 125.9 
1. 13C (125 MHz) and 1H NMR (500 MHz) spectroscopic data for natural yashabushitriol in CDCl3. 13C (100 
MHz) and 1H NMR (400 MHz) spectroscopic data for synthetic yashabushitriol and 5-epi-yashabushitriol in 
CDCl3.  
 
      64 
 
2.2 Asymmetric Transfer Hydrogenation of Functionalized Propargylic 
Ketones. 
2.2.1. Synthesis of Propargylic α-Keto Esters and Their ATH Study. 
Three propargylic α-keto esters (138-140) were prepared by following the procedure 
above (Scheme 4). But when they were treated with HCO2H/TEA(5:2)/CH2Cl2 (TEA 0.3 
M) solution it was found that the compounds were unstable. Assuming that propargylic α-
keto esters are unstable under basic conditions another stability test was performed in 
HCO2Na (1 M) in DMF/H2O 1:1 solution. All of the three α-keto esters completely 
decomposed within 3 h at rt which further confirmed that propargylic α-keto esters are 
sensitive to base. Fortunately compound 138 is relatively stable in 
HCO2H/TEA(5:2)/CH2Cl2 (TEA 0.3 M) solution but when 10 mol% of catalyst (R,R)-c1 
was added there was no reduction at all.  
 
Scheme 4. Synthesis of propargylic α-keto esters. 
Further ATH studies were carried out in isopropanol and with activated catalyst (R,R)-c1; 
the conditions chosen have been proven to be base free. Compound 140 was chosen for 
the ATH tests in isopropanol. Three reactions were carried out independently under the 
same conditions. When only freshly prepared ketone 140 was used there was no reduction 
at all (Table 12, Entry 1). In the test of mixed material reduction neither ketone 140 nor 
acetophenone could be reduced (Table 12, Entry 2). To make sure that the reaction 
conditions and the activated catalyst was working for other ketones, only acetophenone 
was used as starting material. Without 140, acetophenone was completely reduced 
overnight (Table 12, Entry 3). This experimental result suggests that the activated catalyst 
is no longer active in the presence of ketone 140. Looking back the structure of the 
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propargylic α-keto ester, both ketone and ester act as electron-withdrawing groups thus 
making propargylic α-keto ester a very active Michael addition acceptor which could 
potentially inhibit catalyst (R,R)-c1 by reacting with amine ligand. The stability issue may 
also be a result of the electron-withdrawing ability of α-keto esters such that the triple 
bond could be attacked by OH- or some other nucleophiles in HCO2Na/H2O solution. 
Although all the attempts at reducing propargylic α-keto esters failed, the unique property 
of this class of compounds may serve as an example that helps to establish the general 
rules for ATH of propargylic ketones. 
 
Table 12. ATH study of compound 140. 
 
Entry Starting material Result 
1 pure compound 140 no reduction 
2 140 and acetophenone 1/1 mixture no reduction 
3 pure acetophenone complete reduction 
 
2.2.2. Synthesis of Thioesters, Acid Monoesters, Acid Chloride Monoesters 
and Weinreb Diamides. 
The synthesis of thioesters (157-159), acid monoesters (147-150), acid chloride 
monoesters (151-154) and Weinreb diamides (155 and 156) were achieved following by 
literature procedures. Since these are known compounds and some are commercially 
available the full preparation will not be discussed. The preparation and references are 
listed in the experimental section. 
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2.2.3. Synthesis of Propargylic β-Keto Thioesters, Propargylic β-Keto 
Esters and Propargylic α-Methyl-β-keto Esters and Their ATH Study. 
Two propargylic β-keto thioesters (141 and 142) were prepared by a direct Claisen type 
reaction triggered by the soft enolization of thioesters (Scheme 5).126 Under these mild 
reaction conditions self-Claisen condensation of thioesters and other side reactions were 
prevented. Good yields were achieved when both phenyl thioacetate and ethyl thioacetate 
were used as substrates. The products were pure enough from 1H NMR analysis for direct 
use in asymmetric transfer hydrogenation studies. 
 
Scheme 5. Synthesis of propargylic β-keto thioesters. 
Unlike ethyl thioacetate, ethyl acetate is inapplicable to these soft enolization conditions 
due to its relatively high pKa value. An alternative route was developed by using diethyl 
malonate and dimethyl malonate as nucleophilic reagents, both of which readily enolized 
under MgBr2·OEt2/i-Pr2NEt conditions. The reactions happened smoothly when malonate 
nucleophiles were used; after work-up the Bt-H was removed using a silica gel column 
and the condensation products were refluxed in TsOH (0.3 % w/w)/water until the diesters 
were completely consumed.127 The two propargylic β-keto esters (143 and 144) were 
isolated in good yields (Scheme 6). 
 
Scheme 6. Synthesis of propargylic β-keto esters (143 and 144) by Claisen condensation. 
Not all the propargylic β-keto esters could be prepared by the reaction illustrated in 
Scheme 6. The following example in Scheme 7 demonstrates that if the other side of 
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propargylic benzotriazoleamide is H then a Michael addition will happen easily between 
the starting material and MgBr2·OEt2. Hence the soft enolization reaction is conditional, 
and cannot be applied to all the propargylic benzotriazole amide substrates. Additionally, 
propargylic benzotriazole amides prepared from propargylic carboxylic acids are not 
always commercially available, which limits the scope of the methodology.  
 
Scheme 7. A typical side-reaction. 
The synthesis of propargylic β-keto esters and propargylic α-methyl-β-keto esters was 
achieved following Yamaguchi’s conditions128 using chlorides (151 and 152) and in situ-
generated alkynyl boranes. Compared to lithium acetylide, the less reactive alkynyl borane 
species only react with carbonyl chlorides therefore side reactions are minimized. From 
the experimental results, the synthesis of α-methyl-β-keto esters proceeded in generally 
higher yields than the propargylic β-keto esters (Table 13). 
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Table 13. Synthesis of propargylic β-keto esters and propargylic α-methyl-β-keto esters. 
 
  β-Keto esters α-Methyl-β-keto esters 
Entry R Yield1 (%)(No.)2 Yield1 (%)(No.)2 
1 C6H5 - 77 (163) 
2 BnO(CH3)2C 40 (160) 92 (164) 
3 n-C4H9 48 (161) 82 (165) 
4 BnO(CH2)2 45 (162) 72 (166) 
1. Isolated yield. 
2. Compound number. 
 
In the first trial, when 1 mol% of catalyst and β-keto thioester 142 was used and the 
reaction was carried out under standard conditions for 24 h, surprisingly there was no 
reduction at all. Initially it was speculated that compound 142 may have been 
contaminated by thiol because the thioester may be unstable and will release thiol slowly 
during the transfer hydrogenation reaction. Further increase of the catalyst loading (up to 5 
mol%) and using freshly columned substrate also led to no improvement (Scheme 8). 
From this experiment it has been demonstrated that thioesters are stable under 
HCO2H/TEA 5/2 conditions and it is not the thiol that poisoned the catalyst. Due to the 
strong coordination effect of the thioester, catalyst inhibition may happen after catalyst 
activation (Figure 70). Literature reports suggest that the 16-electron Ru (activated (R,R)-
c1) complex is able to coordinate with HCO2H and isopropanol before the hydrogen 
transfer happens. Alternatively, thioester coordination with the 16-electron Ru complex 
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may take place before the hydride is formed. To investigate this hypothesis, propargylic β-
keto ester was prepared with only S changed to O.  
 
Figure 70. How the thioester poison a catalyst. 
 
 
Scheme 8. Differing behaviour between propargylic β-keto esters and propargylic β-keto 
thioesters during the ATH tests. 
In contrast to the thioester 142, compound 144 was reduced smoothly under the same 
conditions by catalyst (R,R)-c2 in high isolated yield (95 %) and excellent ee value (92 %) 
(Scheme 8). The absolute configuration determination and HPLC separation conditions 
for this compound followed those given in the paper published by Park.129 
Encouraged by this result, four more propargylic β-keto esters and four propargylic α-
methyl-β-keto esters were prepared and tested under these ATH conditions. 
All the pure starting materials were found to exist as ketone-enol mixtures (determined by 
1H NMR in CDCl3) therefore the concentration of the β-keto esters species was lower than 
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ketones which do not readily enolize. A 0.5 mol% catalyst loading was chosen to ensure 
that the reaction was complete in 48 h. Decreasing the catalyst loading to 0.2 mol% (Table 
14, Entry 1, bracket) gave product 167 in 77% isolated yield after three days along with 9 % 
of recovered starting material. Unlike aromatic ketones, the experimental results suggest 
that the propargylic ketones share similar reactivity no matter which R group is present. 
The reactivity of propargylic ketones is relatively R group-independent; so the same 
amount of catalyst loading could be applied to all the four substrates (Table 14). In 
general, excellent yields and ee values were achieved in the ATH reactions of propargylic 
β-keto esters.  
 
Table 14. ATH of propargylic β-keto esters.1 
 
Entry R(No.)5 Yield2 (%) Ee3 (%) 
1 C6H5 (R-167) 86(77)
4 96(96)4 
2 BnO(CH3)2C (R-168) 99 99 
3 n-C4H9 (R-169) 92 97 
4 BnO(CH2)2 (R-170) 92 97 
1. The concentration of ketone is 0.15 M and formic acid was used as 5 equivalents. 
2. Isolated yield. 
3. Ee values were determined by chiral HPLC. 
4. Figures in brackets are results when catalyst loading of 0.2 mol% was used. 
5. Compound number. 
 
A more ambitious plan was proposed for reducing propargylic α-methyl-β-keto esters 
using three different catalysts (c1, c2 and c3). This time not only enantioselectivities but 
also diastereoselectivities were examined. Four propargylic α-methyl-β-keto esters were 
treated with catalysts c1, c2 and c3 separately. It was found that dr selectivities in 
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reductions by (R,R)-c1 catalyst (up to 31/1) were generally higher than drs in reductions 
by (R,R)-c2 (up to 14/1) and c3 (up to 13/1) (Table 15). From the results obtained using 
catalysts (R,R)-c1 and c3 it was speculated that the phenyl group on the ligands plays a 
key role in dr selectivity determination. The higher dr selectivity from catalyst c1 may 
result from the physical interaction between phenyl and methyl and ester groups in the 
transition state (Figure 71). Another interesting result came from the use of catalyst c2. 
Although catalyst c2 possesses a phenyl group the general dr selectivities achieved by 
catalyst c2 reduction were close to that of catalyst c3. This result suggests that although 
there is a structural difference between catalysts c2 and c3, the physical interaction with 
the substrates are similar.  
 
Table 15. Dynamic kinetic resolution of propargylic α-methyl-β-keto esters. 
 
 Catalyst (R,R)-c1 Catalyst (R,R)-c2 Catalyst ±c3 
R(No.)5 Yield2 
(%) 
Ee3 
(%) 
Dr4 Yield2 
(%) 
Ee3 
(%) 
Dr4 Yield2 
(%) 
Ee3 
(%) 
Dr4 
C6H5 (172) 99 98 24/1 94 >99 12/1 88 - 11/1 
n-C4H9 (173) 87 99 27/1 92 >99 14/1 21 - 13/1 
BnO(CH3)2C(174) 90 99 27/1 97 >99 12/1 - - - 
BnO(CH2)2 (175) 76 98 31/1 92 >99 14/1 - - - 
1. The concentration of ketone is 0.15 M and 5 equiv of formic acid was used. Catalyst loadings for c1 and c3 
are S/C 30/1 for c2 the loading is S/C 200/1. 
2. Isolated yields. 
3. Ee values were determined by chiral HPLC. 
4. Dr values were determined by 1H NMR using DCCl3 as solvent. 
5. Compound number. 
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Traditionally, the reduction of α-methyl-β-keto ester by Luche reduction (CeCl3·7H2O and 
NaBH4) should follow the Felkin Anh model which will preferentially yield the anti 
product.130 While in the case of Ru-H based dynamic kinetic resolution reaction the syn 
products were formed in a highly selective manner which suggested the reaction went 
through the transition state (Figure 71). From the proposed favoured transition state, it 
makes no difference when nucleophilic reagents are achiral the two enantiomers reacted at 
the same rate. But when the nucleophilic reagent is chiral because of the physical 
interaction between substrate and catalyst, the catalyst will select one enantiomer that can 
form the lower energy transition state preferentially (Figure 71). The excellent enantio and 
diastereoselectivity stems from both electronic and physical interactions. The existence of 
the triple bond is equally important for high diastereoselectivity; without this electronic 
interaction, the dr value will be low. 
 
Figure 71. Transition states of transfer hydrogenation DKR. 
The dr selectivities were determined by 1H NMR. From the spectra, it is possible to 
differentiate and determine the ratios of syn product from anti clearly by analysis of the 
integration of their β-protons and the absolute syn or anti configurations can also be 
determined by the chemical shifts of the β-protons (Figure 72).131 
Spectrum 1, Figure 72 is the compound 172 reduced from the Luche reduction and it is 
expected that this reduction will slightly favour the formation of the anti product. The syn 
product has also been detected as a minor product (anti/syn=3/1) with a chemical shift that 
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is higher than the anti. Spectrum 2, Figure 72 is the same compound reduced by catalyst 
c3 in which the dr was determined to be 11/1 in favour of the syn configuration. A similar 
result was achieved using catalyst (R,R)-c2 (spectrum 3) the corresponding dr 12/1 being 
again in favour of the syn product. The highest dr selectivity came from the use of catalyst 
(R,R)-c1 (spectrum 4, Figure 72 ) which is as high as 23/1.  
 
 
Figure 72. Dr ratios of compound 172 prepared by different methods and catalysts.1 and 2 
1. 1H NMR (400 MHz) spectroscopic data of β-H were collected in CDCl3. 
2. Spectrum 1 is compound 172 reduced by Luche reduction. Spectrum 2 is compound 172 reduced by 
catalyst c3. Spectrum 3 is compound 172 reduced by catalyst (R,R)-c2. Spectrum 4 is compound 172 
reduced by catalyst (R,R)-c1. 
 
2.2.4. Synthesis of Propargylic γ-Keto Esters and Propargylic δ-Keto Esters 
and Their ATH Studies. 
Propargylic γ-keto esters and propargylic δ-keto esters were prepared by two strategies 
(Table 16). Initially, alkynyl boranes132 were used as nucleophilic reagents. Compounds 
syn 
anti 
syn 
 
syn 
 
syn 
 
anti 
anti 
anti 
Spectrum 1 
Spectrum 3 
Spectrum 2 
Spectrum 4 
      74 
 
(176, 177, 178 and 180) were successfully prepared by this method (Reaction 1) but their 
yields were unsatisfactory (Table 16, Entries 2 and 3 n=2). Literature precedent133 
suggests that the in situ generated alkynylzinc reagent serving as a mild nucleophilic 
reagent can react with aliphatic acyl chloride in a very efficient manner. Compounds (179, 
181, 182 and 183) were prepared by this alkynylzinc method and improved yields were 
observed. From this coupling it was found that the dryness of anhydrous ZnCl2 
substantially affected the yields therefore the anhydrous ZnCl2 must be dried under high 
vacuum at 110 °C for at least 6 h before use. Finally, by using this method, under 
optimized conditions the product yield could reach 73% (Entry 4, n=3). 
 
Table 16. Synthesis of propargylic γ-keto esters and propargylic δ-keto esters. 
 
  n=2 n=3 
Entry R Yield1 (%)(No.)2 Yield1 (%)(No.)2 
1 C6H5 49 (176) 43 (180) 
2 n-C4H9 27 (177) 53 (181) 
3 BnO(CH3)2C 22 (178) 48 (182) 
4 BnO(CH2)2 25 (179) 73 (183) 
1. Isolated yield. 
2. Compound number. 
 
Compound 176 was chosen as a representative structure for optimization of the reaction 
conditions. Solvent effects, different catalysts, catalyst loading and temperature were taken 
into account during the optimization (Table 17). From previous experience in aromatic 
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ketone transfer hydrogenation, catalysts in CH2Cl2 and CH3CN are equally efficient with 
respect to reactivities but 4% of enantioselectivity erosion was observed when CH3CN 
was employed (Table 17, Entries 1 and 2). With regard to catalyst efficiency, one (R,R)-c1 
could transform 50 equivalents of 176 within 15 h with an excellent ee value of 94%. 
Catalyst (R,R)-c2 was more active and could reduce 500 equivalents of 176 within 30 h. 
Further decrease of catalyst loading resulted in incomplete conversion of starting material 
(Table 17, Entry 4) even the reaction time was extended to 144 h. From our previous 
aromatic ketone ATH study, elevated temperature has the beneficial effect of increasing 
the reaction rate while the enantioselectivity is maintained at the same level. Under this 
circumstance, rather than accelerate the reaction, the reaction carried out at 30 °C (Table 
17, Entry 5) gave almost the same conversion and yield as the reaction at room 
temperature (Entry 4). One interesting phenomenon that was found is that catalyst (R,R)-
c2 could convert the first 500 molecules of substrates within 30 h but cannot reduce the 
remaining starting material despite the period of reaction time being extended to 144 h. 
Combined with the results in Entries 4, 5 and 6 there is reason to believe that the catalyst 
has been deactivated during the reaction.  
It is well known that amines are active nucleophilic reagent that can readily react with 
propargylic ketones through Michael addition. In that case if the amine ligand has reacted 
with the starting material by this mechanism it will inevitably cause catalyst inhibition. 
The explanation for why elevated temperature did not provide better conversion is 
probably due to the catalyst poisoning process also being accelerated. At room 
temperature, from the experimental results the activity of catalyst (R,R)-c2 can last for 
more than 7 days in the case of aromatic ketone transfer hydrogenation. The maximum life 
time of catalyst (R,R)-c2 appears to be much shorter and it can only last up to 3 days in the 
case in Table 17. 
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Table 17. Optimization of reaction conditions. 
 
Entry Catalyst Solvent1 S/C 
T 
(°C) 
Time 
(h) 
Conv2 
(%) 
Ee3 
(%) 
Yield4 
(%) 
1 (R,R)-c1 CH2Cl2 50/1 rt  15 100 94 (R)  67  
2 (R,R)-c1 CH3CN 50/1 rt  15 100 90 (R)  78  
3 (R,R)-c2 CH2Cl2 500/1 rt  30 100 94 (R)  89 
4 (R,R)-c2 CH2Cl2 1000/1 rt  144 73 95 (R)  69  
5 (R,R)-c2 CH2Cl2 1000/1 30 144 78 95 (R)  73  
6 (R,R)-c2 CH2Cl2 2000/1 40 144 53 94 (R)  30  
1. The concentration of ketone is 0.15 M and 5 equiv of formic acid was used. 
2. Conversions were determined by isolation of starting materials. 
3. Ee values were determined by chiral HPLC. 
4. Isolated yield. 
 
Taking all these observations into consideration the best reaction conditions were 
determined to be the use of 0.2 mol % of catalyst (R,R)-c2 at room temperature in CH2Cl2 
solution (Table 17, Entry 3). By following these reaction conditions, four propargylic γ-
keto esters (176-179) and four propargylic δ-keto esters (180-183) were tested (Table 18). 
As expected, all the reactions reached full conversion within 72 h using 0.2 mol % of 
catalyst (R,R)-c2. The reactions proceeded smoothly without forming any by-products 
(dehydration or lactonization) at any stage of the reaction as assessed by a TLC test. The 
resulting alcohols (184-191) which were formed as the only products were very easy to 
separate by silica gel column chromatography. HPLC results showed that the reductions of 
both γ-keto esters and δ-keto esters were equally highly stereoselective and up to 99% ee 
was achieved in the best case (Table 18).  
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Table 18. ATH of propargylic γ-keto esters and δ-keto esters. 
 
Entry R(No.)1 n Yield %2 Ee %3 
1 C6H5 (R-184) 2 89 94 
2 n-C4H9 (R-185) 2 89 93 
3 BnO(CH3)2C (R-186) 2 77 99 
4 BnO(CH2)2 (R-187) 2 95 98 
5 C6H5 (R-188) 3 89 96 
6 n-C4H9 (R-189) 3 81 99 
7 BnO(CH3)2C (R-190) 3 84 98 
8 BnO(CH2)2 (R-191) 3 99 99 
1. Compound number. 
2. Isolated yield. 
3. Ee values were determined by chiral HPLC. 
 
2.2.5. Synthesis of 4-Pentyne-1,3-diones and Their ATH Studies. 
4-Pentyne-1,3-diketones were prepared by adopting Coltart’s soft enolization strategy.134 
Simply by a MgBr2·OEt2 and i-Pr2NEt meditated Claisen-type condensation of Bt-amide 
and ketone; the 4-pentyne-1,3-diones (192-195) were formed in good yield (Table 19). 
Later in the project the strategy was modified by using Mg(ClO4)2 instead of MgBr2·OEt2 
which is cheaper and more reasonable for large scale preparation. Although generally a 10% 
drop in yield was observed when Mg(ClO4)2 was employed it was still possible to 
synthesize enough material of good purity for transfer hydrogenation studies.   
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Table 19. Preparation of 4-pentyne-1,3-diones. 
 
Entry R(No.)1 Lewis acid Yield2 (%) 
1 Phenyl(192) MgBr2·OEt2 81 
2 4-Methylphenyl(193) Mg(ClO4)2 66 
3 4-Methoxyphenyl(194) Mg(ClO4)2 72 
4 2-Furanyl(195) Mg(ClO4)2 61 
1. Compound number. 
2. Isolated yield. 
 
The ATH of 1,3-diketones is relatively slow because most of the substrates exist in the 
enol form in solution which is inactive to catalyst.62 From our 1H NMR study, more than 
95% of compound 192 exists as the enol in CDCl3. Since the 1,3-diketone and enol ketone 
exist in a dynamic equilibrium, with the consumption of the diketone more enol ketone 
will converted to diketone through the equilibrium which will eventually lead to the 
complete conversion of all the starting material to product.  
Under standard reduction conditions (HCO2H/TEA 5:2 in CH2Cl2, 10 mol% of (R,R)-c1, 
0.15 M of diketone) 1,5-diphenyl-4-pentyne-1,3-dione 192 was completely consumed 
within 12 h. However the Rf of the product from ATH reaction did not match the Rf of the 
racemic sample from the literature.135 The product 196 from reaction mixture was isolated 
and the structure has been assigned (Figure 73) by comparing the 1H NMR data with that 
reported for this compound in the literature (in the 1H NMR of the compound, all the 
protons can be assigned to aromatic and alkenic proton).136 
Soon it was discovered that compound 192 is very sensitive to acid or base. When treated 
with HCO2H/TEA 5:2 it is able to completely cyclize within 12 h (Figure 73). From the 
stability tests the same cyclization reaction in TEA was even faster and was completed in 
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3 h. Considering that catalysts c1 and c2 have no way of competing with the cyclization 
that happens so rapidly in HCO2H/TEA5:2 solution, the only option is to use base free 
conditions to stop the cyclization. Subsequently 10 mol% of activated catalyst (R,R)-c1 
was loaded into an isopropanol solution of diketone 192 (0.15 M) at room temperature; 
surprisingly even under these base-free conditions the intramolecular cyclized product 196 
can still be observed in considerable quantities despite mild reaction conditions but still no 
diol could be found in the reaction mixture.  
 
Figure 73. Decomposition by intramolecular cyclization of diketone 192. 
According to Cossy,137 aromatic 1,3-diketones are good substrates for transfer 
hydrogenation. Reportedly, in the case of 1,3-diphenyl-propan-1,3-dione, under optimized 
conditions (5.0 mol% of (R,R)-c1, HCO2H/TEA 5:2, CH2Cl2 at 50°C) it could be fully 
reduced within 3.5 h. At room temperature the reaction still proceeds but at a slower rate 
(48 h to reach completion). Compared to aromatic 1,3-diketones although propargylic 1,3-
diketones are known to be  more sensitive, the reason why they are not active to even as 
much as 10 mol% of (R,R)-c1 may be due to the very high proportion of enol isomer in the 
mixture (enol/ketone=35/1 in CDCl3). 
Since the properties of 4-pentyne-1,3-dione and the ATH reaction conditions are not 
compatible, attention was focussed instead on propargylic 1,4-diones and 1,5-diones in the 
hope that the structural changes would bring a beneficial effect. 
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2.2.6. Synthesis of Propargylic 1,4-Diketones and Propargylic 1,5-
Diketones and Their ATH Studies. 
Propargylic 1,4-diketones and propargylic 1,5-diketones were prepared by two strategies 
(Table 20). The first one is the direct attack by alkynyl borane. From this reaction it was 
found that the reactivity of diesters is not high enough; after work-up there was still a large 
amount of diester starting material remaining unreacted. After work-up the resulting 
solution was actually a mixture of diester, mono-replaced keto ester and diketone. The 
yields (Table 20, Entries 1 and 2) are disappointingly low because most of the diester was 
unreacted. Additional difficulty was caused by the similar polarities of diester and 
diketone; significant efforts were required to separate the diketone from the diester by 
column chromatography. The low efficiency of this reaction required the consideration of 
other alternatives and a precedent using a Weinreb amide as starting material was found.138 
Indeed not only were side reactions minimized by using the Weinreb amide, it is more 
likely that the Weinreb amide reacted with two molecules of alkynyl lithinates to result in 
complete conversion and higher yields. Even if there was still Weinreb diamide unreacted, 
the polarity difference between the diamide and the resulting propargylic diketone is 
enough to ensure a facile separation. Some propargylic diketones are unstable (Table 20, 
Entries 6 and 7) at room temperature and decomposed on the silica gel column therefore 
rendering the preparation impossible. Despite the elusive nature of propargylic diketones, 
five examples were prepared for evaluation in ATH studies.  
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Table 20. Synthesis of propargylic 1,4-diketones and propargylic 1,5-diketones by 
two different methods. 
 
Entry R(No.)1 n Yield2 (%) Method 
1 C6H5 (197) 2 26 Reaction 1 
2 C6H5 (198) 3 17 Reaction 1 
3 BnO(CH3)2C (199) 2 43 Reaction 2 
4 BnO(CH3)2C (200) 3 79 Reaction 2 
5 n-C4H9 (201) 2 92 Reaction 2 
63 n-C4H9 3 0 Reaction 2 
73 BnO(CH2)2 2 0 Reaction 2 
1. Compound number. 
2. Isolated yield. 
3. In Entries 6 and 7, compounds are thermodynamically unstable at room temperature. 
 
The five propargylic diketones (197-201) are stable at room temperature and in 
HCO2H/TEA(5/2)/CH2Cl2 solution for several days. The transfer hydrogenation reaction 
was carried out under the same conditions that were used to reduce propargylic γ-keto 
esters and δ-keto esters. 1H NMR spectra illustrate that these diketones can exist 
predominantly in the ketone form (ketone/enol > 20/1 in CDCl3) and therefore should be 
reduced easily. Based on this analysis, the catalyst loading was chosen as 0.5 mol%. From 
the results shown in Table 21, the reactivities of 1,4-diketones and 1,5-diketones are 
similar and both of them were fully reduced within 48 h. Since in the reduction each of the 
diketones has been selected twice the ee values were expectedly high. In all the cases ee 
values were higher than 99% and de values were also excellent (all are above 93%). 
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Table 21. ATH of propargylic 1,4-diketones and 1,5-diketones. 
 
Entry Catalyst R(No.)5 n Yield2 (%) Ee3 (%) De3 (%) 
1 (R,R)-c2 C6H5 (R,R-202) 2 81 >99% 93 
2 (R,R)-c2 n-C4H9 (R,R-203) 2 87 >99% 95 
3 (R,R)-c2 BnO(CH3)2C (R,R-204) 2 83 >99% 96 
4 (R,R)-c2 C6H5 (R,R-205) 3 96 >99% 97 
5 (R,R)-c2 BnO(CH3)2C (R,R-206) 3 86 >99% 97 
6 (S,S)-c2 C6H5 (S,S-202) 2 78 >99% 96 
7 (S,S)-c2 n-C4H9 (S,S-203) 2 82 >99% 93 
8 (S,S)-c2 BnO(CH3)2C (S,S-204) 2 70 >99% 98 
9 (S,S)-c2 C6H5 (S,S-205) 3 81 >99% 97 
10 (S,S)-c2 BnO(CH3)2C (S,S-206) 3 97 >99% 98 
1. The concentration of ketone is 0.15 M and 10 equiv of formic acid were used. 
2. Isolated yield. 
3. Ee values and de values were determined by chiral HPLC. 
4. When (S,S)-c2 was used the absolute configuration of products are (S,S). 
5. Compound number. 
 
Another difficulty raised by the chiral diols is the determination of ee and de values. Since 
the 1H chemical shifts exhibit no difference between chiral and meso diols it was not 
possible to determine the de value by proton NMR. Fortunately the mixture of (R,R)-diol, 
(S,S)-diol and meso-diol could be easily separated by HPLC. Under these circumstances, 
all five propargylic diketones (197-201) were treated with (R,R)-c2 and (S,S)-c2 to prepare 
(R,R) and (S,S) HPLC samples. The results are summarized in Table 21, comparing the 
results achieved from (R,R)-c2 and (S,S)-c2 catalysts; with the exception of the absolute 
configuration of diols, the yields, ee and de values were almost identical. It has been 
proved that propargylic diketones with chain numbers n = 2 and 3 are good substrates for 
transfer hydrogenation under HCO2H/TEA conditions. The reaction is highly efficient and 
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selective during the course of the reduction and no intramolecular cyclization (shown in 
Figure 74) was observed at any stage.    
A stability test was carried out before the propargylic diketone transfer hydrogenation tests 
on the 1,4 and 1,5 diketones. Ketone 207 was chosen to test its stability in typical 
reduction conditions. It was found that after 12 h in HCO2H/TEA (5/2)/CH2Cl2 solution all 
the starting material had been consumed but cyclised and dimerized products were 
identified by EI-MS (Figure 74). Fortunately the HCO2H/TEA (5/2) unstable compound 
207 could be fully reduced in isopropanol under aforementioned base free conditions. 
When studying the 1,4-diketone reduction in HCO2H/TEA it is encouraging that primary 
alcohol and secondary alcohol did not share the same stabilities. As shown in Figure 74 
the primary alcohol 207 is readily cyclised through an intramolecular Michael addition. 
The secondary alcohol intermediate which results from mono-reduction of the diketone is 
more stable than primary alcohol. So it can be concluded that the nucleophilic ability of 
the secondary alcohol is not as high as that of the primary alcohol. Even at the end of the 
transfer hydrogenation in Table 21; no cyclised or dimerized product can be found, thus 
allowing the slightly acidic HCO2H/TEA conditions to be employed to reduce the 1,4-
diketones and 1,5-diketones. 
 
 
Figure 74. Possible intramolecular cyclization as a side-reaction. 
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2.2.7. Asymmetric Total Synthesis of (-)-Yashabushidiol B. 
The chiral β-hydroxy-γ-alkynyl ester scaffold is a very versatile building block because 
both sides of the chiral centre have functional groups which can be modified or extended 
easily. As illustrated in Figure 75, overall hydrogenation by Pd/C and Pt is a very 
convenient and high yielding way to unveil CH2CH2 from C≡C which has been adopted at 
the beginning of the total synthesis of (-)-yashabushidiol B in this project. The alkyne unit 
can also be hydrogenated to the (Z)-alkene by a well established Lindlar catalyst catalyzed 
hydrogenation. The alkene can be further modified by other reactions such as ozone 
oxidation and Sharpless asymmetric dihydroxylation. Furthermore if the R1 group is a silyl 
group then it can be easily removed to release the terminal alkyne or replaced bromine in a 
desilylbromination reaction.  
 
Figure75. Modification of β-hydroxy-γ-alkynyl ester. 
The ester unit can be used as the precursor of a Weinreb amide or aldehyde which could 
couple with a nucleophilic reagent such as Grignard reagents, enol or silyl enol ethers. The 
β-hydroxy-γ-alkynyl ester scaffold which could be prepared by ATH on a gram scale and 
high optical purity easily may therefore be applied broadly in target related synthesis. 
The asymmetric formal synthesis and biological activity of (-)-yashabushidiol B was 
reported by Yang.139 From his report the enantiopure (-)-yashabushidiol B could be 
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obtained from hydrogenation of another natural compound; (3R,5S)-trans-3,5-dihydroxy-
1,7-diphenyl-1-heptene. From his paper, (-)-yashabushidiol B has been proved to possess 
anti-emetic effects in young chicks (50 mg/kg, 47% inhibition).  
The total synthesis of (-)-yashabushidiol B has been reported by Shinde by using the 
chiron approach.140 From the chiral building block which was prepared from D-glucose, 5 
extra steps were required to reach completion. The data of the synthetic (-)-yashabushidiol 
B as well as the natural one provide beneficial references for the total synthesis study and 
structure determination in this project. 
Another route for the total synthesis of (-)-yashabushidiol B has been developed by 
Venkateswarlu.141 A chiron approach was also used, the chiral source being D-mannitol. 
From his paper, a total of 12 steps were required to build the full skeleton of (-)-
yashabushidiol B. Biological evaluation shown that (-)-yashabushidiol B was not highly 
functional against cancer cell lines (IC50 values THP-1 (99.75 μg/mL) U-937 (128.25 
μg/mL) A-375 (144.75 μg/mL)). 
The synthetic plan towards (-)-yashabushidiol B is extremely simple and straightforward. 
The chiron approach was discarded in favour of catalytic asymmetric synthesis to build the 
chiral centres of (-)-yashabushidiol B. The retrosynthesis is shown in Figure 76. From the 
knowledge of the diketone reduction it was known that the C2 symmetry of (-)-
yashabushidiol B could not be built from compound 209 by transfer hydrogenation. Since 
the double transfer hydrogenation is not applicable to propargylic 1,3-diketones it is 
necessary to install the chiral hydroxyl groups sequentially. This approach required five 
steps including two highly efficient hydrogenation reactions and one stereoselective 
transfer hydrogenation from compound R-171. Both the chiral hydroxyl groups (1,3-diol) 
can be introduced by transfer hydrogenation. This strategy is also a protective group-free 
one; the first introduced hydroxyl group can survive five synthetic steps without protection. 
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The free hydroxyl group did not jeopardize the yield of each reaction or the dr values of 
the second transfer hydrogenation. In addition, no dehydration or racemisation was 
observed.  
 
Figure 76. Retrosynthesis of (-)-yashabushidiol B. 
The triple bond of compound R-171 (92% ee) was reduced within 1 h by a 
Pd(OH)2/C catalysed hydrogenation at 1 atm H2 atmosphere. The crude product was 
found to be pure enough to be used directly in the next step without purification. 
Subsequent Weinreb amide formation proceeded smoothly and the product 210 was 
formed in 91% yield over two steps (Scheme 9). This Weinreb amide formation 
reaction was achieved without the need for hydroxyl group protection and gave the 
desired compound as a single product. 
 
Scheme 9. Synthesis of Weinreb amide 210. 
The method from Scheme 9 allowed up to 300 mg of intermediate 210 to be readily 
prepared. With sufficient Weinreb amide in hand, the ketone formation was 
attempted under a range of different conditions. Literature precedent142 suggested 
that decent yields could be achieved when coupling the β-hydroxyl Weinreb amide 
with a Grignard reagent or alkyllithium. However the coupling between 210 and a 
Grignard reagent proved to be troublesome, and a maximum of 10% yield, in 
medium purity, of dihydroyashabushiketol 211 was obtained (Scheme 10). From 
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TLC it was found that extension of the reaction time or an increase in the loading of 
Grignard reagent (minimum 3 equiv to maximum 7 equiv) resulted in disappearance 
of the product spot. Since all starting material had disappeared, it was speculated that 
the coupled intermediate is not stable under the strong basic conditions used. 
 
Scheme 10. Synthesis of dihydroyashabushiketol 211. 
An alternative route (Scheme 11) was required to replace the use of Grignard 
reagent. The formation of ketone 212 was achieved through a published 
procedure,143 when phenylacetylene lithinate were used at low temperature (-78 °C) 
the triple bond-containing product 212 was obtained in 85% yield without 
decomposition. The second chiral hydroxyl group was installed by (R,R)-c2 
catalyzed asymmetric transfer hydrogenation. After work-up the resulting crude diol 
was hydrogenated directly using Pd(OH)2/C (20% w/w) to gave the final product (-)-
yashabushidiol B in excellent yield (98% from two steps). During the course of the 
second ATH reaction there was no evidence of starting material 212 self-
condensation, although reportedly these materials structurally similar with 212 are 
unstable under acidic conditions.144 
 
Scheme 11. Complete the synthesis of (-)-yashabushidiol B. 
The experimental data for the synthetic (-)-yashabushidiol B formed by this route 
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matched that for the natural (-)-yashabushidiol B and synthetic (-)-yashabushidiol B 
prepared by the Shinde group.140 The detailed spectroscopic data are listed in the 
experimental section. 
The dr of (-)-yashabushidiol B was determined to be >20/1 by 1H NMR (Figure 77) 
but the ee value of this compound was still undetermined because of the lack of a 
racemic standard. From the knowledge of 1,4 and 1,5-diketone reduction, if the 
substrate was stereoselectively reduced twice by (R,R)-c2 catalyst the ee value 
should be above 99% but how the chiral β-hydroxyl group will affect the 
diastereoselectivity is unknown. The racemic standard was prepared by the 
procedure shown in Scheme 12 from commercially available 3-phenyl 
propionaldehyde 214. From the 1H NMR analysis of the racemic sample 213 it was 
surprisingly found that the ratio of anti/meso is 5/1 and this result was further 
confirmed by HPLC. Since the final diol was from the ATH of racemic 212 by using 
racemic c1 (ca. 1/1 mixture of (R,R)-c1 and (S,S)-c1 formed by combining the 
optically pure catalysts) the result suggested that  the anti-diol formation was  5 
times as fast as meso-diol formation. From the HPLC results, it was established that 
(-)-yashabushidiol B had been formed with >99% ee and 75/1 dr in the asymmetric 
synthesis.  
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Figure 77. 1H NMR chemical shift of (-)-yashabushidiol B C3-H1. 
1. Left figure: racemic standard from the racemic procedure. Right figure: (-)-yashabushidiol B from the 
asymmetric process. 
 
Scheme 12. Synthesis of racemic yashabushidiol B. 
 
2.3. Asymmetric Transfer Hydrogenation of Diynones. 
2.3.1. Synthetic Design. 
As was the case with the work of asymmetric propargylic ketone reduction, some 
interesting questions were raised such as: can chiral diynols be prepared by ATH? Will the 
diynones exhibit the same behaviour as the ynones which were previously studied? To 
date, the only catalytic pathway to the chiral diynol scaffold is through asymmetric 1,3-
diyne addition to aldehydes. The advantages of this method include straightforward 
anti    meso 
anti       meso 
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pathway design, broad substrate scope and the low cost of catalyst. However the 
requirement for the use of a 1,3-diyne in large excess, coupled to the fact that 1,3-diynes 
may be difficult to prepare and in some cases are  unstable, inevitably makes this reaction 
less efficient. Other drawbacks, for example that the enantioselectivity is highly dependent 
on the structures of the aldehydes, make it difficult to optimize reaction conditions.  
As a part of the propargylic ketone ATH project it seemed desirable to introduce an 
alternative route to the synthesis of the chiral diynol scaffold. More interestingly, the chiral 
diynol scaffold has also been found in a number of natural products. In literature, diynone 
intermediates appear not to be accessible through the reaction of 1,3-diynes and Weinreb 
amides no matter which bases (n-BuLi, t-BuLi or LiNHMDS) are used (Figure 78). 145 
Also, 1,3-diynes are unstable species; very difficult to prepare and purify in a large scale, 
and some are too volatile for manipulation. Therefore the application of 1,3-diynes has 
been limited. Although transfer hydrogenation is highly efficient, an inefficient reaction 
before the ATH will have an adverse influence on the overall efficiency and will reduce 
the value of the applications. Since asymmetric 1,3-diyne addition is a published reaction 
there is probably little advantage to begin from making racemic diynols by 1,3-diyne 
addition. Due to the problems associated with 1,3-diynes and balancing all the synthetic 
routes at the design stage, their use should be avoided if possible. 
 
Figure 78. Unsuccessful approach to diynones. 
 
2.3.2. Synthesis of Diynone Precursors. 
Chiral diynols can be obtained by three consecutive reactions from the design shown in 
Figure 79. The racemic diynols could be prepared from corresponding alkynes and 
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bromoalkynes. The successful preparation of bromoalkynes is a well established route. 
They can be obtained in large scales (form 5.0 mmol to 0.2 mol) and with good purity 
without the need for column purification. In contrast to 1,3-diynes, bromoalkynes are not 
volatile, relatively stable and easy to manipulate at room temperature.  
 
Figure 79. Synthetic plan for preparation of chiral diynols. 
The synthesis of diynones commenced from the coupling reaction between a terminal 
alkyne and a bromoalkyne. As shown in Table 22 the first step requires a well established 
Cadiot-Chodkiewicz cross-coupling which has been proved to be one of the most efficient 
ways of forming 1,3-diyne species. In the Cadiot-Chodkiewicz reaction described, racemic 
1-yne-3-ols are used as coupling reagents which are either commercially available or 
easily accessible via organic synthesis. The oxidation of diynols to diynones is unknown 
and for this reason a strategy (MnO2 oxidation)
146 commonly used to oxidize ynols to 
ynones was applied to this system. Finally, a catalytic ATH which works very well in 
ynone reduction would be used directly and it was hoped that that in the case of diynones 
the same level of efficiency and enantioselectivities would be maintained. 
Eight racemic diynols (215-222) containing different R1 and R2 groups were prepared by 
the Cadiot-Chodkiewicz cross-coupling (Table 22, Reaction 2). Diynols were formed in 
good to excellent yields (72-98%) as single products. No bromoalkyne-bromoalkyne cross 
coupling was observed in the Cadiot-Chodkiewicz reaction. After purification, the 
resulting diynols were oxidized by activated MnO2 powder (Table 22, Reaction 2). 
With the exception of Table 22, Entry 6, in all the other cases clean diynones (223-230) 
were formed as the only products by TLC analysis and were easily isolated using silica gel 
column chromatography. Activated MnO2 power can oxidize diynols preferentially 
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without breaking the electron-rich 1,3-diyne bond or oxidizing the terminal hydroxyl 
(Table 22, Entry 5). In Entry 6, when R2 is equal to CH2C6H5 the resulting ketone is more 
likely to enolize than the rest, therefore it could be further oxidized by MnO2 which would 
explain why the yield in Entry 6 is much lower than the others. In Entry 3 pure diynone 
225 has not been separated because it is highly volatile and was used subsequently as a 
CH2Cl2 solution. 
 
Table 22. Synthesis of diynones. 
 
Entry R1 R2 Step 1  
Yield1 (%)/(No.)3 
Step 2  
Yield1 (%)/(No.)3 
1 C6H5 CH3 90 (215) 98 (223) 
2 BnO(CH3)2C CH3 79 (216) 85 (224) 
3 n-C4H9 CH3 69 (217)  -   (225)
2 
4 n-C4H9 n-C3H7 88 (218) 82 (226) 
5 HO(CH2)4 CH3 98 (219) 90 (227) 
6 n-C4H9 CH2C6H5 72 (220) 25 (228) 
7 BnO(CH2)5C CH3 97 (221) 71 (229) 
8 BnO(CH3)2C i-C3H7 73 (222) 98 (230) 
1. Isolated yield. 
2. This compound was not isolated.  
3. Compound number. 
 
2.3.3. Asymmetric Transfer Hydrogenation of Diynones. 
Initially, 6-phenyl-3,5-hexadiyn-2-one 223 was selected as an example for testing in order 
to establish its behaviour in the ATH reaction. It was quickly found that the ATH of this 
      93 
 
compound is problematic. Ketone 223 is not only sensitive to TEA or HCO2Na but also a 
disfavoured side reaction was detected during attempts at ATH.  
A standard ATH reaction using compound 223 was carried out and monitored by 1H 
NMR. After the reaction, peaks were observed at 5.4 and 6.3 ppm which were identified 
as belonging to alkene. TLC showed a spot close to the spot of 6-phenyl-3,5-hexadiyn-ol 
215. Based on this result it was believed that a competing hydrogen transfer process takes 
place on the dialkyne (Figure 80). 
 
Figure 80. Possible pathway of side reactions. 
In contrast to 6-phenyl-3,5-hexadiyn-2-one 223, when the rest of the ketones were tested 
there were almost no decomposition or alkyne reduction observed during ATH. The 
structure of the side-products shown in Figure 80 were not isolated or determined 
therefore the position of addition of the Ru-H is not known. Although the yield of S-215 is 
low (25%) the ee from the isolated product was 94% which is still very encouraging 
(Table 23, Entry 1). 
Considering that the reduction of alkyne and carbonyl are competing reactions, it was 
reasoned that installing a bulky group at the end of the diyne may slow down the rate of 
alkyne reduction. Ketone 224 bearing a BnO(CH3)2C group (Table 22, Entry 2) was 
tested under the same conditions. Surprisingly this compound 224 was not only stable in 
HCO2H/TEA 5:2/CH2Cl2 solution but also only a trace amount (<5%) of the alkyne 
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reduction product was detected in the 1H NMR spectrum. It appears that the R1 group on 
the diyne side plays a key role in determining the behaviour of the substrates.  
The relatively low stabilities of diynones required an increase of the catalyst loading to 10 
mol% to allow the reaction to finish within a few hours (1 h when (S,S)-c2 was used, 3 h 
when (S,S)-c1 was used). The reduction of diynones with an aliphatic chain gives both 
excellent yield (up to 95%) and ee (up to 99%). In Table 23, Entry 5 even with a free 
hydroxyl group on the side of R1 group, neither the yield nor the selectivity of the 
reduction is compromised. 
 
Table 23. ATH of diynones. 
 
Entry R1 R2/(No.)
4 Yield1,3 (%) ee2,3 (%) 
1 C6H5 CH3 (S-215) 25 94 
2 BnO(CH3)2C CH3 (S-216) 86(82) 94(93) 
3 n-C4H9 CH3 (S-217) 94(75) 97(97) 
4 n-C4H9 n-C3H7 (S-218) 91(95) 97(98) 
5 HO(CH2)4 CH3 (S-219) 89(96) >90 (>90) 
6 n-C4H9 CH2C6H5 (S-220) 90(92) 97(98) 
7 BnO(CH2)5C CH3 (S-221) 85(76) 95(90) 
8 BnO(CH3)2C i-C3H7 (S-222) 79(95) 96(99) 
1. Isolated yield. 
2.  Ee values were determined by chiral HPLC. 
3. Figures in brackets are yields and ees achieved by using catalyst (S,S)-c2. 
4. Compound number. 
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2.3.4. Asymmetric Total Synthesis of Panaxjapyne A. 
Panaxjapyne A-C were isolated in 2010 as secondary metabolites from the roots of Panax 
japonicus C. A. Meyer var. major alongside four other closely structurally related 
compounds. The structure of panaxjapyne A was determined by extensive NMR and 
HRMS studies. Structurally, panaxjapyne A combines a highly light and heat-sensitive 
diyneol and a skipped enyne subunit which are quite synthetically challenging to construct 
(Figure 81). In this section, a catalytic asymmetric transfer hydrogenation reaction of 
diynones is described, which allows panaxjapyne A to be an ideal target to demonstrate 
the power of diynone ATH. 
 
Figure 81. The composition of panaxjapyne A. 
To build the full skeleton of panaxjapyne A, the synthetic plan was to first obtain the key 
intermediate, a skipped enyne 234. Then by a well-established and reliable desilyl-
bromination and Cadiot-Chodkiewicz cross-coupling reaction, it will be possible to build 
the full structure of racemic panaxjapyne A (Figure 82). Since a very efficient method for 
converting the racemic diynol to enantio-enriched one has been developed, it was 
anticipated that the late stage installation of the C-3 chirality would be possible without 
significant difficulty.   
 
Figure 82. Retrosynthesis of panaxjapyne A. 
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The initial attempt at making the key intermediate 234 started from commercially 
available 2-decyn-1-ol 231 (Scheme 13). Compound 233 was prepared by known 
procedures. Treatment of alcohol 231 with Lindlar’s catalyst and quinoline under a 1 atm 
H2 atmosphere afforded the (Z)-alkene 232 in excellent yield and good Z selectivity. 
Under standard bromination conditions, the hydroxyl group was replaced by Br. With 
sufficient material in hand, a coupling reaction was used as the third step to build the 
skipped enyne scaffold. Although previous publications147 have highlighted the problem 
of low regioselectivity during the allyl bromide species coupling with 
ethynyltrimethylsilane (2.5/1 by using CuI, K2CO3, Et4NCl, DMF coupling condition by 
Rai, 3/1 by using CuI, K2CO3, NaI, DMF coupling condition by Trost), as the most 
straightforward approach it was considered to be worthy of investigation. The TMS-
acetylene Grignard reagent and bromoalkene were coupled together successfully using a 
CuCN catalyzed reaction reported by Zezschwitz.147b, 147cAccording to the author, when 
(E)-bromoalkene was used, only one regioisomer was found in his case, a result which 
matched that reported in Braddock’s paper.148 A subsequent 1H NMR study showed that 
the regioisomers 234 and 235 were formed as a ca.1:1 mixture. It is speculated that the 
ratio of regioisomers is relatively independent of the coupling conditions but can be 
significantly affected by the (E)/(Z) structural difference in the bromoalkenes. All efforts 
failed when trying to isolate the desired regioisomer 234 from the undesired one 235 and 
this led to the requirement for the development of another route.  
 
Scheme 13. Synthesis of panaxjapyne A - an initial attempt. 
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An alternative route was developed (Scheme 14) in an attempt to avoid the formation of 
regioisomers. 1-Iodo-2-decyne 236 was prepared by a standard procedure in high yield 
using the combination of I2, PPh3 and imidazole. The resulting product was combined with 
ethynyltrimethylsilane in a Sonogashira coupling.149 By using the procedure reported by 
Prati et al it was found that compound was formed as a single regioisomer by 1H NMR, 
and in good yield (74%). The skipped diyne 237 however is unstable and therefore needs 
to be used freshly or stored in hexane at low temperature.  
 
Scheme 14. Synthesis of skipped diyne 237. 
A regio and Z-selective hydrogenation using a P-2 Ni catalyst150 was adopted to prepare 
(4Z)-4-dodecen-1-ynyltrimethylsilane 234 (Scheme 15). The reaction is highly 
regioselective but to achieve the highest yield and Z/E selectivity it was found that the in 
situ generated P-2 Ni has to be poisoned by ethylenediamine for at least 1.5 h and the 
reaction must be completed in 1 h. The yield decreased (33%) when the reaction was 
extended to 3.5 h, probably due to the base sensitivity of the TMS acetylene. The highest 
Z/E selectivity measured by 1H NMR was Z/E=23/1; however, decreasing the poisoning 
time caused a drop in the Z/E selectivity. Subsequent AgF and NBS meditated 
desilylbromination gave the corresponding bromoalkyne 238 in excellent yield (93%).  
A highly efficient Cadiot-Chodkiewicz cross-coupling151 was used to link bromoalkyne 
238 and 1-pentyn-3-ol together. Under the conditions modified by Marino,152 the coupling 
was completed within 30 min and racemic panaxjapyne A ±-239 was isolated as the only 
product. Activated MnO2 power served as an efficient oxidative reagent to oxidize the 
propargylic alcohol and was utilized to oxidize the diynols. The MnO2 oxidation was clean, 
and when the reaction was finished, only the product 240 spot could be detected by TLC. 
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At the final stage a very chemo and stereoselective ATH was performed by using 10 mol% 
of catalyst (S,S)-c2 and the final product panaxjapyne A 239 was isolated in 85% yield and 
96% ee (determined after modification see experimental part). The ee value of the 
synthetic panaxjapyne A was determined using three methods. The ee was shown to 
be>90% using a modified Mosher ester method and ca. ee 95% by HPLC analysis of 
racemic panaxjapyne A against the chiral panaxjapyne A. To have better resolution, the 
enantioselectivity was determined by chiral HPLC to be of 96% ee by analysis of 4-
methoxybenzonate derivative of racemic panaxjapyne A and chiral panaxjapyne A. 
 
Scheme 15. Completion of the synthesis of panaxjapyne A. 
The experimental data for the synthetic panaxjapyne A, including 1H NMR, 13C NMR, 
optical rotation and Mosher ester were consistent with those reported for the natural 
panaxjapyne A. The absolute configuration of panaxjapyne A prepared by ATH was 
assigned to be (S) by comparing the natural panaxjapyne A Mosher ester, with racemic 
and enantio-enriched panaxjapyne A Mosher ester 1H NMR spectra (Table 24) of the 
compounds prepared in this project. (S)-Mosher acid was used to synthesize the analytical 
sample. According to Wu’s99 assignment of natural panaxjapyne A, the chemical shift of 
(R)-MTPA ester minus (S)-MTPA ester are: H-1 (-0.026 ppm), H-2 (-0.068 ppm) and H-8 
(+0.005 ppm). Based on this chemical shift difference the absolute structure of natural 
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panaxjapyne A was assigned to be (S). Although there are few publications153 available 
involving the absolute structure determination of diynols using a modified Mosher ester 
method, based on the general principal established by Kakisawa,154 the absolute structure 
of the synthetic panaxjapyne A prepared herein can be assigned unambiguously (Table 
25). 
 
Table 24. 1H NMR and 13C NMR of natural panaxjapyne A and synthetic panaxjapyne A. 
1H 
(ppm) 
Natural 
panaxjapyne A 
Synthetic 
panaxjapyne A 
13C 
(ppm) 
Natural 
panaxjapyne A 
Synthetic 
panaxjapyne A 
H-1 1.00, t (7.4) 1.01, t (7.4) C-1 9.3 9.3 
H-2 1.72, m 1.79-1.69, m C-2 30.7 30.7 
H-3 4.34,t (6.0) 4.36, q (6.1) C-3 64.0 64.1 
H-8 3.01, d (6.8) 3.03, d (6.9) C-4 76.7 76.7 
H-9 5.49, dt (6.8) 5.55-5.47, m C-5 69.9 69.9 
H-10 5.36, dt (10.4, 7.0) 5.42-5.34, m C-6 79.5 79.6 
H-11 2.01, q (7.0) 2.02, q (7.1) C-7 64.1 64.1 
H-12 1.35, m 1.40-1.22, m C-8 17.6 17.7 
H-13 1.27, m 1.40-1.22, m C-9 122.0 122.0 
H-14 1.27, m 1.40-1.22, m C-10 133.0 133.0 
H-15 1.27, m 1.40-1.22, m C-11 27.2 27.2 
H-16 1.27, m 1.40-1.22, m C-12 29.2 29.2 
H-17 0.99, t (6.6) 0.88, t (7.0) C-13 29.2 29.2 
   C-14 29.2 29.2 
   C-15 31.8 31.8 
   C-16 22.6 22.7 
   C-17 14.1 14.1 
1. 13C (125 MHz) and 1H NMR (500 MHz) spectroscopic data reported for natural panaxjapyne A in CDCl3. 
13C (100 MHz) and 1H NMR (400 MHz) spectroscopic data for synthetic panaxjapyne A in CDCl3.  
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Scheme 16. Synthesis of panaxjapyne A (S)-MTPA ester. 
 
Table 25. 1H NMR Difference between R and S panaxjapyne A Mosher ester. 
H (S)-panaxjapyne A (S)-Mosher ester (±)-panaxjapyne A(S)-Mosher ester 
H-1 0.93, t, J 7.4 0.93, t, J 7.4/1.03, t, J 7.4 
H-2 1.86-1.78, m 1.85-1.78, m/1.92-1.78, m 
H-3 5.54, t, J 6.4  5.54, t, J 5.9/5.51, t, J 6.5 
OCH3 3.59, s 3.59, s/3.55, s 
H-8 3.04, d, J 6.9 3.04, d, J 6.5 
1.  1H NMR (400 MHz) spectroscopic data for Mosher esters in CDCl3. 
 
2.4. Synthesis of Chiral 1-(2’-Naphthyl)ethyl-(4-phenylbenzoate) and 
Scanning Tunnelling Microscopy (STM). 
2-Acetonaphthone 240 was reduced independently by (R,R)-c2 and (S,S)-c2 at 0.05 mol% 
catalyst loading under standard transfer hydrogenation conditions (Scheme 17). The 
resulting chiral 1-(2’-naphthyl)ethanol (S-241 and R-241) were formed in similar yields 
and ee values; 96%, 93% ee from catalyst (R,R)-c2 and 97%, 93% ee from (S,S)-c2. The 
absolute configurations of were determined by comparison of the optical rotations and GC 
retention times with reported values.155 
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Scheme 17. ATH of 2-acetonaphthone by using catalyst c2. 
The 93 % ee 1-(2’-naphthyl)ethanol (S-241 and R-241) were used for esterfication with 4-
phenylbenzoyl chloride 242 (Scheme 18). Both (R) and (S) 1-(2’-naphthyl)ethyl-4-
phenylbenzoate 243 were formed as solids in satisfactory yields. Simply by a 
recrystallization from hexane/CH2Cl2 (6/1) the ee value was increased to >99 %. The ee 
values of esters S-243 and R-243 were determined by HPLC. From 1H NMR analysis, the 
sample after recrystallization is pure enough for the planned scanning tunnelling 
microscopy imaging experiments.  
 
 Scheme 18. Synthesis of chiral 1-(2’-naphthyl)ethyl-4-phenylbenzoate 243. 
Scanning tunnelling microscopy has developed into a useful tool for molecular 
characterisation over recent years. Specifically, there have been many instances 
where the chirality of molecules has been inferred from molecular packing or has 
been imaged unambiguously with the STM. STM can also be used to view the 
starting materials and products of reactions on surfaces. Considering the imaging of 
enantio-enriched molecules is an interesting subject chiral compounds S-243 and R-
243 were prepared and the behaviours were studied under scanning tunnelling 
microscopy. 
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The STM experimentation was carried out on the single crystal surfaces Cu(110) and  
Au(111) respectively. On the Cu(110) surface at rt, ester was found unable to be 
imaged due to the copper reduce it to the two corresponding primary alcohols. The 
proposed mechanism suggests the decomposition based on the dissociative 
adsorption along the RO-CRO bond to generate the RO(Cu) and RC(Cu)O species 
which then undergo hydrogenation to generate the alcohols. When was deposited on 
Cu(110) that holding at -140 °C only 20% of the molecules have fragmented (Figure 
83, picture middle). 
  
Figure 83. Possible main conformations and STM image. 
1. Picture left is computer predicted two possible main conformations of molecule S-243.   
2. Picture middle is the STM image that sample S-243 was deposited at -140 °C on Cu(110) surface; 
the two main conformations were highlighted in this image. 
3. Picture right is the STM image that sample S-243 was deposited at -196 °C on Au(111) surface; 
 
In contrast to Cu(110),  Au(111) did not show any type of dissociation on the surface 
because it is more inert and (111) as the most compacted therefore less reactive 
orientation. The ester which contains two structurally distinct extended aromatic ring 
systems, each of which has the potential to bind to a surface and therefore to 'hold 
down' the molecule in a predictable conformation with the methyl substituent 
oriented out of the plane (Figure 83, picture right).. On the surface there are two 
favoured conformations of the ester 90° lobes and 130° lobes (Figure 83, picture left). 
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The scanning tunnelling microscopy analysis was carried out by Ben. Moreton under the 
supervision of Dr Giovanni Costantini. The results from this study were published as part 
of a collaborative project.156 
 
2.5. Conclusions 
A group of functionalized aromatic ketones (98-110, 112 and 113) were prepared and 
subjected to asymmetric transfer hydrogenation tests. For this group of compound, high 
enantioselectivities (up to 99% ee) were found in most of the examples. To demonstrate 
the use of this transformation, one of the products R-114 was used in the total synthesis of 
yashabushitriol 129.   
Propargylic α-keto esters (138-140), β-keto esters (160-162 and 143, 144), β-keto 
thioesters (141 and 142), α-methyl-β-keto esters (163-166), γ-keto esters (176-179), δ-keto 
esters (180-183), 4-pentyne-1,3-diones (192-195), 1,4-diketones (197, 199 and 201)  and 
1,5-diketones (198 and 200) were prepared and subjected to asymmetric transfer 
hydrogenation. In general, high ee, dr values and yields were achieved and the behaviour 
of the different propargylic ketones was fully understood. The method also serves as a key 
step in the total synthesis of yashabushidiol B 213. 
The first asymmetric transfer hydrogenation of diynones (223-230) was investigated. In 
general, high ee values (up to 99% ee) and yields (up to 95% yield) were achieved. The 
yields were highly dependent on the structures/stabilities of diynones while the ee values 
were not. ATH of diynones was also used in the total synthesis of panaxjapyne A 239.  
More application including synthesis of highly optically pure ester 1-(2’-naphthyl)ethyl-4-
phenylbenzoate 243 (>99% ee) for scanning tunnelling microscopy imaging was 
described.  
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3. Experimental Section. 
General Remarks 
Unless otherwise stated, all reactions were performed using dry solvents and under 
an atmosphere of nitrogen. Reactions were monitored by thin layer chromatography 
(TLC) using silica gel 60 (F254) aluminium plate; visualised using UV254 lamp or 
potassium permanganate dip. NMRs were measured by either a Bruker DPX-300 
(300 MHz) or a Bruker DPX-400 (400 MHz). All NMR δ values are in ppm and all J 
values are in Hz. Low resolution mass spectrometry was run on a Bruker Esquire 
2000 electrospray mass spectrometer. High resolution mass spectrometry was run on 
Bruker MicroTOF. Melting points were obtained using a Stuart Scientific Melting 
Point SMP1 and are uncorrected. Infrared spectroscopy was run on a PerkinElmer 
Spectrum 100. Optical rotation was obtained from an Optical Activity Ltd. AA-1000 
Polarimeter. GC was run on a Hewlett Packard 5890 gas chromatograph linked to a 
Hewlett Packard HP3396A integrator and column chrompaccyclodextrin-β-236M-19 
50 m. HPLC was run on a chromatograph consisting of a Gilson 305 Piston Pump, a 
Gilson 805 Manometric Module, a Gilson 811B Dynamic Mixer and a Gilson 115 
Variable Wavelength Detector linked to a Hewlett Packard 3396 Series II integrator. 
 
3.1. Synthesis of Acid Monoesters and Acid Chloride Monoesters. 
Propanedioic acid, methyl ester 147. This compound is known and has been fully 
characterized.157a 
 
Dimethyl malonate (39.60 g, 299.8mmol), acetonitrile (3 cm3) and water (25 cm3) were 
added together and the mixture was stirred at 0 °C for 30 min. KOH (60 cm3, 5 M aqueous 
solution, 0.3 mol) solution was added dropwise within 15 min with vigorous stirring and 
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the resulting mixture was stirred for another hour. The mixture was extracted with 
EtOAc/hexane (2 × 150 cm3, 1:2 mixture) followed by addition of aqueous HCl (38 cm3, 
12 M solution) and the resulting solution was saturated with NaCl and extracted with 
EtOAc (4 × 200 cm3).The combined organic phase was washed with sat NaCl solution 
(100 cm3), and dried over sodium sulfate. After vacuum concentration, the crude product 
was distilled under reduced pressure (88-96 °C, 1-2 bar) to afford pure monomethyl 
malonate as a colourless oil (25.3 g, 214 mmol, 71%) and a mixture of dimethyl malonate, 
monomethyl malonate and water as the other fraction (<6% w/w).H (400 MHz, CDCl3) 
3.79 (3H, s, CH3), 3.46 (2H, s, CH2). 
 
2-Methyl-propanedioic acid, ethyl ester 148. This compound is known and has been 
fully characterized.157b 
 
Diethyl methylmalonate (34.8 g, 200 mmol), acetonitrile (3 cm3) and water (25 cm3) was 
added together and the mixture was stirred at 0 °C for 30 min. KOH (60 cm3, 5 M aqueous 
solution, 0.3 mol) solution was added dropwise within 15 min with vigorous stirring and 
the resulting mixture was stirred for another hour. The mixture was extracted with 
EtOAc/hexane (2 × 150 cm3, 1:2 mixture) followed by addition of aqueous HCl (24 
cm3,12 M solution) and the resulting solution was saturated with NaCl and extracted with 
EtOAc (4 × 200 cm3). The organic phase was washed with sat NaCl solution (100 cm3), 
then dried over sodium sulfate. After vacuum concentration, the crude product was 
distilled under reduced pressure to afford the pure product as a colourless oil (19.9 g, 0.136 
mmol, 68 %). H (400 MHz, CDCl3) 4.23 (2H, q, J 7.2, COOCH2), 3.48 (1H, q, J 7.3, CH), 
1.46 (3H, d, J 7.3, CHCH3), 1.29 (3H, t, J 7.2, CH2CH3). 
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Butanedioic acid, monomethyl ester 149. This compound is known and has been fully 
characterized.158 
 
Succinic anhydride (20.0 g, 200 mmol), CHCl3 (30 cm
3) and anhydrous methanol (7.68 g, 
240 mmol) were refluxed for 4 h. Solvent and the excess methanol were removed under 
reduced pressure and the crude product was used without purification. H (400 MHz, 
CDCl3) 3.71(3H, s, CH3), 2.72-2.68 (2H, m, CH2), 2.65-2.62 (2H, m, CH2).   
 
Pentanedioic acid, monomethyl ester 150. This compound is known and has been fully 
characterized.158 
 
Glutaric anhydride (22.8 g, 200 mmol), CHCl3 (30 cm
3) and anhydrous methanol (7.68 g, 
240 mmol) were refluxed for 5 h. Solvent and the excess methanol was removed under 
reduced pressure and the crude product was used without further purification. H (400 
MHz, CDCl3) 3.69 (3H, s, CH3), 2.47-2.39 (4H, m, CH2CO), 2.00-1.93 (2H, m, CH2).   
 
3-Chloro-3-oxo-propanoic acid, methyl ester 151. This compound is known and has 
been fully characterized.159 
 
Propanedioic acid, monomethyl ester (2.36 g, 20.0 mmol) and SOCl2 (4.76 g, 2.92 cm
3, 
40.0 mmol) were warmed to 30-35 °C for 18 h. The excess thionyl chloride was removed 
and the crude product was distilled into a collecting flask cooled by a dry ice/acetone bath 
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to afford product 151 (20-24 °C, 1 mm Hg) as colourless liquid (2.33 g, 17.1 mmol, 85%). 
H (400 MHz, CDCl3) 3.86 (2H, s, CH2), 3.79 (3H, s, COOCH3). 
 
2-Methyl 3-chloro-3-oxo-propanoic acid, ethyl ester 152. This compound is known and 
has been fully characterized.159 
 
Propanedioic acid, 2-methyl-1-ethyl ester (2.92 g, 20.0 mmol) and SOCl2 (4.76 g, 2.92 
cm3, 40.0 mmol) were warmed to 30 °C for 20 h. The excess thionyl chloride was 
removed and the crude product was distilled into a collecting flask cooled by a dry 
ice/acetone bath to afford product 152 (38-40 °C, 1 mm Hg) as a colourless liquid (2.65 g, 
16 mmol, 80%). H (400 MHz, CDCl3) 4.19(2H, qd, J 7.1 2.8, COOCH2), 3.78 (1H, q, J 
7.2, CH), 1.46 (3H, d, J 7.2, CHCH3), 1.24 (3H, t, J 7.1, CH3). 
 
4-Chloro-4-oxo-butanoic acid, methyl ester 153. This compound is known and has been 
fully characterized.160 
 
Butanedioic acid, monomethyl ester (23.1 g, 200 mmol) and SOCl2 (47.2 g, 29.2 cm
3, 400 
mmol) was warmed to 35 °C for 3 h. The excess thionyl chloride was removed and the 
crude product was distilled into a collecting flask cooled by a dry ice/acetone bath to 
afford product 153 (38-40 °C, 1 mm Hg) as a colourless liquid (24.35 g, 161.8 mmol, 
82%). H (400 MHz, CDCl3) 3.72(3H, s, COOCH3) 3.23 (2H, t, J 6.7, CH2), 2.69 (2H, t, J 
6.7, CH2).   
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5-Chloro-5-oxo-pentanoic acid, methyl ester 154. This compound is known and has 
been fully characterized. 160 
 
Pentanedioic acid, monomethyl ester (13.2 g, 100 mmol) and SOCl2 (23.6 g, 14.6 cm
3, 
200mmol) was wormed to 35 °C for 3 h. The excess thionyl chloride was removed and the 
crude product was distilled into a collecting flask cooled by a dry ice/acetone bath to 
afford product 154 (49-52 °C, 1 mm Hg) as a colourless liquid (14.81g, 90.0 nmol, 90%). 
H (400 MHz, CDCl3) 3.67 (3H, s, COOCH3) 2.98 (2H, t, J 7.1, CH2), 2.29 (2H, t, J 7.1, 
CH2), 1.99-1.90 (2H, m, CH2). 
 
3.2. Synthesis of Weinreb Diamides. 
N,N’-Dimethoxy-N,N’-dimethylsuccinamide 155. This compound is known and has 
been fully characterized.161 
 
Triethylamine (1.44 g, 14.3 mmol) was added to a stirred suspension of N,O-
dimethylhydroxylamine hydrochloride (720 mg, 7.38 mmol) in CH2Cl2 (30 cm
3) and the 
solution was cooled to -30 °C, succinyl chloride (545 mg, 3.52 mmol) in CH2Cl2 (3 cm
3) 
was added dropwise. After 2 h, the solution was allowed to warm up to room temperature 
for another 1 h and quenched with saturated aqueous NaHCO3 (10 cm
3). The layers were 
separated and the aqueous layer extracted with CH2Cl2 (2 × 20 cm
3). The combined 
organic extracts were washed with brine (5 cm3) and dried over MgSO4. The crude 
product was purified by silica gel column chromatography (eluent CH2Cl2) to give pure 
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product 155 (684 mg, 3.35 mmol, 95%) as a white solid. H (400 MHz, CDCl3) 3.74 (6H, 
s, 2 × OCH3), 3.19 (6H, s, 2 × CH3), 2.78 (4H, s, 2 × CH2). 
 
N,N’-Dimethoxy-N,N’-dimethylglutaramide 156. This compound is known and has 
been fully characterized. 161 
 
Triethylamine (1.43 g, 14.3 mmol) was added to a stirred suspension of N,O-
dimethylhydroxylamine hydrochloride (720 mg,  7.38 mmol) in CH2Cl2 (30 cm
3) and the 
solution was cooled to 0 °C. Glutaryl chloride (591 mg, 3.50 mmol) in CH2Cl2 (5 cm
3) 
was then added dropwise. After 2 h, the solution was allowed to warm up to room 
temperature overnight and quenched with saturated aqueous NaHCO3 (10 cm
3). The 
layers were separated and the aqueous layer extracted with CH2Cl2 (2 × 20 cm
3). The 
combined organic extracts were washed with brine (5 cm3) and dried over MgSO4. The 
crude product was purified by silica gel column chromatography (eluent 
CH2Cl2/EtOAc=2:1) to afford the pure Weinreb diamide 156 (700 mg, 3.2 mmol, 92%) as 
a brown oil. H (400 MHz, CDCl3) 3.61 (6H, s, 2 × OCH3), 3.11 (6H, s, 2 × CH3), 2.45 
(4H, t, J 7.1, 2 × COCH2), 1.91 (2H, p, J 7.1, CH2). 
 
3.3 Synthesis of Thioesters. 
General Procedure 
 
To a stirred mixture of acid chloride (1 mmol) and thiol (1 mmol), zinc oxide powder (0.5 
mmol, variable) was added carefully at rt. Stirring was continued for 1 h and CH2Cl2 (10 
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mL) was added, zinc oxide was filtered off and washed with more CH2Cl2 (20 cm
3). The 
combined organic phase was washed with sat NaHCO3 (5 cm
3), brine (5 cm3) and dried 
over anhydrous MgSO4. Removal of the solvent under reduced pressure furnished product 
pure enough for next step. 
 
S-Phenyl thiopropionate 157. This compound is known and has been fully 
characterized.162 
 
This compound was prepared following the general procedure above using propionyl 
chloride (1.85 g, 20.0 mmol), thiophenol (2.20 g, 20.0 mmol) and zinc oxide (0.82 g, 10.0 
mmol). The product 157 was isolated as described above as a colourless oil (2.86 g, 17.2 
mmol, 86%). H (400 MHz, CDCl3) 7.42-7.38 (5H, m, Ph), 2.68 (2H, q, J 7.5, CH2), 1.23 
(3H, t, J 7.5, CH3). 
 
S-Phenyl thioacetate 158. This compound is known and has been fully characterized. 162 
 
This compound was prepared following the general procedure above using acetyl chloride 
(7.85 g, 100 mmol), thiophenol (11.0 g, 100 mmol) and zinc oxide (2.0 g, 24.6 mmol). 
The product 158 was isolated as described above as a colourless oil (13.90 g, 91.4 mmol, 
92%). H (400 MHz, CDCl3) 7.43-7.38 (5H, m, Ph), 2.41 (3H, s, CH3). 
 
S-Ethyl thioacetate 159. This compound is known and has been fully characterized. 162 
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This compound was prepared following the general procedure above using acetyl chloride 
(4.40 g, 56.0 mmol), ethylthiol (3.31 g, 53.4 mmol) and zinc oxide (2.20 g, 27.0 mmol). 
The product 159 was isolated as described above as a colourless oil (4.68 g, 44.9 mmol, 
84%). H (400 MHz, CDCl3) 2.87 (2H, q, J 7.4, CH2), 2.32 (3H, s, CH3), 1.25 (3H, t, J 7.4, 
CH2CH3). 
 
3.4. Synthesis of N-Acylbenzotriazoles. 
General Procedure [1] 
 
Benzotriazole (5.95 g, 50.0 mmol) in dichloromethane (100 cm3) was cooled to 0 °C and 
triethylamine (9.0 cm3, 60.0 mmol) was added, followed by addition of the acid chloride 
(55.0 mmol). The mixture was stirred at room temperature for 30 min then HCl (2 M, 50 
cm3) was added to the mixture. The aqueous phase was extracted with dichloromethane 
once (50 cm3) and the combined organic phase was washed with sat Na2CO3 (2 × 30 cm
3), 
brine (30 cm3) and dried over anhydrous MgSO4. The solvent was evaporated and the 
product was dried under vacuum before use. 
 
1-o-Bromobenzoylbenzotriazole 83. This compound is novel. 
 
This compound was prepared following the general procedure above using benzotriazole 
(1.19 g, 10.0 mmol), triethylamine (1.8 cm3, 12.0 mmol) and o-bromobenzoyl chloride 
(2.4 g, 11.0 mmol). The product was isolated as described above as light yellow crystals 
(2.9 g, 9.6 mmol, 96%). MP 59 °C; (found (ESI): M+ + Na, 323.9743. C13H8N3O
79Br 
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requires M, 323.9748); νmax 1721, 1355, 1285, 1046, 1031, 934, 885, 744, 732, 686 cm-1; 
H (300 MHz, CDCl3) 8.42 (1H, d, J 8.3, Ar), 8.06 (1H, d, J 8.3, Ar), 7.77-7.72 (2H, m, 
Ar), 7.65-7.45 (4H, m, Ar); C (75 MHz, CDCl3) 166.5, 146.3, 135.1, 133.3, 132.6, 131.3, 
130.8, 130.1, 127.3, 126.7, 120.6, 120.4, 114.5; m/z (EI-MS) 323.9 (M+Na)+.  
 
1-o-Toluoylbenzotriazole 84. This compound is known but not fully characterized.163 
 
This compound was prepared following the general procedure above using benzotriazole 
(3.96 g, 33.0 mmol), triethylamine (6.0 cm3, 39.6 mmol) and o-toluoyl chloride (5.6 g, 
36.3 mmol). The product was isolated as described above as white crystals (7.8 g, 33 
mmol, 99%). MP 112 °C; (found (ESI): M+ + Na, 260.0794. C14H11N3O requires M, 
260.0799); νmax 1703, 1358, 1286, 1045, 933, 889, 750, 729 cm-1; H (300 MHz, CDCl3) 
8.40 (1H, d, J 8.1, Ar), 8.15 (1H, d, J 8.1, Ar), 7.71 (1H, t, J 7.3, Ar), 7.64 (1H, d, J 7.3, 
Ar), 7.58-7.49 (2H, m, Ar), 7.38-7.33 (2H, m, Ar), 2.42 (3H, s, CH3); C (75 MHz, CDCl3) 
167.7, 145.5, 137.4, 131.7, 131.3, 131.2, 130.5, 129.8, 129.5, 125.8, 124.9, 119.7, 114.0, 
19.5; m/z (EI-MS) 260.1 (M+Na)+. 
 
1-(2-Furanylcarbonyl)benzotriazole 85. This compound is known and has been fully 
characterized.164 
 
This compound was prepared following the general procedure above using benzotriazole 
(3.96 g, 33.0 mmol), triethylamine (6.0 cm3, 39.6 mmol) and 2-furoyl chloride (4.7 g, 36.3 
mmol). The product was isolated as described above as white crystals (7.1 g, 33 mmol, 
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99%). H (300 MHz, CDCl3) 8.42 (1H, d, J 8.3, Ar), 8.19-8.15 (2H, m, Ar), 7.88 (1H, d, J 
1.7, Ar), 7.73-7.68 (1H, m, Ar), 7.58-7.53 (1H, m, Ar), 6.74 (1H, dd, J 3.7, 1.7, Ar); C (75 
MHz, CDCl3) 155.0, 149.0, 145.6, 144.6, 132.1, 130.5, 126,4, 124.8, 120.2, 114.7, 130.0; 
m/z (EI-MS) 236.1 (M+Na)+. 
 
1-p-Toluoylbenzotriazole 86. This compound is known and has been fully 
characterized.164 
 
This compound was prepared following the general procedure above using benzotriazole 
(2.00 g, 16.5 mmol), triethylamine (3.0 cm3, 19.8 mmol) and p-toluoyl chloride (2.8 g, 
18.2 mmol). The product was isolated as described above as white crystals (3.9 g, 16.4 
mmol, 99%). H (300 MHz, CDCl3) 8.37 (1H, d, J 8.1, Ar), 8.17 (1H, d, masked, Ar), 8.14 
(2H, d, J 7.8, Ar), 7.70 (1H, dd, J 7.7, 7.5, Ar), 7.54 (1H, d, J 8.1, 7.5, Ar), 7.38 (2H, d, J 
7.8, Ar), 2.50 (3H, s, CH3); C (75 MHz, CDCl3) 166.6, 144.9, 132.4, 131.9, 130.3, 129.2, 
128.6, 126.2, 124.8, 120.1, 114.8, 21.8; m/z (EI-MS) 260.1 (M+Na)+. 
 
1-p-Fluorobenzoylbenzotriazole 87. This compound is novel. 
 
This compound was prepared following the general procedure above using benzotriazole 
(3.64 g, 30.6 mmol), triethylamine (5.5 cm3, 36.7 mmol) and p-fluorobenzoyl chloride 
(5.34 g, 33.6 mmol). The product was isolated as described above as white crystals (8.0 g, 
29 mmol, 96%). MP 118 °C; (found (ESI): M+ + Na, 264.0544. C13H8FN3O requires M, 
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264.0549); νmax 1708, 1366, 1288, 1228, 1039, 935, 845, 748 cm-1; H (300 MHz, CDCl3) 
8.35 (1H, d, J 8.2, Ar), 8.31-8.27 (2H, m, Ar), 8.14 (1H, d, J 8.2, Ar), 7.71-7.66 (1H, m, 
Ar), 7.56-7.51 (1H, m, Ar), 7.27-7.21 (2H, m, Ar); C (75 MHz, CDCl3) 167.2, 164.7, 
163.8, 134.0 (d, J 9.5), 131.7, 129.9, 127.0, 125.8, 119.6, 115.2, 114.2 (d, J 22.1); m/z (EI-
MS) 264.1 (M+Na)+. 
 
1-p-Methoxylbenzoylbenzotriazole 88. This compound is known and has been fully 
characterized.165 
 
This compound was prepared following the general procedure above using benzotriazole 
(4.77 g, 40.1 mmol), triethylamine (7.2 cm3, 48.1 mmol) and p-methoxylbenzoyl chloride 
(7.52 g, 44.1 mmol). The product was isolated as described above as white crystals (10.1 g, 
40 mmol, 99%). H (300 MHz, CDCl3) 8.35 (1H, d, J 8.3, Ar), 8.29 (2H, d, J 9.0, Ar), 
8.15 (1H, d, J 8.2, Ar), 7.67 (1H, dd, J 8.3, 7.2, Ar), 7.52 (1H, d, J 8.2, 7.2, Ar), 7.06 (2H, 
d, J 9.0, Ar), 3.92 (3H, s, OCH3); C (75 MHz, CDCl3) 165.0, 163.6, 145.0, 133.8, 131.9, 
129.5, 125.5, 122.8, 119.5, 114.2, 113.3, 55.0; m/z (EI-MS) 276.1 (M+Na)+.   
 
1-m-Toluoylbenzotriazole 89. This compound is known but not fully characterized.166 
 
This compound was prepared following the general procedure above using benzotriazole 
(2.00 g, 16.5 mmol), triethylamine (3.0 cm3, 19.8 mmol) and m-toluoyl chloride (2.8 g, 
18.2 mmol). The product was isolated as described above as white crystals (3.9 g, 16.4 
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mmol, 99%). MP 65 °C; (found (ESI): M+ + Na, 260.0794. C14H11N3O4 requires M, 
260.0799); νmax 1701, 1364, 1289,1153, 1044, 950, 748, 730 cm-1; H (300 MHz, CDCl3) 
8.36 (1H, d, J 8.3, Ar), 8.15 (1H, d, J 8.3, Ar), 8.01-7.99 (2H, m, Ar), 7.68 (1H, t, J 8.0, 
Ar), 7.55-7.43 (3H, m, Ar), 2.46 (3H, s, CH3); C (75 MHz, CDCl3) 166.9, 145.8, 138.3, 
134.5, 132.4, 132.1, 131.5, 130.3, 129.0, 128.3, 126.3, 120.1, 114.8, 21.4; m/z (EI-MS) 
260.1 (M+Na)+. 
 
1-(3-Methyl-1-oxo-2-butenyl)-benzotriazole 90. This compound is known and has been 
fully characterized.167 
 
This compound was prepared following the general procedure above using benzotriazole 
(2.00 g, 16.5 mmol), triethylamine (3.0 cm3, 19.8 mmol) and 3,3-dimethylacryloyl 
chloride (2.16 g, 18.2 mmol). The product was isolated as described above as a white solid 
(3.1 g, 15.3 mmol, 93%). H (300 MHz, CDCl3) 8.36 (1H, d, J 8.3, Ar), 8.15 (1H, d, J 8.3, 
Ar), 8.01-7.99 (2H, m, Ar), 7.68 (1H, t, J 8.0, Ar), 7.55-7.43 (3H, m, Ar), 2.46 (3H, s, 
CH3); C (75 MHz, CDCl3) 164.4, 163.4, 146.2, 131.6, 129.9, 125.8, 120.0, 118.2, 114.8, 
28.6, 21.7. 
 
1-(1H-benzotriazol-1-yl)-2-phenyl-ethanone 94. This compound is known and has 
been fully characterized.168 
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This compound was prepared following the general procedure above using benzotriazole 
(2.98 g, 25.0 mmol), triethylamine (4.5 cm3, 30.0 mmol) and phenylacetyl chloride (4.25 g, 
27.5 mmol). The product was isolated as described above as a white solid (5.90 g, 25.0 
mmol, 99%). H (300 MHz, CDCl3) 8.24 (1H, d, J 8.3, Ar), 8.10 (1H, d, J 8.3, Ar), 7.61 
(1H, t, J 8.1, Ar), 7.50-7.45 (3H, m, Ar), 7.39-7.30 (3H, m, Ar), 4.72 (2H, s, CH2); C (75 
MHz, CDCl3) 170.3, 146.3, 132.5, 131.3, 130.5, 129.9, 128.9, 127.7, 126.3, 120.2, 114.5, 
42.1; m/z (EI-MS) 260.1 (M+Na)+. 
 
General Procedure [2] 
 
Benzotriazole (1.19 g, 10.0 mmol) in dichloromethane (13 cm3) was cooled to 0 °C then 
SOCl2 (0.19 cm
3, 2.5 mmol) was added dropwise. The mixture was stirred at room 
temperature for 30 min then acid (0.42 g, 2.5 mmol) in CH2Cl2 (10 cm
3) was added. The 
mixture was stirred at rt for 3 h, the precipitate was removed by filtration and rinsed with 
more CH2Cl2. The filtrate was washed with NaOH solution (2 M, 2 × 10 cm
3), brine (10 
cm3) and dried over anhydrous MgSO4. The solvent was evaporated under reduced 
pressure and the product was dried under vacuum before use.  
1-p-Nitrobenzoylbenzotriazole 97. This compound is known and has been fully 
characterized.164 
 
This compound was prepared following the general procedure above using benzotriazole 
(1.19 g, 10.0 mmol), SOCl2 (0.19 cm
3, 2.5 mmol) and p-nitrobenzoyl acid (0.42 g, 2.5 
mmol). The product was isolated as white crystals (0.54 g, 2.0 mmol, 81%). H (300 MHz, 
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CDCl3) 8.45-8.38 (5H, m, Ar), 8.20 (1H, d, J 8.3, Ar), 7.77 (1H, d, J 7.2, Ar), 7.61 (1H, d, 
J 7.2, Ar); C (75 MHz, CDCl3) 164.1, 145.0, 136.3, 135.9, 132.0, 130.4, 126.4, 122.9, 
120.7, 119.9, 114. 
 
1-(3-Phenyl-1-oxo-2-propynyl)-benzotriazole 95. This compound is known and has 
been fully characterized.169 
 
This compound was prepared following the general procedure above using benzotriazole 
(2.38 g, 20.0 mmol), SOCl2 (0.38 cm
3, 5.0 mmol) and propiolic acid (0.73 g, 5.0 mmol). 
The product was isolated as a white solid (1.16 g, 0.47 mmol, 93%). H (300 MHz, CDCl3) 
8.29 (1H, d, J 8.2, Ar), 8.14 (1H, d, J 8.3, Ar), 7.80-7.76 (2H, m, Ar), 7.67 (1H, t, J 7.7 Ar), 
7.56-7.50 (2H, m, Ar), 7.46-7.42 (2H, m, Ar); C (75 MHz, CDCl3) 150.4, 146.3, 133.7, 
131.7, 130.9, 130.6, 128.8, 126.6, 120.4, 119.0, 114.3, 96.0, 81.3; m/z (EI-MS) 270.1 
(M+Na)+. 
 
1-(2-Thienylcarbonyl)-benzotriazole 96. This compound is known and has been fully 
characterized.168 
 
This compound was prepared following the general procedure above using benzotriazole 
(9.52 g, 80.0 mmol), SOCl2 (1.52 cm
3, 20.0 mmol) and 2-thiophenecarboxylic acid (2.56 g, 
20.0 mmol). The product was isolated as white solid (3.60 g, 15.7 mmol, 79%). H (300 
MHz, CDCl3) 8.56 (1H, dd, J 4.0, 1.3, Ar), 8.15 (1H, d, J 8.3, Ar), 7.87 (1H, dd, J 4.0, 1.3, 
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Ar), 7.67 (1H, t, J 8.2, Ar), 7.53 (1H, t, J 8.2, Ar), 7.27 (1H, t, J4.0, Ar); C (75 MHz, 
CDCl3) 159.3, 145.8, 138.5, 137.3, 133.4, 132.2, 130.5, 128.1, 126.4, 120.3, 114.9;  m/z 
(EI-MS) 252.0 (M+Na)+. 
 
3.5. Synthesis of 2,2-Dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-ones. 
General Procedure [1] 
 
To a solution of diisopropylamine (6.2 g, 60 mmol) in THF (100 cm3) at –78 °C was 
added n-BuLi (1.6 M in hexane, 41.2 cm3, 66 mmol) dropwise over 20 min then a solution 
of 2,2,6-trimethyl-1,3-dioxin-4-one (7.04 g, 49.6 mmol) in THF (50 cm3) was added 
dropwise over 20 min. After stirring for 1.5 h, the acid chloride (33 mmol) was added in 
one portion. The resulting mixture was stirred at –78 °C for 30 min and sat NH4Cl (100 
cm3) was added. The mixture was extracted with ethyl acetate (3 × 60 cm3) and the 
combined organic phase was washed with brine (50 cm3) and dried over anhydrous 
MgSO4. The crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=8:1-4:1). 
 
2,2-Dimethyl-6-(2-oxo-2-methylethyl)-4H-1,3-dioxin-4-one 98. This compound is 
known and has been fully characterized.170 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.77 g, 7.5 mmol), n-BuLi (1.6 cm3, 7.0 mmol), 2,2,6-trimethyl-1,3-
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dioxin-4-one (0.88 g, 6.2 mmol) and acetyl chloride (0.44 g, 5.1 mmol). The product was 
isolated as described above as a colourless oil (0.15 g, 0.8 mmol, 15%). (found (ESI): M+ 
+ Na, 207.0625. C9H12O4 requires M, 207.0633); H (300 MHz, CDCl3) 5.35 (1H, s, =CH), 
3.37 (2H, s, CH2), 2.25, (3H, s, COCH3), 1.72 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 
200.9, 164.4, 160.7, 107.2, 96.6, 47.9, 30.2, 25.0; m/z (EI-MS) 207.1 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-2-phenylethyl)-4H-1,3-dioxin-4-one 99. This compound is 
known and has been fully characterized.171 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.77 g, 7.5 mmol), n-BuLi (1.6 cm3, 7.0 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.88 g, 6.2 mmol) and benzoyl chloride (0.82 g, 5.8 mmol). The product 
was isolated as described above as a light yellow solid (0.40 g, 1.6 mmol, 26%). (found 
(ESI): M+ + Na, 269.0789. C9H12O4 requires M, 269.0784); νmax 1715, 1683, 1639, 1390, 
1375, 1329, 1271, 1219, 1188, 1016, 820, 762, 691 cm-1; H (300 MHz, CDCl3) 7.94 (2H, 
d, J 7.7, Ph), 7.65-7.61 (1H, m, Ph), 7.53-7.49 (2H, m, Ph), 5.43 (1H, s, =CH), 3.90 (2H, s, 
CH2), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 192.5, 164.6, 160.1, 135.2, 133.4, 
128.3, 127.7, 106.7, 96.4, 42.7, 24.4; m/z (EI-MS) 269.1 (M+Na)+. 
 
2,2-Dimethyl-6-[(3E)-2-oxo-4-phenyl-3-buten-1-yl]-4H-1,3-dioxin-4-one 100. This 
compound is known and has been fully characterized.171a 
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This compound was prepared following the general procedure above using 
diisopropylamine (5.35 g, 7.5 mmol), n-BuLi (31 cm3, 49.5 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (5.3 g, 37.5 mmol) and trans-cinnamoyl chloride (5.7 g, 34.8 mmol) and the 
product was isolated as described above as colourless crystals (1.23 g, 4.5 mmol, 13%). 
(found (ESI): M+ + Na, 273.1121. C16H17O4 requires M, 273.1126); νmax 1726, 1663, 1626, 
1368, 1182, 1015, 979, 805, 744, 687 cm-1; H (300 MHz, CDCl3) 7.62 (1H, d, J 16.1, 
PhCH=C), 7.57-7.55 (2H, m, Ph), 7.47-7.40 (3H, m, Ph), 6.77 (1H, d, J 16.1, PhCH=CH), 
5.43 (1H, s, =CHCOO), 3.59 (2H, s, CH2), 1.72 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 
191.8, 164.3, 164.1, 144.3, 133.2, 130.6, 128.5, 127.9, 124.0, 106.6, 96.2, 44.8, 22.4; m/z 
(EI-MS) 273.1 (M+Na)+. 
 
General Procedure [2] 
 
To a solution of diisopropylamine (6.2 g, 60 mmol) in THF (100 cm3) at –78 °C was 
added n-BuLi (1.6 M in hexane, 41.2 cm3, 66 mmol) dropwise over 20 min then a solution 
of 2,2,6-trimethyl-1,3-dioxin-4-one (7.04 g, 49.6 mmol) in THF (50 cm3) was added 
dropwise over 20 min. After stirring for 1.5 h, a solution of 1-acylbenzotriazole (43 mmol) 
in THF (40 cm3) was added in one portion. The resulting mixture was stirred at –78 °C for 
3 h and allowed to warm to room temperature overnight. Sat NH4Cl (10 cm
3) was added 
to quench the reaction, and water (200 cm3) was added. The mixture was extracted with 
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ethyl acetate (3 × 60 cm3). The combined organic phase was washed with Na2CO3 (2 × 50 
cm3), brine (50 cm3), dried over anhydrous MgSO4. The crude product was purified by 
silica gel column chromatography (eluent hexane/EtOAc=8:1-4:1). 
 
2,2-Dimethyl-6-(2-oxo-2-o-bromo-phenylethyl)-4H-1,3-dioxin-4-one 101. This 
compound is novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (6.0 g, 6.0 mmol), n-BuLi (4.0 cm3, 6.3 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.69 g, 4.8 mmol) and 1-o-bromobenzoylbenzotriazole (1.23 g, 4.1 mmol) 
and the product was isolated as described above as a yellow oil (0.28 g, 0.86 mmol, 21%). 
(found (ESI): M+ + Na, 346.9889. C14H13O4
79Br requires M, 346.9894); νmax 1709, 1634, 
1390, 1373, 1272, 1251, 1200, 1015, 751 cm-1; H (300 MHz, CDCl3) 7.64 (1H, dd, J 7.6, 
1.4, Ar), 7.17-7.11 (3H, m, Ar), 5.44 (1H, s, =CH), 3.90 (2H, s, CH2), 1.65 (6H, s, 2 × 
CH3); C (75 MHz, CDCl3) 196.5, 164.4, 161.0, 139.8, 134.1, 132.7, 129.2, 127.7, 119.1, 
107.4, 96.9, 46.7, 24.9; m/z (EI-MS) 347.0 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-2-o-methyl-phenylethyl)-4H-1,3-dioxin-4-one 102. This 
compound is novel. 
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This compound was prepared following the general procedure above using 
diisopropylamine (0.75 g, 7.5 mmol), n-BuLi (5.1 cm3, 8.3 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.85 g, 5.7 mmol) and 1-o-toluoylbenzotriazole (1.18 g, 5.0 mmol) and the 
product was isolated as described above as a light yellow solid (0.39 g, 1.5 mmol, 30%). 
MP 84 °C; (found (ESI): M+ + Na, 283.0941. C15H16O4 requires M, 283.0946); νmax 1723, 
1681, 1636, 1374, 1272, 1201, 1015, 761 cm-1; H (300 MHz, CDCl3) 7.59 (1H, d, J 7.5, 
Ar), 7.37 (1H, t, J 7.5, Ar), 7.27-7.22 (2H, m, Ar), 5.34 (1H, s, =CH), 3.79 (2H, s, CH2), 
2.46 (3H, s, CH3), 1.59 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 196.1, 165.3, 160.8, 139.1, 
136.2, 132.4, 129.0, 125.9, 107.2, 96.8, 45.9, 24.9, 21.4; m/z (EI-MS) 283.1 (M+Na)+. 
 
2,2-Dimethyl-6-[2-(2-furanyl)-2-oxoethyl]-4H-1,3-dioxin-4-one 103. This compound is 
known and has been fully characterized.171a 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.60 g, 6.0 mmol), n-BuLi (4.0 cm3, 6.3 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.69 g, 4.8 mmol) and 1-(2-furanylcarbonyl)benzotriazole (0.87 g, 4.1 
mmol) and the product was isolated as described above as a dark brown solid (0.27 g, 1.1 
mmol, 27%). (found (ESI): M+ + Na, 237.0757. C12H13O5 requires M, 237.0763); νmax 
1715, 1670, 1640, 1463, 1389, 1373, 1271, 1247, 1200, 1191, 1155, 1014, 778 cm-1; H 
(300 MHz, CDCl3) 7.64 (1H, d, J 1.7, Ar), 7.29 (1H, d, J 3.6, Ar), 6.60 (1H, dd, J 3.6, 1.7, 
Ar), 5.46 (1H, s, =CH), 3.78 (2H, s, CH2), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 
192.5, 164.6, 160.1, 135.2, 133.4, 128.3, 127.7, 106.7, 96.4, 42.7, 24.4; m/z (EI-MS) 259.0 
(M+Na)+. 
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2,2-Dimethyl-6-(2-oxo-2-p-methyl-phenylethyl)-4H-1,3-dioxin-4-one 104. This 
compound is known and has been fully characterized.171a 
 
This compound was prepared following the general procedure above using 
diisopropylamine (1.5 g, 15 mmol), n-BuLi (10.3 cm3, 16.5 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (1.7 g, 11.4 mmol) and 1-p-toluoylbenzotriazole (2.37 g, 10.0 mmol) and the 
product was isolated as described above as a light yellow solid (1.2 g, 4.6 mmol, 46%). 
(found (ESI): M+ + Na, 283.0941. C15H16O4 requires M, 283.0946); νmax 1725, 1683, 1605, 
1373, 1200, 1013, 828, 804 cm-1; H (300 MHz, CDCl3) 7.83 (2H, d, J 8.2, Ar), 7.30 (2H, 
d, J 8.2, Ar),  5.41 (1H, s, =CH), 3.88 (2H, s, CH2), 2.43 (3H, s, CH3), 1.70 (6H, s, 2 × 
CH3); C (75 MHz, CDCl3) 192.3, 164.8, 160.2, 144.5, 132.8, 129.0, 127.8, 106.6, 96.3, 
42.6, 24.4, 21.1; m/z (EI-MS) 283.1 (M+Na)+.  
 
2,2-Dimethyl-6-(2-oxo-2-p-fluoro-phenylethyl)-4H-1,3-dioxin-4-one 105. This 
compound is novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.3 g, 3.0 mmol), n-BuLi (2.0 cm3, 3.2 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.32 g, 2.2 mmol) and1-p-fluorobenzoylbenzotriazole (0.48 g, 2.0 mmol) 
and the product was isolated as described above as light yellow crystals (0.20 g, 0.76 
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mmol, 38%). MP 118 °C; (found (ESI): M+ + Na, 287.0690. C14H13FO4 requires M, 
287.0695); νmax 1731, 1688, 1595, 1377, 1202, 1016, 986, 837, 813 cm-1; H (300 MHz, 
CDCl3) 7.99-7.96 (2H, m, Ar), 7.20-7.16 (2H, m, Ar), 5.42 (1H, s, =CH), 3.88 (2H, s, 
CH2), 1.71 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 191.5, 167.5, 164.9, 160.7, 132.3, 131.1 
(d, J 9.5), 116.1 (d, J 22.0), 107.4, 97.1, 43.2, 25.0; m/z (EI-MS) 287.1 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-2-p-methoxyl-phenylethyl)-4H-1,3-dioxin-4-one 106. This 
compound is novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (1.5 g, 15.0 mmol), n-BuLi (10.3 cm3, 16.5 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (1.70 g, 11.4 mmol) and1-p-methoxylbenzoylbenzotriazole (2.53 g, 10.0 
mmol) and the product was isolated as described above as a light yellow solid (1.1 g, 3.9 
mmol, 39%). (found (ESI): M+ + Na, 299.0890. C15H16O5 requires M, 299.0895); νmax 
1722, 1678, 1595, 1375, 1258, 1220, 1203, 1189, 1164, 1016, 1003, 988, 834, 811 cm-1; 
H (300 MHz, CDCl3) 7.91 (2H, d, J 8.9, Ar), 6.96 (2H, d, J 8.9, Ar), 5.41 (1H, s, =CH), 
3.89 (3H, s, OCH3), 3.85 (2H, s, CH2), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 191.5, 
165.4, 164.2, 160.9, 130.7, 128.9, 114.1, 107.3, 96.8, 55.6, 43.1, 25.0; m/z (EI-MS) 299.1 
(M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-2-p-nitro-phenylethyl)-4H-1,3-dioxin-4-one 107. This 
compound is novel. 
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This compound was prepared following the general procedure above using 
diisopropylamine (0.15 g, 1.5 mmol), n-BuLi (1.0 cm3, 1.6 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.16 g, 1.1 mmol) and1-p-nitrobenzoylbenzotriazole (0.27 g, 1.0 mmol) and 
the product was isolated as described above as a light yellow solid (0.1 g, 0.36 mmol, 
36%). MP 74 °C; (found (ESI): M+ + Na, 314.0635. C14H13NO6 requires M, 314.0640); 
νmax 1720, 1693, 1529, 1376, 1345, 1319, 1199, 1015, 989, 849, 815, 746 cm-1; H (300 
MHz, CDCl3) 8.36 (2H, d, J 8.8, Ar), 8.12 (2H, d, J 8.8, Ar), 5.46 (1H, s, =CH), 3.97 (2H, 
s, CH2), 1.72 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 191.7, 164.0, 160.5, 150.8, 140.1, 
129.4, 124.1, 107.5, 97.4, 43.6, 25.0; m/z (EI-MS) 314.1 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-4-phenylpropynyl)-4H-1,3-dioxin-4-one 108. This compound is 
novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.77 g, 7.5 mmol), n-BuLi (5.2 cm3, 8.3 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.85 g, 5.7 mmol) and 1-(3-methyl-1-oxo-2-butenyl)-benzotriazole (1.0 g, 
5.0 mmol) and the product was isolated as described above as light yellow oil (0.31 g, 1.4 
mmol, 28%); (found (ESI): 2M+ + Na, 471.1989. C24H32O8 requires M, 471.1994); 
νmax1724, 1691, 1617, 1372, 1270, 1201, 1013, 991 cm-1; H (300 MHz, CDCl3) 6.09 (1H, 
s, (CH3)2C=CH), 5.35 (1H, s, =CH), 3.33 (2H, s, CH2), 2.17 (3H, s, CH3C=), 1.94 (3H, s, 
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CH3C=), 1.71 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 192.2, 165.4, 160.8, 159.2, 122.4, 
107.0, 96.3, 48.5, 27.8, 25.0, 21.1; m/z (EI-MS) 470.9 (2M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-4phenylacryloyl)-4H-1,3-dioxin-4-one 109. This compound is 
novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (0.71 g, 7.5 mmol), n-BuLi (5.2 cm3, 8.25 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (0.85 g, 5.7 mmol) and 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (1.14 g, 
5.0 mmol) and the product was isolated as described above as a brown solid (0.19 g, 0.70 
mmol, 15%). MP 60 °C; (found (ESI): M+ + Na, 293.0784. C16H14O4 requires M, 
293.0789); νmax 2198,1725, 1671, 1373, 1273, 1074, 1014, 769, 690cm-1; H (300 MHz, 
CDCl3) 7.57 (1H, d, J 8.5, Ph), 7.50 (1H, t, J 8.7, Ph), 7.43-7.39 (2H, m, Ph), 5.48 (1H, s, 
=CH), 3.58 (2H, s, CH2), 1.73 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 179.4, 163.3, 160.6, 
133.3, 131.5, 128.9,  119.1, 107.4, 97.3, 93.6, 87.1, 49.5, 25.0; m/z (EI-MS) 293.1 
(M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-2-m-methyl-phenylethyl)-4H-1,3-dioxin-4-one 110. This 
compound is novel. 
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This compound was prepared following the general procedure above using 
diisopropylamine (1.50 g, 15 mmol), n-BuLi (10.2 cm3, 16.6 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (1.70 g,  11.2 mmol) and 1-m-toluoylbenzotriazole (2.4 g, 10 mmol) and the 
product was isolated as described above as a light yellow solid (1.20 g, 4.6 mmol, 46%). 
MP 81 °C; (found (ESI): M+ + Na, 283.0941. C15H16O4 requires M, 283.0946); νmax 1727, 
1682, 1644, 1389, 1372, 1271, 1160, 1242, 1182, 1015, 802 cm-1; H (300 MHz, CDCl3) 
7.75 (1H, s, Ar), 7.73 (1H, d, J 8.6, Ar), 7.45-7.36 (2H, m, Ar), 5.41 (1H, s, =CH), 3.89 
(2H, s, CH2), 2.43 (3H, s, CH3), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 193.3, 165.3, 
160.8, 138.8, 135.9, 134.8, 128.81, 128.78, 125.6, 107.3, 96.9, 43.3, 25.0, 21.3; m/z  (EI-
MS) 283.1 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-3-phenylpropyl)-4H-1,3-dioxin-4-one 111. This compound is 
novel. 
 
This compound was prepared following the general procedure above using 
diisopropylamine (1.50 g, 15 mmol), n-BuLi (10.2 cm3, 16.6 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one(1.70 g,  11.2 mmol) and 1-m-toluoylbenzotriazole (2.4 g, 10 mmol) and the 
product was isolated as described above as a white solid (78 mg,  mmol, 15%). MP 81 °C; 
(found (ESI): M+ + Na, 283.0941. C15H16O4 requires M, 283.0946); νmax 1727, 1682, 1644, 
1389, 1372, 1271, 1160, 1242, 1182, 1015, 802 cm-1; H (300 MHz, CDCl3) 7.75 (1H, s, 
Ar), 7.73 (1H, d, J 8.6, Ar), 7.45-7.36 (2H, m, Ar), 5.41 (1H, s, =CH), 3.89 (2H, s, CH2), 
2.43 (3H, s, CH3), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 200.3, 163.9, 160.3, 132.2, 
128.9, 128.4, 127.0, 106.7, 96.1, 49.7, 45.5, 24.4; m/z (EI-MS) 283.1 (M+Na)+. 
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General Procedure [3] 
 
To a solution of diisopropylamine (3.1 g, 30 mmol) in THF (40 cm3) at –78 °C was added 
n-BuLi (1.6 M in hexane, 20.6 cm3, 33 mmol) dropwise over 20 min then a solution of 
2,2,6-trimethyl-1,3-dioxin-4-one (3.70 g, 26.0 mmol) in THF (20 cm3) was added 
dropwise over 20 min. After stirring for 1.5 h, a solution of aromatic aldehyde (22 mmol, 
aldehydes were used directly without distillation) in THF (10 cm3) was added in one 
portion. The resulting mixture was stirred at –78 °C for 1 h and sat NH4Cl (40 cm3) was 
added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 20 cm3) 
and the combined organic phase was washed with brine (10 cm3), dried over anhydrous 
MgSO4. The crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=5:1-3:1).  
To a solution of alcohol (27.4 mmol) in CH2Cl2 (130 cm
3) PCC powder (14.8 g, 68.5 
mmol) was added. The mixture was stirred at rt for 6 h. After reaction complete solid was 
filtered and washed with CH2Cl2 (3 × 30 cm
3). The combined organic phase was 
concentrated and the crude product was purified directly by silica gel column 
chromatography (eluent hexane/EtOAc/DCM=4:1:0.5).  
Only full data for new compounds were given.  Full data for alcohols will be found in the 
next section. 
 
6-(2-Hydroxy-2-thienylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 129.  
This compound was prepared following the general procedure above using 
diisopropylamine (2.06 g, 20.0 mmol), n-BuLi (13.7 cm3, 23.0 mmol), 2,2,6-trimethyl-1,3-
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dioxin-4-one(2.35 g, 16.5 mmol), 2-thiophenecarbaldehyde (1.61 g, 14.4 mmol) and the 
product was isolated as described above as brown oil (2.20 g, 8.4 mmol, 58%). 
 
6-(2-Hydroxy-2-p-bromo-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 118. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-
1,3-dioxin-4-one (3.70 g, 26.0 mmol), 4-bromobenzaldehyde (4.07 g, 22.0 mmol) and the 
product was isolated as white crystals (4.22 g, 12.9 mmol, 60%). 
 
6-(2-Hydroxy-2-p-nitro-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 115. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (3.70 g, 26.0 mmol), 4-nitrobenzaldehyde (3.32 g, 22.0 mmol) and the 
product was isolated as light yellow crystals (4.27 g, 14.4 mmol, 66%). 
 
6-(2-Hydroxy-2-p-methyl-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 116.. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (3.70 g, 26.0 mmol), 4-methylbenzaldehyde (2.64 g, 22.0 mmol) and the 
product was isolated as described above as white crystals (3.48 g, 13.3 mmol, 60%). 
 
6-(2-Hydroxy-2-m-methyl-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 117. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-1,3-
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dioxin-4-one (3.70 g, 26.0 mmol), 3-methylbenzaldehyde (2.64 g, 22.0 mmol) and the 
product was isolated as colourless oil (4.69 g, 17.9 mmol, 81%). 
 
6-(2-Hydroxy-2-o-methyl-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 120. 
This compound was prepared following the general procedure above using 
diisopropylamine (1.55 g, 15.0 mmol), n-BuLi (10.3 cm3, 16.5 mmol), 2,2,6-trimethyl-
1,3-dioxin-4-one (1.85 g, 13.0 mmol), 2-methylbenzaldehyde (1.32 g, 11.0 mmol) and the 
product was isolated as white crystals (2.43 g, 9.3 mmol, 84%). 
 
6-(2-Hydroxy-2-p-fluoro-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 121. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-
1,3-dioxin-4-one (3.70 g, 26.0 mmol), 4- fluorobenzaldehyde (2.73 g, 22.0 mmol) and the 
product was isolated as white crystals (4.76 g, 17.9 mmol, 81%). 
 
6-(2-Hydroxy-2-p-methoxyl-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 122.  
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (3.70 g, 26.0 mmol), 4-methoxybenzaldehyde (2.72 g, 20.0 mmol) and the 
product was isolated as white crystals (4.28 g, 15.4 mmol, 77%). 
 
2,2-Dimethyl-6-(2-oxo-2-phenylethyl)-4H-1,3-dioxin-4-one 99.  
This compound was prepared following the general procedure above using alcohol 114 
(6.80 g, 27.4 mmol) and PCC (14.0 g, 68.5 mmol). The product was isolated as light 
yellow solid (6.03 g, 24.5 mmol, 89%). 
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2,2-Dimethyl-6-(2-oxo-2-p-nitro-phenylethyl)-4H-1,3-dioxin-4-one 107.  
This compound was prepared following the general procedure above using alcohol 115 
(1.63 g, 5.6 mmol) and PCC (3.0 g, 14.0 mmol). The product was isolated as light yellow 
solid (765 mg, 2.6 mmol, 46%). 
 
2,2-Dimethyl-6-(2-oxo-2-p-methyl-phenylethyl)-4H-1,3-dioxin-4-one 104.  
This compound was prepared following the general procedure above using alcohol 116 
(936 mg, 3.6 mmol) and PCC (1.95 g, 9.0 mmol). The product was isolated as white solid 
(679 mg, 2.6 mmol, 73%). 
 
2,2-Dimethyl-6-(2-oxo-2-m-methyl-phenylethyl)-4H-1,3-dioxin-4-one 110.  
This compound was prepared following the general procedure above using alcohol 117 
(1.78 g, 6.8 mmol) and PCC (3.68 g, 17.0 mmol). The product was isolated as white solid 
(1.45 g, 5.6 mmol, 81%). 
 
2,2-Dimethyl-6-(2-oxo-2-o-methyl-phenylethyl)-4H-1,3-dioxin-4-one 102. 
This compound was prepared following the general procedure above using alcohol 120 
(1.89 g, 7.2 mmol) and PCC (3.9 g, 18.1 mmol) and the product was isolated as light 
yellow solid (1.26 g, 4.8 mmol, 67%). 
 
2,2-Dimethyl-6-(2-oxo-2-p-fluoro-phenylethyl)- 4H-1,3-dioxin-4-one 105.  
This compound was prepared following the general procedure above using alcohol 121 
(1.23 g, 4.6 mmol) and PCC (2.5 g, 11.6 mmol) and the product was isolated as white 
crystals (791mg, 3.0 mmol, 64%). 
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2,2-Dimethyl-6-(2-oxo-2-p-methoxyl-phenylethyl)-4H-1,3-dioxin-4-one 106. 
This compound was prepared following the general procedure above using alcohol 122 
(1.41 g, 5.1 mmol), PCC (2.78 g, 12.8 mmol). The product was isolated as described 
above as white crystals (1.31 g, 4.7 mmol, 93%). 
 
2,2-Dimethyl-6-(2-oxo-2-p-bromo-phenylethyl)-4H-1,3-dioxin-4-one 112. This 
compound is novel. 
 
This compound was prepared following the general procedure above using alcohol (1.93 g, 
5.9 mmol) and PCC (3.2 g, 14.8 mmol) and the product was isolated as white crystals 
(1.50 g, 4.6 mmol, 80%). MP 98 °C; (found (ESI): M+ + Na, 346.9889. C14H13
79BrO4 
requires M, 346.9894); νmax 1723, 1688, 1636, 1583, 1387, 1376, 1200, 832, 805 cm-1; H 
(300 MHz, CDCl3) 7.80 (2H, d, J 8.6, Ar), 7.65 (2H, d, J 8.6, Ar), 5.42 (1H, s, =CH), 3.87 
(2H, s, CH2), 1.71 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 193.7, 164.7, 160.6, 134.6, 132.3, 
129.8, 129.4, 107.4, 97.1, 43.2, 25.0; m/z (EI-MS) 348.9 (M+Na)+. 
 
2,2-Dimethyl-6-(2-oxo-thienylethyl)-4H-1,3-dioxin-4-one 113. This compound is 
known and has been fully characterized.171a 
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This compound was prepared following the general procedure above using alcohol (1.02 g, 
4.0 mmol), PCC (2.17 g, 10.0 mmol). The product was as light yellow solid (778 mg, 3.1 
mmol, 76%). νmax 1724, 1656, 1637, 1414, 1354, 1374, 1227, 1201, 1014, 819, 733 cm-1; 
H (300 MHz, CDCl3) 7.78 (1H, d, J 3.8, Ar), 7.75 (1H, d, J 5.0, Ar), 7.18 (1H, dd, J 5.0, 
3.8, Ar), 5.45 (1H, s, =CH), 3.87 (2H, s, CH2), 1.70 (6H, s, 2 × CH3); C (75 MHz, CDCl3) 
185.7, 164.7, 160.7, 142.9, 135.2, 133.3, 133.2, 128.5, 107.3, 96.9, 43.8, 24.9; m/z (EI-MS) 
275.0 (M+Na)+. 
 
6-(2-Hydroxy-2-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 114. 
This compound was prepared following the general procedure above using 
diisopropylamine (3.10 g, 30.0 mmol), n-BuLi (20.6 cm3, 33.0 mmol), 2,2,6-trimethyl-1,3-
dioxin-4-one (3.70 g, 26.0 mmol), benzaldehyde (2.33 g, 22.0 mmol) and the product was 
isolated as white crystals (3.58 g, 14.4 mmol, 66%). 
 
3.6. Asymmetric Transfer Hydrogenation of 2,2-Dimethyl-6-(2-oxoalkyl)-
1,3-dioxin-4-ones. 
General Procedure  
 
(R,R)-c2 (0.5 mg, 8 × 10-4 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
(32.5 mg) and 2,2-dimethyl-6-(2-oxoalkylethyl)-1,3-dioxin-4-one (8 × 10-2 mmol) in 
degassed CH2Cl2 (0.5 cm
3) was injected under a nitrogen atmosphere. The mixture was 
stirred at rt until starting material was completely consumed. After the reaction was 
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complete, the reaction mixture was directly purified by silica gel column chromatography 
(eluent hexane/EtOAc=3:1) to give the product. 
 
6-[(2R)-2-Hydroxypropyl]-2,2-dimethyl-4H-1,3-dioxin-4-one S-128.  This compound 
is known but not fully characterized.172 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (14.7 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as a colourless oil (13.5 mg, 0.072 mmol, 
91%, 59% ee). [α]D24 +19.7 (c 1.33 in CHCl3) 59% ee (S); [α]D+25.2 (c 1.0 in CHCl3) 90% 
ee (S);172 (found (ESI): M+ + Na, 209.0788. C9H14O4 requires M, 209.0789); νmax 3418, 
1706, 1630, 1389, 1374, 1272, 1200, 802 cm-1; H (300 MHz, CDCl3) 5.33 (1H, s, =CH), 
4.16-4.08 (1H, m, CHOH), 2.38 (1H, d, J 2.8, HCH), 2.37 (1H, s, HCH), 1.70 (6H, s, 
2CH3), 1.27 (3H, d, J 6.2, CHCH3); C (75 MHz, CDCl3) 169.3, 161.3, 106.6, 94.9, 65.1, 
43.2, 25.2, 24.9, 23.5; m/z (EI-MS) 209.1 (M+Na)+; HPLC separation conditions: 
CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 98:2, 1.0 cm3/min, T = 
20 °C. Retention times: (major - R) 70.3 min, (minor - S) 77.6 min. 
 
6-[(2R)-2-Hydroxy-2-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-114. This 
compound is known and has been fully characterized.88a 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (19.8 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as white crystals (17.6 mg, 0.072 mmol, 89%, 
98% ee). [α]D26 +44.9 (c 0.7 in CHCl3) 98% ee (R); lit. [α]D19 +35.9 (c 1.0 in CHCl3) 84% 
ee (R);88a (found (ESI): M+ + Na, 271.0941. C14H16O4 requires M, 271.0946); νmax 3430, 
1691, 1635, 1375, 1277, 1203, 1020, 810 cm-1; H (300 MHz, CDCl3) 7.41-7.27 (5H, m, 
Ph), 5.30 (1H, s, =CH), 4.98 (1H, dd, J 8.6, 4.9, CHOH), 2.69 (1H, dd, J 14.6, 8.6, HCH), 
2.60 (1H, dd, J 14.6, 4.9, HCH), 2.43 (1H, br, OH), 1.67 (3H, s, CH3), 1.65 (3H, s, CH3); 
C (75 MHz, CDCl3) 167.8, 160.5, 142.1, 128.1, 127.7, 125.1, 106.1, 94.7, 70.6, 42.6, 24.8, 
24.1; m/z (EI-MS) 271.1 (M+Na)+; HPLC separation conditions: CHIRALPAK IB 
column (250 mm × 4.6 mm), hexane:i-PrOH 90:10, 1.0 cm3/min, T = 20 °C. Retention 
times: (major - R) 19.3 min, (minor - S) 26.6 min. 
 
6-[(2R,3E)-2-Hydroxy-4-phenyl-3-buten-1-yl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-
120. This compound is known and has been fully characterized.88b 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8×10-4 mmol), ketone (22.0 mg, 8×10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and the 
product was isolated as described above as white crystals (22.0 mg, 0.080 mmol, 99%, 79% 
ee). [α]D24 +7.2 (c 0.63 in CHCl3) 79% ee (R); lit. [α]D19 +6.2 (c 1.0 in CHCl3) 92% ee 
(R);88b (found (ESI): M+ + Na, 297.1097. C16H18O4 requires M, 297.1102); νmax 3382, 
1713, 1626, 1396, 1377, 1279, 1200, 1015, 967, 792, 744, 690 cm-1; H (300 MHz, CDCl3) 
7.27-7.15 (5H, m, Ph), 6.53 (1H, d, J 15.9, =CHPh), 6.10 (1H, dd, J 15.9, 6.6, 
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=CHCHOH), 5.25 (1H, s, C=CH), 4.51-4.45 (1H, m, CHOH), 2.44-2.42 (2H, m, CH2), 
2.23 (1H, br, OH), 1.58 (3H, s, CH3), 1.57 (3H, s, CH3); C (75 MHz, CDCl3) 167.8, 160.6, 
135.4, 130.8, 129.7, 128.1, 127.5, 125.9, 106.1, 94.8, 69.1, 40.9, 24.7, 24.3; m/z (EI-MS) 
297.1 (M+Na)+; HPLC separation conditions: CHIRALCEL OD column (250 mm × 4.6 
mm), hexane:i-PrOH 80:20, 0.8 cm3/min, T = 17 °C. Retention times: (major - R) 19.5 
min, (minor - S) 46. 0 min. 
 
6-[(2R)-2-Hydroxy-2-o-bromo-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-126. 
This compound is novel.  
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (26.0 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as white solid (22.0 mg, 0.070 mmol, 88%, 82% 
ee). [α]D20 +132.1 (c 0.25 in CHCl3) 82% ee (R); (found (ESI): M+ + Na, 349.0046. 
C14H15
79BrO4 requires M, 349.0051); νmax 3414, 1707, 1630, 1389, 1374, 1273, 1200, 
1016, 803, 755 cm-1; H (300 MHz, CDCl3) 7.67 (1H, dd, J 7.7, 1.6, Ar), 7.50 (1H, dd, J 
8.0, 1.2, Ar), 7.34 (1H, td, J 7.5, 1.0, Ar), 7.14 (1H, td, J 7.5, 1.6, Ar), 5.35 (1H, s, C=CH), 
5.32 (1H, dd, J 9.3, 3.4, CHOH), 2.73 (1H, dd, J 14.8, 3.4, HCH), 2.48 (1H, dd, J 14.8, 9.3, 
HCH), 2.19 (1H, br, OH), 1.69 (3H, s, CH3), 1.66 (3H, s, CH3); C (75 MHz, CDCl3) 
167.9, 164.2, 141.1, 132.2, 128.9, 127.4, 126.6, 120.9, 106.2, 94.6, 69.5, 40.9, 24.7, 24.1; 
m/z (EI-MS) 349.0 (M+Na)+; HPLC separation conditions: CHIRALPAK IB column (250 
mm × 4.6 mm), hexane:i-PrOH 90:10, 1.0 cm3/min, T= 20 °C. Retention times, (major - R) 
10.9 min, (minor - S) 12.7 min. 
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6-[(2R)-2-(2-Furanyl)-2-hydroxyethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-123. This 
compound is known and has been fully characterized.88a 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (18.9 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as a white solid (17.3 mg, 0.073 mmol, 91%, 
99% ee). [α]D24 +28.0 (c 0.70 in CHCl3) 99 % ee (R); lit. [α]D25 +27.0 (c 0.58 in CHCl3) 94% 
ee (R);88a (found (ESI): M+ + Na, 261.0733. C12H14O5 requires M, 261.0739); νmax 3404, 
1703, 1623, 1390, 1374, 1274, 1201, 1009, 807, 740 cm-1; H (300 MHz, CDCl3) 7.39 (1H, 
d, J 2.0, Ar), 6.34 (1H, dd, J 3.2, 2.0, Ar), 6.28 (1H, d, J 3.2, Ar), 5.32 (1H, s, C=CH), 5.00 
(1H, t, J 7.0, CHOH), 2.80-2.78 (2H, m, CH2), 2.56 (1H, br, OH), 1.67 (1H, s, CH3), 1.64 
(3H, s, CH3); C (75 MHz, CDCl3) 167.8, 161.2, 154.7, 142.5, 110.4, 106.8, 106.6, 95.5, 
64.5, 39.8, 25.2, 24.8; m/z (EI-MS) 261.1 (M+Na)+; HPLC separation conditions: 
CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 90:10, 1.0 cm3/min, T= 
20 °C. Retention times, (major - R) 12.7 min, (minor - S) 14.1 min. 
 
6-[(2R)-2-Hydroxy-2-o-methyl-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-116. 
This compound is known but not fully characterized.173 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (20.1 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
      138 
 
the product was isolated as described above as white crystals (19.3 mg, 0.077 mmol, 96%, 
97% ee). [α]D20 +40.6 (c 1.6 in CHCl3) 97 % ee (R); (found (ESI): M+ + Na, 285.1097. 
C15H18O4 requires M, 285.1102);νmax 3371, 1708, 1629, 1394, 1376, 1275, 1183, 1066, 
1028, 1012, 795, 773 cm-1; H (300 MHz, CDCl3) 7.23 (2H, d, J 8.0, Ar), 7.15 (2H, d, J 
8.0, Ar), 5.25 (1H, s, =CH), 4.91 (1H, dd, J 8.6, 4.8, CHOH), 2.66 (1H, dd, J 14.6, 8.6, 
HCH), 2.56 (1H, dd, J 14,6, 4.8, HCH), 2.34 (3H, s, CH3), 1.65 (3H, s, CH3), 1.63 (3H, s, 
CH3); C (75 MHz, CDCl3) 168.7, 161.4, 139.9, 137.9, 129.3, 125.7, 106.7, 95.2, 70.9, 
43.1, 25.4, 24.7, 21.1; m/z (EI-MS) 285.1 (M+Na)+; HPLC separation conditions: 
CHIRALPAK IB column (250 mm × 4.6 mm) hexane:i-PrOH 90:10, 1.0 cm3/min, T = 
19 °C. Retention times, (major - R) 14.1 min, (minor - S) 25.8 min.  
 
6-[(2R)-2-Hydroxy-2-o-methyl-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-120. 
This compound is known but not fully characterized.173 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (20.1 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as white crystals (18.1 mg, 0.072 mmol, 90%, 
98% ee). [α]D24 +55.9 (c 3.0 in CHCl3) 98% ee (R); (found (ESI): M+ + H, 263.1281. 
C15H18O4 requires M, 263.1283); νmax 3429, 1704, 1631, 1389, 1374, 1273, 1254, 1201, 
1015, 804, 758 cm-1; H (300 MHz, CDCl3) 7.47 (1H, d, J 7.4, Ar), 7.27-7.12 (3H, m, Ar), 
5.32 (1H, s, =CH), 5.19 (1H, dd, J 8.5, 4.5, CHOH), 2.63-2.52 (2H, m, CH2), 2.34 (3H, s, 
CH3), 1.68 (3H, s, CH3), 1.64 (3H, s, CH3); C (75 MHz, CDCl3) 168.9, 160.4, 141.0, 
134.2, 130.6, 127.8, 126.5, 125.1, 106.7, 95.1, 67.5, 42.1, 25.4, 24.6, 18.9; m/z (EI-MS) 
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263.1 (M+Na)+; HPLC separation conditions: CHIRALPAK IB column (250 mm × 4.6 
mm), hexane:i-PrOH 90:10, 1.0 cm3/min, T = 19 °C. Retention times, (major - R) 12.8 
min, (minor - S) 12.9 min. 
 
6-[(2R)-2-Hydroxy-2-p-fluoro-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-
121. This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (21.1 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as white crystals (20.8 mg, 0.078 mmol, 98%, 
99% ee). MP 89 °C; [α]D24 +45.3 (c 0.62 in CHCl3) 99% ee (R); (found (ESI): M+ + Na, 
289.0847. C14H15FO4 requires M, 289.0852); νmax 3357, 1705, 1509, 1396, 1377, 1260, 
1063, 1014 cm-1; H (300 MHz, CDCl3) 7.36-7.32 (2H, m, Ar), 7.06-7.02 (2H, m, Ar), 
5.28 (1H, s, =CH), 4.95 (1H, dd, J 8.6, 4.8, CHOH), 2.87 (1H, br, OH), 2.66 (1H, dd, J 
14.6, 8.6, HCH), 2.56 (1H, dd, J 14.6, 4.8, HCH), 1.67 (3H, s, CH3), 1.65 (3H, s, CH3); C 
(75 MHz, CDCl3) 168.5, 163,7, 161.3 (d, J 15.3), 138.8, 127.4 (d, J 8.2), 115.5 (d, J 21.5), 
106.8, 95.3, 70.4, 43.3, 25.3, 24.7; m/z (EI-MS) 289.1 (M+Na)+; HPLC separation 
conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane: i-PrOH 90:10, 0.6 
cm3/min, T = 19 °C. Retention times, (major - R) 21.9 min, (minor - S) 25.4 min. 
 
6-[(2R)-2-Hydroxy-2-p-nitro-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-115. 
This compound is known and has been fully characterized.174 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.5 
mg, 8 × 10-4 mmol), ketone (23.3 mg, 8.0 × 10-2 mmol), HCO2H/Et3N 5:2 (32.5 mg), and 
the product was isolated as described above as white crystals (21.9 mg, 0.075 mmol, 94%, 
96% ee). [α]D24 +49.6 (c 0.45 in CHCl3) 96% ee (R); [α]D25 +21 (c 1.2 in CHCl3) 75% ee 
(R);174 (found (ESI): M+ + Na, 317.0796. C14H15NO6 requires M, 317.0797); νmax 3314, 
1704, 1515, 1400, 1380, 1348, 1281, 1085, 1009, 845, 790 cm-1; H (300 MHz, CDCl3) 
8.22 (2H, d, J 8.6, Ar), 7.57 (2H, d, J 8.6, Ar), 5.35 (1H, s, =CH), 5.13 (1H, t, J 3.0, 
CHOH), 3.09 (1H, br, OH), 2.64 (1H, d, J 3.0, HCH), 2.63 (1H, s, HCH), 1.70 (3H, s, 
CH3), 1.69 (3H, s, CH3); C (75 MHz, CDCl3) 167.8, 161.2, 150.2, 147.6, 126.6, 123.9, 
107.0, 95.6, 70.0, 43.3, 25.4, 24.7; m/z (EI-MS) 317.1 (M+Na)+; HPLC separation 
conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 90:10, 1.0 
cm3/min, T = 19 °C. Retention times, (major - R) 27.1 min, (minor - S) 33.9 min. 
 
6-[(2R)-2-Hydroxy-2-o-methoyl-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-
180. This compound is known and has been fully characterized.88b 
 
This compound was prepared following the general procedure above using (R,R)-c2 (1.8 
mg, 3.2 × 10-3 mmol), ketone (90.0 mg, 0.32 mmol), HCO2H/Et3N 5:2 (136 mg), and the 
product was isolated as described above as white crystals (82.4 mg, 0.29 mmol, 92%, 98% 
ee). [α]D24 +28.8 (c 3.0 in CHCl3) 98% ee (R); [α]D20 +33.9 (c 1.2 in CHCl3) 94% ee (R);88b 
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(found (ESI): M+ + Na, 301.1046. C15H18O5 requires M, 301.1051); νmax 3428, 1705, 1631, 
1512, 1389, 1374, 1244, 1202, 1175, 1012, 830, 804 cm-1; H (300 MHz, CDCl3) 7.26 (2H, 
d, J 8.6, Ar), 6.87 (2H, d, J 8.6, Ar), 5.25 (1H, s, =CH), 4.90 (1H, dd, J 8.6, 5.0, CHOH), 
3.79 (3H, s, OCH3), (1H, dd, J 14.6, 8.6, HCH), (1H, dd, J 14.6, 5.0, HCH), 1.64 (3H, s, 
CH3), 1.63 (3H, s, CH3); C (75 MHz, CDCl3) 168.8, 151.5, 159.4, 135.0, 127.1, 114.0, 
106.7, 95.1, 70.6, 55.3, 43.1, 25.3, 24.7; m/z (EI-MS) 301.1 (M+Na)+; HPLC separation 
conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH  90:10, 1.0 
cm3/min, T = 20 °C. Retention times, (major - R) 23.9 min, (minor - S) 38.0 min. 
 
6-[(2R)-2-Hydroxy-2-m-methyl-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-126. 
This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (1.2 
mg, 2 × 10-3 mmol), ketone (52.0 mg, 0.20 mmol), HCO2H/Et3N 5:2 (81 mg), and the 
product was isolated as described above as a colourless oil (49.0 mg, 0.19 mmol, 98%, 98% 
ee). [α]D28 +36.5 (c 2.0 in CHCl3); (found (ESI): M+ + Na, 285.1097. C15H18O4 requires M, 
285.1102); νmax 3424, 1706, 1613, 1390, 1375, 1272, 1202, 1012, 703 cm-1; H (300 MHz, 
CDCl3) 7.27-7.22 (1H, m, Ar), 7.17-7.10 (3H, m, Ar), 5.28 (1H, s, =CH), 4.91 (1H, dd, J 
8.8, 4.7, CHOH), 2.81 (1H, br, OH), 2.66 (1H, dd, J 14.6, 8.8, HCH), 2.57 (1H, dd, J 14.6, 
4.7, HCH), 2.35 (3H, s, CH3), 1.66 (3H, s, CH3), 1.64 (3H, s, CH3); C (75 MHz, CDCl3) 
168.7, 161.4, 142.9, 136.4, 128.9, 128.6, 126.4, 122.8, 106.7, 95.2, 71.1, 43.2, 25.4, 24.7, 
21.4; m/z (EI-MS) 285.1 (M+Na)+; HPLC separation conditions: CHIRALPAK IB 
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column (250 mm × 4.6 mm) hexane:i-PrOH 90:10, 1.0 cm3/min, T = 28 °C. Retention 
times, (major - R) 12.9 min, (minor - S) 19.1 min. 
 
6-[(2R)-2-Hydroxy-4,4-dimethylacryloyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-127. 
This compound is known and has been fully characterized.88b 
 
This compound was prepared following the general procedure above using (R,R)-c2 (1.3 
mg, 2.3 × 10-3 mmol), ketone (51.0 mg, 0.23 mmol), HCO2H/Et3N 5:2 (93 mg), and the 
product was isolated as described above as a colourless oil (9.2 mg, 0.04 mmol, 18%, 70% 
ee). The yield and ee value of over reduction product were not determined. (found (ESI): 
M+ + Na, 249.1097. C12H18O4 requires M, 249.1102); νmax 3426, 1709, 1631, 1389, 1374, 
1273, 1202, 1013, 804 cm-1; H (300 MHz, CDCl3) 5.31 (1H, s, =CH), 5.19 (1H, d, J 8.8, 
CH3)2C=CH), 4.67-4.62 (1H, m, CHOH), 2.59 (1H, dd, J 14.4, 7.6, HCH), 2.35 (1H, dd, 
J14.4, 5.6, HCH), 1.75 (3H, s, CH3), 1.71 (3H, s, CH3), 1.70 (3H, s, CH3C=), 1.68 (3H, s, 
CH3C=); C (75 MHz, CDCl3) 168.7, 161.2, 137.0, 126.3, 106.6, 95.1, 66.7, 41.8, 25.7, 
25.3, 24.8, 18.3; m/z (EI-MS) 475.0 (2M+Na)+; HPLC separation conditions: 
CHIRALPAK H-OD column (250 mm × 4.6 mm) hexane:i-PrOH 95:5, 0.8 cm3/min, T = 
27 °C. Retention times, (major - R) 19.1 min, (minor - S) 20.3 min.  
 
6-[(2R)-2-Hydroxy-2-p-bromo-phenylethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-118. 
This compound is novel. 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.8 
mg, 1.4 × 10-3 mmol), ketone (45.0 mg, 0.138 mmol), HCO2H/Et3N 5:2 (60 mg), and the 
product was isolated as described above as white crystals (39.0 mg, 0.12 mmol, 87%, 98% 
ee). [α]D30 +39.8 (c 1.5 in CHCl3); MP 80 °C; (found (ESI): M+ + H, 327.0226. 
C14H13O4
79Br requires M, 327.0232); νmax 3404,1303, 1631, 1390, 1375, 1273, 1201, 1069, 
1009, 819, 734 cm-1; H (300 MHz, CDCl3) 7.50 (2H, d, J 8.4, Ar), 7.25 (2H, d, J 8.4, Ar), 
5.31 (1H, s, =CH), 4.95-4.99 (1H, m, CHOH), 2.92 (1H, br, OH), 2.65 (1H, d, J 14.7, 8.7, 
HCH), 2.58 (1H, J 14.7, 4.6, HCH), 1.68 (3H, s, CH3), 1.67 (3H, s, CH3); C (75 MHz, 
CDCl3) 168.4, 161.4, 142.0, 131.8, 127.5, 121.9, 106.8, 95.3, 70.3, 43.2, 25.4, 24.7; m/z 
(EI-MS) 349.0 (M+Na)+; HPLC separation conditions: CHIRALPAK IB column (250 
mm × 4.6 mm) hexane:i-PrOH 90:10, 1.0 cm3/min, T = 30 °C. Retention times, (major - R) 
14.6 min, (minor - S) 22.4 min. 
 
6-[(2R)-2-Hydroxy-4-phenyl-3-butyn-1-yl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-124. 
This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.7 
mg, 1.1 × 10-3 mmol), ketone (30.4 mg, 0.108 mmol), HCO2H/Et3N 5:2 (47 mg), and the 
product was isolated as described above as a colourless oil (24.8 mg, 0.088 mmol, 82%, 
98% ee). [α]D30 +16.2 (c 0.85 in CHCl3); (found (ESI): M+ + Na, 295.0941 C14H16O4 
requires M, 295.0946); νmax 3397, 2234, 1705, 1390, 1375, 1273, 1201, 1013, 756 cm-1; H 
(300 MHz, CDCl3) 7.41-7.39 (2H, m, Ph), 7.34-7.29 (3H, m, Ph), 5.43 (1H, s, =CH), 4.89-
4.86 (1H, m, CHOH), 2.78-2.68 (3H, m, CH2, OH), 1.70 (6H, s, 2 × CH3); C (75 MHz, 
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CDCl3) 167.3, 161.2, 131.7, 128.9, 128.5, 121.9, 106.9, 96.0, 88.0, 86.1, 51.7, 42.0, 25.1, 
25.0; m/z (EI-MS) 295.1 (M+Na)+; HPLC separation conditions: CHIRALPAK IA 
column (250 mm × 4.6 mm), hexane:i-PrOH 95:5, 1.0 cm3/min, T = 30 °C. Retention 
times: (major - R) 36.9 min, (minor - S) 39.9 min. 
 
6-[(2R)-2-(2-Thienyl)-2-hydroxyethyl]-2,2-dimethyl-4H-1,3-dioxin-4-one R-129. This 
compound is known but not fully characterized.88b 
 
This compound was prepared following the general procedure above using (R,R)-c2 (1.7 
mg, 2.8 × 10-3 mmol), ketone (70.0 mg, 0.28 mmol), HCO2H/Et3N 5:2 (118 mg), and the 
product was isolated as described above as a white solid (66.2 mg, 0.26 mmol, 95%, 98% 
ee). [α]D32 +20.7 (c 2.12 in CHCl3) 98% ee (R); [α]D25 +24.0 (c 0.88 in CHCl3) 95 % ee 
(R);88b (found (ESI): M+ + Na, 277.0505. C12H14O5 requires M, 277.0510); νmax 3427, 1704, 
1632, 1390, 1372, 1273, 1200, 1015, 806, 699 cm-1; H (300 MHz, CDCl3) 7.27-7.26 (1H, 
d, J 2.0, Ar), 7.00-6.95 (2H, m, Ar), 5.29 (1H, s, C=CH), 5.21 (1H, dd, J 8.3, 5.1, CHOH), 
2.91 (1H, br, OH), 2.79 (1H, dd, J 14.6, 8.3, HCH), 2.71 (1H, dd, J 14.6, 5.1, HCH), 1.66 
(1H, s, CH3), 1.64 (3H, s, CH3); C (75 MHz, CDCl3) 168.1, 161.4, 146.7, 126.8, 125.2, 
124.2, 106.8, 96.5, 66.8, 43.3, 25.3, 24.7; m/z (EI-MS) 277.0 (M+Na)+;  HPLC separation 
conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 90:10, 1.0 
cm3/min, T= 30 °C. Retention times, (major - R) 15.2 min, (minor - S) 18.0 min. 
A selection of ketones was reduced by the following reaction conditions at elevated 
temperature. Experimental results were listed in Table 9. The 1H NMR data of those 
products were identical to data described above therefore will not be listed here. 
General Procedure 
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(R,R)-c2 (0.6 mg, 1.0 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
(420 mg) and 2,2-dimethyl-6-(2-oxo-alkylethyl)-1,3-dioxin-4-ones (1.0 mmol) in CH2Cl2 
(6.0 cm3) was injected into a flask. The mixture was stirred at 50 °C until starting material 
was completely consumed (48 h). The mixture was washed with 10% Na2CO3 (the 
amount of Na2CO3 solution added was dependant on the amount of formic acid) and 
extracted with CH2Cl2 (3 × 10 cm
3). The combined organic phase was dried over 
anhydrous MgSO4 and concentrated. The crude product was purified by silica gel column 
chromatography (eluent hexane/EtOAc=3:1-2/1) to afford the pure product. 
 
3.7. Asymmetric Total Synthesis of Yashabushitriol. 
3-Oxo-(5R)-hydroxy-benzenepentanoic acid, n-butyl ester 132. This compound is 
novel. 
 
Chiral alcohol R-114 (351 mg, 1.41 mmol) was dissolved in anhydrous n-butanol (5 cm3) 
and the resulting solution was heated to 140 °C for 1.5 h. After excess n-butanol was 
removed the crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=5:1-3:1) to afford product 132 as a colourless oil (330 mg, 1.25 mmol, 
88%). [α]D24 + 54.1 (c 0.6 in CHCl3) 98% ee (R); (found (ESI): M+ + Na, 287.1254. 
C15H20O4 requires M, 287.1259); νmax 3487, 2960, 1735, 1709, 1191, 1058, 699 cm-1; H 
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(400 MHz, CDCl3) 7.35-7.24 (5H, m, Ph), 5.15 (1H, dt, J 9.1, 3.2, CHOH), 4.11 (2H, t, J 
6.7, COOCH2), 3.46 (2H, s, CH2COO), 3.22 (1H, d, J 3.2, OH), 2.97 (1H, dd, J 17.3, 9.1, 
HCHCHOH), 2.60 (1H, dd, J 17.3, 3.3, HCHCHOH), 1.64-1.57 (2H, m, COOCH2CH2), 
1.41-1.32 (2H, m, CH2CH3), 0.92 (3H, t, J 7.4, CH3); C (100 MHz, CDCl3) 202.8, 167.0, 
142.7, 128.6, 127.8, 125.7, 69.8, 65.4, 51.6, 49.9, 30.5, 19.1, 13.7; m/z (ESI-MS) 265.1 
(M+H)+. 
 
2,2-Dimethyl-(6R)-phenyl-1,3-dioxane-(4S)-acetic acid, n-butyl ester 133. This 
compound is novel. 
 
Et2BOMe (1M in THF, 0.65 cm
3, 0.65 mmol) was added dropwise to a solution of β-keto 
ester 132 (156 mg, 0.59 mmol) in THF (2.8 cm3) and MeOH (0.7 cm3) at –78 °C. The 
mixture was stirred at the same temperature for 20 min then NaBH4 (24.5 mg, 0.65 mmol) 
was added and the resulting mixture was stirred at -78 °C for 4 h and quenched by sat 
NH4Cl (10 cm
3). The aqueous layer was extracted with EtOAc (3 × 30 cm3) and the 
combined organic phase was washed with brine (10 cm3), dried over MgSO4 and 
concentrated under high vacuum to afford crude diol. 2,2-Dimethoxypropane (620 mg, 6.0 
mol) and TsOH·H2O (5.6 mg, 0.030 mmol) were added to the crude diol and the resulting 
mixture was stirred at room temperature for 36 h. The reaction was quenched with solid 
NaHCO3 and washed with Et2O, concentrated and purified directly by silica gel column 
chromatography (eluent hexane/EtOAc=15:1) to give the major syn product 133 as a 
colourless oil (124.9 mg, 68% over two steps, diastereomer ratio of syn/anti was 
determined to be 5:1 and the two diastereomers can be separated by column 
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chromatography). [α]D26+ 26.9 (c 0.9 in CHCl3); (found (ESI): M+ + Na, 329.1723. 
C18H26O4 requires M, 329.1723); vmax 1732, 1379, 1311, 1198, 1163, 1099, 963, 875, 754, 
698 cm MHz, CDCl3) 7.39-7.31 (4H, m, Ph), 7.29-7.23 (1H, m, Ph), 4.93 (1H, 
dd, J 11.6, 2.6, H-6), 4.47-4.43 (1H, m, H-4), 4.10 (2H, t, J 6.6, COOCH2), 2.57 (1H, dd, J 
15.4, 7.1, CH2COO), 2.41 (1H, dd, J 15.4, 5.9, CH2COO), 1.83 (1H, dt, J 12.9, 2.5, H-5), 
1.64-1.56 (5H, m, COOCH2CH2 and CCH3), 1.54-1.47 (4H, m, H-5 and CCH3), 1.43-1.34 
(2H, m, CH2CH3), 0.93 (3H, t, J 7.4, CH2CH3); C (100 MHz, CDCl3) 171.0, 142.1, 128.5, 
127.7, 125.9, 99.3, 71.4, 66.2, 64.4, 41.5, 38.9, 30.7, 30.2, 19.7, 19.1, 13.7; m/z (ESI-MS) 
329.2 (M+Na)+. 
 
2,2-Dimethyl-(6R)-phenyl-1,3-dioxane-(4S)-N-methoxy-N-methyl acetamide 134. 
This compound is novel. 
 
A solution of isopropylmagnesium chloride (2 M in hexane, 0.4 cm3, 0.8 mmol) was 
slowly added to a THF (1 cm3) solution of ester 133 (49 mg, 0.16 mmol) and N,O-
dimethylhydroxylamine hydrochloride (38.8 mg, 0.4 mmol) at 0 °C. After stirring for 1 h 
at 0 °C, the reaction was quenched with sat NH4Cl solution (2 cm
3) and extracted with 
EtOAc (3 × 10 cm3), the combined organic phases were washed with brine, dried over 
MgSO4, and concentrated. The crude product was purified by silica gel column 
chromatography (eluent hexane/EtOAc=4:1-2:1) to afford the amide as a white solid (42.5 
mg, 0.145 mmol, 91%). MP 70 °C; [α]D27+48.1 (c 0.2 in CHCl3); (found (ESI): M+ + Na, 
316.1519. C16H23NO4 requires M, 316.1519); vmax 2992, 2940, 1657, 1379, 1253, 1198, 
1163, 998, 753, 699 cm-1(400 MHz, CDCl3) 7.39-7.22 (5H, m, Ph), 4.96 (1H, dd, J 
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11.6, 2.5, H-6), 4.59-4.53 (1H, m, H-4), 3.69, (3H, s, NOCH3), 3.18 (3H, s, NCH3), 2.82 
(1H, dd, J 15.5, 6.0, CH2CON), 2.49 (1H, dd, J 15.5, 6.5, CH2CON), 1.92 (1H, dt, J 12.9, 
2.4, H-5), 1.59 (3H, s, CCH3), 1.49 (3H, m, CCH3), 1.48 (1H, dd, J 12.9, 11.8, H-5); C 
(100 MHz, CDCl3) 150.8, 142.3, 128.4, 127.5, 125.9, 99.3, 71.4, 66.3, 61.4, 39.3, 38.6, 
30.2, 19.9; m/z (ESI-MS) 316.1 (M+Na)+. 
 
Compound 135. This compound is novel. 
 
To a solution of phenylacetylene (135 mg, 1.38mmol) in anhydrous THF (6 cm3) at -78 
°C, n-BuLi (1.6 M in hexane, 0.73 cm3, 1.16 mmol) was added in 3 min. The mixture was 
stirred at -78 °C for 1 h and a Weinreb amide 134 (136.0 mg in 2.0 cm3 THF, 0.46 mmol) 
solution was added dropwise. After 30 min at -78 °C, temperature was raised to -10 °C for 
2 h and sat NH4Cl (8 cm
3) was added at -10 °C and the mixture was extracted with EtOAc 
(3 × 30 cm3) and combined organic phase was dried over anhydrous MgSO4. The crude 
product was purified by silica gel column chromatography (eluent hexane/EtOAc=12:1-
8:1) to afford the ketone 135 as a colourless oil (129.7 mg, 0.388 mmol, 84%). [α]D27+ 
77.8 (c 0.1 in CHCl3); (found (ESI): M
+ + Na, 357.1461. C22H22O3 requires M, 357.1461); 
vmax 2992, 2202, 1666, 959, 755, 688 cm
-1; (400 MHz, CDCl3) 7.59-7.25 (10H, m, Ph), 
4.98 (1H, d, J 11.6, PhCH), 4.75-4.67 (1H, m, CH), 2.96 (1H, dd, J 16.3, 7.3, HCHCO), 
2.74 (1H, dd, J 16.3, 5.4, HCHCO), 1.91-1.84 (1H, m, HCH), 1.60 (3H, s, CCH3), 1.59-
1.53 (1H, m, HCH), 1.49 (3H, s, CCH3);C (100 MHz, CDCl3) 185.0, 142.1, 133.1, 130.9, 
128.7, 128.5, 127.7, 125.9, 119.9, 99.4, 91.3, 88.0, 71.4, 65.6, 51.8, 38.9, 30.1, 19.7; m/z 
(ESI-MS) 357.1 (M+Na)+. 
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Compound 136. This compound is novel. 
 
(R,R)-c2 (0.3 mg, 5 × 10-4 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
(28.5 mg) and ketone 135 (22.7 mg, 0.068 mmol) in degassed CH2Cl2 (0.5 cm
3) was 
injected under nitrogen atmosphere. The mixture was stirred at rt until starting material 
was completely consumed then the reaction was quenched by sat NaHCO3 (0.5 cm
3) 
extracted with CH2Cl2 (3 × 6 cm
3) and the combined organic phase was dried over 
anhydrous MgSO4. The crude product was purified by silica gel column chromatography 
(eluent hexane/EtOAc=6:1-4:1) to afford the chiral alcohol as colourless oil (21.7 mg, 
0.064 mmol, 94%, dr 37/1). [α]D26+ 22.3 (c 0.9 in CHCl3); (found (ESI): M+ + Na, 
359.1618. C22H24O3 requires M, 359.1617); vmax 3426, 2991, 1159, 75, 691 cm
-1;(400 
MHz, CDCl3) 7.45-7.28 (10 H, m, 2 × Ph), 4.99 (1H, dd, J 11.5, 2.7, HCPh), 4.85-4.81 
(1H, m, CHC≡), 4.99 (1H, tt, J 10.6, 2.7, CH), 3.57 (1H, d, J 8.4, OH), 2.04 (1H, ddd, J 
14.5, 11.9, 3.1, HCHCHOHC≡), 1.91 (1H, ddd, J 14.5, 5.9, 2.7, HCHCHOHC≡), 1.75 
(1H, dt, J 13.0, 2.7, HCHCHOPh), 1.69-1.60 (1H, m, HCHCHOPh overlap with CH3), 
1.65 (3H, s, CH3), 1.53 (3H, s, CH3);C (100 MHz, CDCl3) 142.0, 131.7, 128.5, 128.4, 
128.3, 127.8, 125.9, 122.8, 99.4, 89.6, 85.1, 71.6, 67.8, 61.3, 42.1, 39.0, 30.3, 19.9.m/z 
(ESI-MS)  359.1 (M+Na)+. 
 
 
 
 
      150 
 
Compound 137. This compound is novel. 
 
(S,S)-c2 (1.5 mg, 2.5 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
(20 mg) and ketone 135 (11.5 mg, 0.034 mmol) in degassed CH2Cl2 (0.3 cm
3) was 
injected under a nitrogen atmosphere. The mixture was stirred at rt until starting material 
was completely consumed then the reaction was quenched by addition of sat NaHCO3 (0.5 
cm3), extracted with CH2Cl2 (3 × 6 cm
3) and the combined organic phase was dried over 
anhydrous MgSO4. The crude product was purified by silica gel column chromatography 
(eluent hexane/EtOAc=6:1-4:1) to afford the chiral alcohol as colourless oil (11.5 mg, 
0.034 mmol, 99%, dr 37/1). [α]D26+17.1(c 0.9 in CHCl3); H (400 MHz, CDCl3) 7.46-7.25 
(10H, m, 2 × Ph), 4.94 (1H, dd, J 11.6, 2.4, HCPh), 4.85-4.81 (1H, t, J 6.6, CHC≡), 4.42-
4.33 (1H, m, CH), 2.92 (1H, br, OH), 2.15-2.07 (1H, m, HCHCHOHC≡), 1.92 (1H, ddd, J 
13.9, 5.8, 3.4, HCHCHOHC≡), 1.75 (1H, dt, J 13.1, 2.5, HCHCHOHPh), 1.67-1.56 (1H, 
m, HCHCHOHPh overlap with CH3), 1.60 (3H, s, CH3), 1.52 (3H, s, CH3);C (100 MHz, 
CDCl3) 142.0, 131.7, 128.5, 128.4, 128.3, 127.7, 125.9, 122.7, 99.4, 89.5, 84.8, 71.5, 68.5, 
61.6, 43.8, 39.2, 30.3, 19.9. m/z (ESI-MS) 359.1 (M+Na)+. 
 
Yashabushitriol 129. This compound is known but not fully characterized.115 
 
Alcohol (45.2 mg, 0.135 mmol) and PPTS (18 mg, 0.072 mmol) were dissolved in MeOH 
(3 cm3) and the resulting solution was stirred overnight. MeOH was removed and the 
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residue was passed through a short silica gel column (eluent pure EtOAc) and 
concentrated. PtO2 powder (2.0 mg, 8.8×10
-3 mmol) was added followed by MeOH (3 
cm3). The mixture was degassed once and stirred vigorously under a 1 atm H2 atmosphere 
for 30 min. The catalyst was removed by filtration and the solid residue was rinsed with 
MeOH (20 cm3). The eluent was concentrated and purified by silica gel column 
chromatography (eluent hexane/EtOAc=2:1-1:2) to afford yashabushitriol 129 (34.6 mg, 
0.115 mmol, 86% for 2 steps). MP 87 °C; [α]D25+ 25.0(c 1.4 in CHCl3); (lit MP 88.5-
90 °C; [α]D+ 29.5 (in CHCl3)); (found (ESI): M+ + Na, 323.1618. C19H24O3 requires M, 
323.1617); vmax 3324, 2914, 1105, 1059, 1028, 749, 697 cm
-1;  (400 MHz, CDCl3) 7.38-
7.15 (10H, m, 2 × Ph), 4.98 (2H, dt, J 10.4 2.1, H-1), 4.38-4.31 (1H, m, H-3), 4.04-3.96 
(2H, m, H-5 and OH), 3.13-3.15 (1H, br, OH), 2.80 (1H, ddd, J 13.7 9.0 5.9, H-7), 2.73 
(1H, d, J 4.2, OH), 2.66 (1H, ddd, J 13.7 8.4 6.4, H-7), 2.02 (1H, dt, J 14.5 10.3, H-2), 
1.93-1.83 (1H, m, H-6), 1.81-1.78 (1H, m, H-6), 1.73-1.67 (3H, m, H-4, H-2); C (100 
MHz, CDCl3) 144.3, 142.0, 128.6, 128.5, 128.4, 127.7, 126.9, 125.7, 75.4, 70.4, 68.6, 45.1, 
42.8, 39.2, 32.1. m/z (ESI-MS) 323.1 (M+Na)+. 
 
5-epi-Yashabushitriol 5-epi-129. This compound is novel. 
 
Alcohol (17.0 mg, 0.051 mmol) and PPTS (12 mg) was dissolved MeOH (2 cm3) 
and the resulting solution was stirred overnight. MeOH was removed and the residue 
was passed through a short silica gel column (eluent pure EtOAc) and concentrated. 
PtO2 (0.7 mg, 3.1×10
-3 mmol) was added followed by MeOH (1 cm3), the mixture 
was degassed once and stirred vigorously for 30 min under a 1 atm H2 atmosphere. 
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The catalyst was removed by filtration and the solid residue was rinsed with MeOH. 
The eluent was concentrated and purified by silica gel column chromatography 
(eluent hexane/EtOAc=2:1-1:2) to afford 5-epi-Yashabushitriol 5-epi-129 (11.2 mg, 
0.037 mmol, 74%). [α]D25+ 32.6 (c 0.5 in CHCl3); vmax 3316, 2922, 1058, 1028, 749, 
697 cm-1; H (400 MHz, CDCl3) 7.37-7.15 (10H, m, 2 × Ph), 4.94 (1H, dd, J 10.2, 
2.6, H-1), 4.36 (1H, br, OH), 4.20 (1H, tt, J 9.7, 2.2, H-3), 3.96-3.88 (1H, m, H-5), 
3.36 (1H, br, OH), 3.21(1H, br, OH), 2.79-2.59 (2H, m, H-7), 1.95-1.52 (6H, m, H-2, 
H-4, H-6); C (100 MHz, CDCl3) 144.3, 141.9, 128.6, 128.5, 128.4, 127.7, 125.9, 
125.7, 75.3, 73.5, 72.2, 46.0, 43.5, 39.7, 31.7. m/z (ESI-MS) 323.1 (M+Na)+. 
 
3.8. Synthesis of Acetylenic α-Keto Esters. 
General Procedure 
 
To a solution of acetylene (7.5 mmol) in anhydrous THF (6 cm3) at -78 °C, n-BuLi (1.6 M 
in hexane, 4.7 cm3, 7.5 mmol) was added over 3 min. The mixture was stirred at -78 °C 
for 1h then diethyl oxalate (1.46 g in 8 cm3 THF, 10.0 mmol) was added dropwise over 3 
min followed by BF3·OEt2 (1.1 cm
3, 8.2 mmol). After 30 min the reaction was quenched 
by sat NH4Cl (8 cm
3), extracted with EtOAc (2 × 15 cm3) and dried over anhydrous 
MgSO4. After concentration and removal of excess diethyl oxalate under reduced pressure, 
the crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=15:1-10:1). 
 
2-Oxo-4-phenyl-3-butynoic acid, ethyl ester 138. This compound is known and has 
been fully characterized.175 
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This compound was prepared following the general procedure above using 
phenylacetylene (765 mg, 7.5 mmol), n-BuLi (4.7 cm3, 7.5 mmol), diethyl oxalate (1.46 g, 
10.0 mmol) and BF3·OEt2 (1.1 cm
3, 8.2 mmol). The product was isolated as a yellow oil 
(1.15 g, 5.7 mmol, 76%). H (400 MHz, CDCl3) 7.71-7.66 (2H, m, Ph), 7.55-7.51 (1H, m, 
Ph), 7.44-7.41 (2H, m, Ph), 4.41 (2H, q, J 7.1, CH2), 1.43 (3H, t, J 7.1, CH3); C (100 MHz, 
CDCl3) 169.6, 155.2, 133.8, 131.9, 128.8, 119.1, 98.0, 87.2, 63.3, 14.0.  
 
5-Benzyloxy-2-oxo-3-pentynoic acid, ethyl ester 139. This compound is novel. 
 
This compound was prepared following the general procedure above using acetylene (548 
mg, 3.75 mmol), n-BuLi (2.40 cm3, 3.85 mmol), diethyl oxalate (730 mg, 5.0 mmol) and 
BF3·OEt2 (0.55 cm
3, 4.1 mmol). The product was isolated as yellow oil (737 mg, 3.0 
mmol, 80%). (found (ESI): M+ + Na, 269.0784; C14H14O4 requires M, 269.0784); νmax 
2212, 1740, 1686, 1265, 1143, 739, 697 cm -1; H (400 MHz, CDCl3) 7.40-7.31 (5H, m, 
Ph), 4.67 (2H, s, PhCH2), 4.41 (2H, s, CH2C≡), 4.38 (2H, q, J 7.1, CH2), 1.40 (3H, t, J 
7.1, CH3); C (100 MHz, CDCl3) 169.1, 158.7, 136.6, 128.6, 128.3, 128.2, 95.3, 84.2, 72.1, 
63.4, 56.9, 13.9. m/z (EI-MS) 269.0 (M+Na)+. 
 
6-Benzyloxy-2-oxo-3-hexynoic acid, ethyl ester 140. This compound is novel. 
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This compound was prepared following the general procedure above using acetylene (600 
mg, 3.75 mmol), n-BuLi (2.40 cm3, 3.85 mmol), diethyl oxalate (730 mg, 5.0 mmol) and 
BF3·OEt2 (0.55 cm
3, 4.1 mmol). The product was isolated as a colourless oil (820 mg, 
3.20 mmol, 84%). (found (ESI): M+ + H, 261.1121; C15H16O4 requires M, 261.1121); νmax 
2213, 1738, 1680, 1156, 1096, 1017, 698, 650 cm-1; H (400 MHz, CDCl3) 7.35-7.28 (5H, 
m, Ph), 4.57 (2H, s, PhCH2), 4.35 (2H, q, J 7.1, COOCH2), 3.68 (2H, t, J 6.7, BnOCH2), 
2.78 (2H, t, J 6.7, CH2C≡), 1.37 (3H, t, J 7.1, CH3); C (100 MHz, CDCl3) 169.6, 159.2, 
137.7, 128.5, 127.9, 127.7, 98.8, 80.2, 73.2, 66.8, 63.2, 21.1, 14.0. m/z (EI-MS) 283.1 
(M+Na)+. 
 
3.9. Synthesis of Propargylic β-Keto Esters, Propargylic β-Keto Thioesters 
and Propargylic α-Methyl-β-keto Esters. 
General Procedure [1] Claisen-type Condensation: 
 
3-Oxo-5-phenyl-4-pentynethioic acid, methyl ester 143. This compound is known but 
not fully characterized.176 
Dimethyl malonate (1.58 g, 12.0 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole 95 
(2.47 g, 10.0 mmol), anhydrous MgBr2·OEt2 powder (5.16 g, 20.0 mmol) was added to a 
flask and CH2Cl2 (30 cm
3) was added. The suspension was stirred at rt for 2 h then i-
Pr2NEt (3.87 g, 30.0 mmol) was added dropwise. A clear orange coloured solution was 
formed immediately and the solution was allowed to stir at rt for 0.5 h. Sat NH4Cl (15 cm
3) 
was added followed by aqueous HCl (10%, 15 cm3) and stirring was continued for 5 min. 
After a clear solution was formed the aqueous layer was extracted with CH2Cl2 (2 × 50 
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cm3) and the combined organic extract was dried over MgSO4. Solvent was evaporated 
under reduced pressure and the crude product was semi-purified by a short silica gel 
column (eluent hexane/EtOAc= 12/1) to afford a mixture of Claison condensation adduct 
and dimethyl malonate.  
TsOH·H2O (270 mg) and water (80 cm
3) was added to the aforementioned mixture and 
the resulting solution was refluxed for 6 h. The aqueous phase was extracted with Et2O (3 
× 40 cm3) and the combined organic phase was dried over MgSO4. The solvent was 
evaporated under reduced pressure and the crude product was purified by a silica gel 
column (eluent hexane/EtOAc= 20/1-15/1) to afford product 143 as a colourless oil (1.37 
g, 6.78 mmol, 68% for two steps, enol/β-keto=1.9/1). H (400 MHz, CDCl3) 11.87 (0.27H, 
s, OH), 7.62-7.34 (5H, m, Ph), 5.47 (0.27H, s, =CH), 3.80, 3.79 (3H, s, OCH3), 3.71 
(1.32H, s, CH2). 
 
3-Oxo-5-phenyl-4-pentynethioic acid, ethyl ester 144. This compound is known and has 
been fully characterized.177 
Diethyl malonate (96 mg, 0.6 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole 95 
(123 mg, 0.5 mmol), anhydrous MgBr2·OEt2 powder (258 mg, 1.0 mmol) was added to a 
flask and CH2Cl2 (2.5 cm
3) was added. The suspension was stirred at rt for 2 h then i-
Pr2NEt (194 mg, 1.5 mmol) was added dropwise. A clear orange colour solution was 
formed immediately and the solution was allowed to stir at rt for 1 h. Sat NH4Cl (1.5 cm
3) 
was added followed by aqueous HCl (10%, 1.0 cm3) and stirring was continued for 5 min. 
After a clear solution was formed, the aqueous layer was extracted with CH2Cl2 (2 × 10 
cm3) the combined organic extract was dried over MgSO4. The solvent was evaporated 
under reduced pressure and the crude product was semi-purified by a short silica gel 
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column (eluent hexane/EtOAc= 15/1) to afford a mixture of Claisen adduct and diethyl 
malonate.  
TsOH·H2O (20 mg) and water (6.0 cm
3) was added to the aforementioned mixture 
and the resulting solution was refluxed for 6 h.  The aqueous phase was extracted 
with Et2O (3 × 10 cm
3) and the combined organic phase was dried over MgSO4. The 
solvent was evaporated under reduced pressure and the crude product was purified 
by a silica gel column (eluent hexane/EtOAc= 15/1) to afford the product 144 as 
colourless oil (71 mg, 0.33 mmol, 66% for two steps). νmax 2983, 2203, 1739, 1671, 
1613, 1207, 1029, 756, 688 cm-1; H (400 MHz, CDCl3) 11.98 (0.32H, s, OH), 7.58-
7.32 (5H, m, Ph), 5.45 (0.32H, s, =CH), 4.27-4.20 (2H, m, COOCH2), 3.69 (1.27H, s, 
CH2), 1.32-1.27 (3H, m, CH3); C (100 MHz, CDCl3) 178.8, 172.2, 166.1, 155.3, 
133.3, 133.1, 132.2, 130.2, 130.8, 129.9, 128.7, 128.6, 128.5, 120.8, 119.5, 97.2, 
93.4, 87.3, 83.4, 61.7, 60.7, 51.4, 50.6, 14.2, 14.1; m/z (EI-MS) 239.1 (M+Na)+. 
 
 
Thioester (2.0 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (2.0 mmol), 
anhydrous MgBr2·OEt2 powder (1.54 g, 6.0 mmol) were combined in a flask and CH2Cl2 
(8.0 cm3) was added. The suspension was stirred at rt for 2 h then i-Pr2NEt (257 g, 2.0 
mmol) was added dropwise. The solution was allowed to stir at rt for 0.5 h. Sat NH4Cl (4 
cm3) was added follow by aqueous HCl (10%, 4 cm3) and stirring was continued for 5 min. 
After a clear solution was formed the aqueous layer was extracted with CH2Cl2 (2 × 30 
cm3) and the combined organic extract was dried over MgSO4. Solvent was evaporated 
under reduced pressure and the crude product was purified by silica gel column (eluent 
hexane/EtOAc= 20/1-15/1) to afford pure product.  
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3-Oxo-5-phenyl-4-pentynethioic acid, S-ethyl ester 142. This compound is novel. 
This compound was prepared following the general procedure above using S-ethyl 
thioacetate (52 mg, 0.5 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole 95 (124 mg, 
0.5 mmol), anhydrous MgBr2·OEt2 powder (387 mg, 1.5 mmol) and i-Pr2NEt (257 mg, 
2.0 mmol). The product 142 was isolated as colourless oil (90 mg, 0.39 mmol, 78%, 
enol/β-keto=1.9/1). (found (ESI): M+ + Na, 255.0450. C13H12O2S requires M, 255.0455); 
νmax 2931, 2972, 2003, 1706, 1666, 1602, 1587, 1366, 1284, 1076, 865, 754, 686 cm-1; H 
(400 MHz, CDCl3) 12.53 (0.65H, s, OH), 7.59-7.35 (5H, m, Ph), 5.84 (0.65H, s, =CH), 
3.89 (0.69H, s, CH2), 2.97 (2H, q, J 7.4, OCH2), 1.33-1.27 (3H, m, CH3); C (100 MHz, 
CDCl3) 195.1, 178.2, 152.6, 133.3, 130.0, 132.3, 131.3, 130.6, 130.1, 128.7, 128.6, 120.7, 
119.4, 106.3, 94.1, 83.3, 62.1, 59.4, 24.2, 23.1, 14.7, 14.1; m/z (EI-MS) 250.0 (M+Na)+. 
 
3-Oxo-5-phenyl-4-pentynethioic acid, S-phenyl ester 141. This compound is novel. 
This compound was prepared following the general procedure above using S-phenyl 
thioacetate (304 mg, 2.0 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole 95 (500 mg, 
2.0 mmol), anhydrous MgBr2·OEt2 powder (1.54 g, 6.0 mmol) and i-Pr2NEt (1.04 g, 8.0 
mmol). The product 141 was isolated as a white solid (500 mg, 1.79 mmol, 88%, enol/β-
keto=2.0/1).P 52 °C; (found (ESI): M+ + Na, 303.0449. C17H12O2S requires M, 
303.0455); H (400 MHz, CDCl3) 12.29 (0.67H, s, OH), 7.48-7.24 (10H, m, 2 × Ph), 5.80 
(0.67H, s, =CH), 3.87 (0.68H, s, CH2); C (100 MHz, CDCl3) 193.8, 177.9, 153.9, 135.0, 
134.5, 133.4, 132.5, 131.4, 130.3, 130.0, 129.5, 129.4, 128.8, 128.7, 126.6, 120.5, 105.0, 
94.9, 83.3, 58.9; m/z (EI-MS) 303.0 (M+Na)+. 
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General Procedure [2] Condensation with Acid Chlorides: 
 
To a solution of alkyne (8.6 mmol) in anhydrous THF (12 cm3) at -78 °C, n-BuLi (1.6 M 
in hexane, 5.0 cm3, 8.0 mmol) was added via a syringe in 3 min. The mixture was stirred 
at the same temperature for 60 min then BF3·Et2O (1.1 cm
3, 8.5 mmol) was injected, and 
after 10 min malonic acid chloride monomethyl ester (495 mg, 3.63 mmol) in THF (1 cm3) 
was added. The mixture was stirred for 2 h then was quenched by sat NH4Cl (5 cm
3) and 
water (5 cm3), extracted with Et2O (3 × 20 cm
3) and dried over anhydrous MgSO4. After 
concentration under reduced pressure, the crude product was purified by silica gel column 
chromatography (eluent hexane/EtOAc=20:1-15:1) to afford the pure product. 
 
3-Oxo-4-nonynoic acid, methyl ester 161. This compound is novel. 
 
This compound was prepared following the general procedure above using 1-hexyne (705 
mg, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), BF3·Et2O (1.1 cm
3, 8.5 
mmol) and malonic acid chloride monomethyl ester (495 mg, 3.63 mmol). The product 
was isolated as a colourless oil (320 mg, 1.75 mmol, 48%). (found (ESI): M+ + Na, 
205.0837. C10H14O3 requires M, 205.0840); νmax 2958, 2935, 2213, 1746, 1676, 1611, 
1441, 1245, 1169, 1142, 805 cm-1; H (400 MHz, CDCl3) 11.81 (0.23H, s, OH), 5.29 
(0.23H, s, =CH), 3.76 (major), 3.75 (minor),  (3H, s, OCH3), 3.58 (1.42H, s, COCH2), 
2.41-2.35 (2H, m, ≡CCH2), 1.61-1.54 (2H, m, CH2), 1.48-1.39 (2H, m, CH2), 0.93 (3H, t, 
J 7.3, CH3); C (100 MHz, CDCl3) 178.7, 172.6, 166.6, 165.9, 97.1, 96.4, 95.8, 80.3, 52.5, 
51.5, 51.1, 29.9, 29.5, 21.9, 18.9, 18.7, 13.4; m/z (EI-MS) 205.1 (M+Na)+. 
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3-Oxo-6-benzyloxy-6 methyl-4-heptynoic acid, methyl ester 160. This compound is 
novel. 
 
This compound was prepared following the general procedure above using alkyne (1.36 g, 
7.9 mmol), n-BuLi (1.6 M in hexane, 4.6 cm3, 7.4 mmol), BF3·Et2O (1.01 cm
3, 7.8 mmol) 
and malonic acid chloride monomethyl ester (390 mg, 2.8 mmol). The product was 
isolated as a colourless oil (313 mg, 1.14 mmol, 40%). (found (ESI): M+ + Na, 297.1097. 
C16H18O4 requires M, 297.1102); νmax 2989, 2954, 2220, 1748, 1610, 1443, 1382, 1214, 
1156, 805, 734, 697 cm-1; H (400 MHz, CDCl3) 11.79 (0.41H, s, OH), 7.39-7.26 (5H, m, 
Ph), 5.35 (0.41H, s, =CH), 4.63 (major), 4.62 (minor), (2H, s, PhCH2), 3.73 (major), 3.76 
(minor), (3H, s, COOCH3), 3.58 (1.04H, s, COCH2), 1.60 (6H, s, 2 × CH3); C (100 MHz, 
CDCl3) 178.4, 154.9, 138.5, 138.2, 128.44, 128.39, 127.74, 127.67, 127.57, 97.0, 96.1, 
82.7, 78.8, 70.8, 70.6, 67.1, 67.0, 52.6, 51.7, 51.1, 28.4, 28.1; m/z (EI-MS)  297.1 
(M+Na)+. 
 
3-Oxo-7-benzyloxy-4-heptynoic acid, methyl ester 162. This compound is novel. 
 
This compound was prepared following the general procedure above using alkyne (963 
mg, 6.0 mmol), n-BuLi (1.6 M in hexane, 3.5 cm3, 5.6 mmol), BF3·Et2O (0.77 cm
3, 6.0 
mmol) and malonic acid chloride monomethyl ester (300 mg, 2.2 mmol). The product was 
isolated as a colourless oil (230 mg, 0.88 mmol, 45%). (found (ESI): M+ + Na, 283.0941. 
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C15H16O4 requires M, 283.0946); νmax 2869, 2217, 1743, 1676, 1250, 1099, 737, 698 cm-1; 
H (400 MHz, CDCl3) 11.80 (0.21H, s, OH), 7.37-7.26 (5H, m, Ph), 5.27 (0.21H, s, =CH), 
4.53 (major), 4.54 (minor), (2H, s, PhCH2), 3.72 (major), 3.73 (minor), (3H, s, OCH3), 
3.62 (2H, t, J 6.7, BnOCH2), 3.57 (1.33H, s, COCH2), 2.67 (2H, t, J 6.7, ≡CCH2); C (100 
MHz, CDCl3) 178.6, 172.6, 166.6, 155.5, 137.7, 128.5, 127.9, 127.7, 96.3, 93.5, 92.9, 80.9, 
76.3, 73.1, 73.0, 67.3, 67.0, 52.5, 51.6, 51.0, 20.8, 20.6; m/z (EI-MS) 283.1 (M+Na)+. 
 
General Procedure  
 
To a solution of alkyne (8.6 mmol) in anhydrous THF (12 cm3) at -78 °C n-BuLi (1.6 M 
in hexane, 5.0 cm3, 8.0 mmol) was added via a syringe in 3 min. The mixture was stirred 
at the same temperature for 10 min then BF3·Et2O (1.1 cm
3, 8.5 mmol) was injected. After 
10 min, 3-chloro-2-methyl-3-oxo-propanoic acid, ethyl ester (510 mg, 3.10 mmol) in THF 
(1 cm3) was added in one portion. The mixture was stirred for 1.5 h then was quenched by 
sat NH4Cl (5 cm
3) and water (5 cm3), extracted with Et2O (2 × 20 cm
3), dried over 
anhydrous MgSO4. After concentration under reduced pressure the crude product was 
purified by silica gel column chromatography (eluent hexane/DCM=10:1-10:3) to afford 
the pure product. 
 
2-Methyl-3-oxo-5-phenyl-4-pentynethioic acid, ethyl ester 163. This compound is 
novel. 
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This compound was prepared following the general procedure above using 
phenylacetylene (877 mg, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), 
BF3·Et2O (1.1 cm
3, 8.5 mmol) and freshly prepared 3-chloro-2-methyl-3-oxo-propanoic 
acid, ethyl ester (510 mg, 3.10 mmol). The product was isolated as light yellow crystals 
(551 mg, 2.40 mmol, 77%). MP 59 °C; (found (ESI): M+ + Na, 253.0835. C14H14O3 
requires M, 253.0840); νmax 2994, 2931, 2905, 2211, 1631, 1604, 1379, 1276, 1188, 1061, 
789, 753, 688 cm-1; H (400 MHz, CDCl3) 12.21 (0.74H, s, OH), 7.60-7.51 (2H, m, Ph), 
7.46-7.33 (3H, m, Ph), 4.28-4.21 (2H, m, COOCH2), 3.68 (0.26H, q, J 7.2, CH), 2.00 
(2.22H, s, =CCH3), 1.50 (0.78H, d, J 7.2, CHCH3), 1.33 (2.26H, t, J 7.1, COOCH2CH3), 
1.28 (0.74H, t, J 7.1, COOCH2CH3); C (100 MHz, CDCl3) 128.9, 173.0, 152.0, 133.2, 
132.0, 131.1, 129.7, 128.7, 128.5, 121.3, 119.6, 104.2, 97.7, 96.3, 86.4, 83.0, 61.6, 61.0, 
55.0, 14.2, 14.1, 13.2, 12.9; m/z (EI-MS) 253.1 (M+Na)+. 
 
2-Methyl-3-oxo-4-nonynoic acid, ethyl ester 165. This compound is novel. 
 
This compound was prepared following the general procedure above using 1-hexyne (706 
mg, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), BF3·Et2O (1.1 cm
3, 8.5 
mmol) and freshly prepared 3-chloro-2-methyl-3-oxo-propanoic acid, ethyl ester (510 mg, 
3.10 mmol). The product was isolated as alight yellow oil (538 mg, 2.56 mmol, 82%). 
(found (ESI): M+ + Na, 233.1148. C12H18O3 requires M, 233.1153); νmax 2961, 2935, 2211, 
1741, 1678, 1644, 1600, 1334, 1243, 1121cm-1; H (400 MHz, CDCl3) 12.15 (0.52H, s, 
OH), 4.24 (q, J 7.1) and 4.21 (qd, J 7.1 2.0) (total 2H, COOCH2), 3.54 (0.34H, q, J 7.2, 
CH), 2.44 (1.29H, t, J 7.1, CH2C≡), 2.39 (0.71H, t, J 7.1, CH2C≡), 1.89 (1.72H, s, =CCH3), 
1.62-1.53 (2H, m, CH2), 1.50-1.41 (2H, m, CH2), 1.42 (1.17H, d, J 7.2, CHCH3), 1.32 (t, J 
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7.1, COOCH2CH3) and 1.28 (t, J 7.1) (total 3H, COOCH2CH3), 0.934 (t, J 7.3) and 0.928 
(t, J 7.3) (total 3H, CH3); C (100 MHz, CDCl3) 173.1, 169.7, 152.4, 103.0, 100.3, 97.1, 
79.4, 74.9, 61.4, 60.8, 54.9, 30.1, 29.6, 21.94, 21.89, 19.1, 18.7, 14.2 14.0, 13.5 13.4, 12.9, 
12.8; m/z (EI-MS) 233.1 (M+Na)+. 
 
2-Methyl-3-oxo-7-benzyloxy-4-heptynoic acid, ethyl ester 166. This compound is novel. 
 
This compound was prepared following the general procedure above using acetylene (640 
mg, mmol), n-BuLi (1.6 M in hexane, 2.32 cm3, 3.71 mmol), BF3·Et2O (0.50 cm
3, 3.9 
mmol) and freshly prepared 3-chloro-2-methyl-3-oxo-propanoic acid, ethyl ester (237 mg, 
1.44 mmol). The product was isolated as colourless oil (298 mg, 1.03 mmol, 72%). (found 
(ESI): M+ + Na, 311.1254. C17H20O4 requires M, 311.1259); νmax 2865, 2225, 1738, 1643, 
1600, 1374, 1334, 1243, 1119, 1096, 1025, 804, 734, 697 cm-1; H (400 MHz, CDCl3) 
12.05 (0.68H, s, OH), 7.35-7.18 (5H, m, Ph), 4.49 (major), 4.47(minor) (2H total, s, 
PhCH2O), 4.19-4.06 (2H, m, COOCH2), 3.61-3.40 (2.53H, m, OCH2CH2, CH), 2.67 
(major, J 6.9) 2.61(minor, J 6.8) (2H, t, OCH2CH2C≡), 1.81 (2.33H, s, =CCH3), 1.37-1.36 
(0.87H, d, J 7.2, CHCH3), 1.26-1.11 (3H, m, COOCH2CH3); C (100 MHz, CDCl3) 173.1, 
152.0, 137.9, 128.6, 128.5, 128.3, 128.1, 127.8, 127.7, 103.5, 96.7, 75.8, 73.1, 67.7, 67.1, 
67.0, 61.5, 61.4, 60.9, 54.8, 46.2, 21.0, 20.6, 14.2, 14.0, 13.6, 13.0; m/z (EI-MS) 311.1 
(M+Na)+. 
 
2-Methyl-3-oxo-6-benzyloxy-6-methyl-4-heptynoic acid, ethyl ester 164. This 
compound is novel. 
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This compound was prepared following the general procedure above using acetylene (1.50 
g, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), BF3·OEt2 (1.1 cm
3, 8.5 mmol) 
and freshly prepared 3-chloro-2-methyl-3-oxo-propanoic acid, ethyl ester (510 mg, 3.10 
mmol). The product was isolated as a colourless oil (864 mg, 2.86 mmol, 92%). (found 
(ESI): M+ + Na, 325.1410. C18H22O4 requires M, 325.1415); νmax 2986, 2218, 1735, 1643, 
1600, 1374, 1333, 1207, 1155, 1086, 735, 697 cm-1; H (400 MHz, CDCl3) 12.06 (0.71H, 
s, OH), 7.12-7.39 (5H, m, Ph), 4.58 (major), 4.54 (minor) (2H, s, PhCH2O), 4.19-4.05 (2H, 
m, COOCH2), 3.50 (q, J 7.2) and 3.35 (q, J 7.3) (0.22H total, CH), 1.83 (2.28H, s, 
=CCH3), 1.54 (6H, s, 2 × CH3), 1.52 (masked by other peaks CHCH3), 1.35 (0.80, t, J 7.0, 
COOCH2CH3), 1.24 (2.20H, t, J 7.1, COOCH2CH3); C (100 MHz, CDCl3) 172.9, 151.5, 
138.6, 128.4, 128.3, 127.8, 127.7, 127.6, 104.2, 100.3, 96.1, 86.9, 78.3, 71.0, 67.0, 61.6, 
61.4, 61.0, 55.0, 46.2, 40.9, 30.5, 28.6, 28.2, 19.0, 14.2, 14.1, 13.1, 12.8; m/z (EI-MS) 
325.1 (M+Na)+. 
 
3.10. Synthesis of Acetylenic γ-Keto Esters and δ-Keto Esters. 
General Procedure [1] Preparation from Alkynyl Boranes: 
 
To a solution of acetylene (7.5 mmol) in anhydrous THF (6 cm3) at -78 °C, n-BuLi (1.6 M 
in hexane, 4.7 cm3, 7.5 mmol) was added in 3 min. The mixture was stirred at 0 °C for 1 h 
after cooling to -78 °C, when BF3·OEt2 (1.46 g in 8 cm
3 THF, 10.0 mmol) was added 
dropwise. After 10 min the mixture was cooled to -90 °C and 4-chloro-4-oxo-butanoic 
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acid methyl ester (1.46 g in 2 cm3 THF, 10.0 mmol) was added in one portion. The 
reaction was quenched by sat NH4Cl (8 cm
3) and water (8 cm3) after 2 h, extracted with 
Et2O (2 × 30 cm
3), dried over anhydrous MgSO4. After concentration under reduced 
pressure the crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=15:1-8:1). 
 
4-Oxo-6-phenyl-5-hexynoic acid methyl ester 176. This compound is novel. 
 
This compound was prepared following the general procedure above using phenylactylene 
(1.63 g, 16 mmol), n-BuLi (1.6 M in hexane, 9.5 cm3, 15.0 mmol), BF3·Et2O (2.0cm
3, 
16.0 mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (2.62 g, 17.4 mmol). The 
product was isolated as a colourless oil (1.61 g, 7.4 mmol, 49%). (found (ESI): M+ + Na, 
239.0682. C13H12O3 requires M 239.0684); νmax 2953, 2200, 1734, 1667, 1205, 1168, 1093, 
758, 688 cm-1; H (400 MHz, CDCl3) 7.60-7.56 (2H, m, Ph), 7.49-7.44 (1H, m, Ph), 7.41-
7.36(2H, m, Ph), 3.71 (3H, s, COOCH3), 3.03 (2H, t, J 6.7, CH2),2.72 (2H, t, J 6.7, CH2); 
C (100 MHz, CDCl3) 185.4, 172.5, 133.0, 130.8, 128.7, 119.8, 91.4, 87.4, 51.9, 40.0, 
27.8; m/z (EI-MS) 239.1 (M+Na)+. 
 
4-Oxo-5-decynoic acid, methyl ester 177. This compound is novel. 
 
This compound was prepared following the general procedure above using 1-hexyne (705 
mg, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), BF3·Et2O (1.1cm
3, 8.5 
mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (1.57 g, 10.4 mmol). The product 
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was isolated as a colourless oil (417 mg, 2.1 mmol, 27%). (found (ESI): M+ + Na, 
219.0992. C11H16O3 requires M 219.0997); νmax 2958, 2210, 1737, 1675, 1208, 1154 cm-1; 
H (400 MHz, CDCl3) 3.69 (3H, s, COOCH3), 2.88 (2H, t, J 6.7, CH2), 2.64 (2H, t, J 6.7, 
CH2), 2.38 (2H, t, J 7.1, CH2C≡), 1.63-1.51 (2H, m, CH2), 1.51-1.35 (2H, m, CH2), 0.93 
(3H, t, J 7.2, CH3); C (100 MHz, CDCl3) 185.5, 172.6, 95.1, 80.4, 51.8, 40.0, 29.6, 27.8, 
21.9, 18.6, 13.4; m/z (EI-MS) 219.1 (M+Na)+. 
 
4-Oxo-7-benzyloxy-7-methyl-5-octynoic acid, methyl ester 178. This compound is 
novel. 
 
This compound was prepared following the general procedure above using alkyne (1.50 g, 
8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), BF3·Et2O (1.1cm
3, 8.5 mmol) 
and 4-chloro-4-oxo-butanoic acid methyl ester (1.57 g, 10.4 mmol). The product was 
isolated as a colourless oil (541 mg, 1.9 mmol, 22%). (found (ESI): M+ + Na, 311.1254. 
C17H20O4 requires M 311.1259); νmax 3032, 2210, 1737, 1679, 1122, 736, 697cm-1; H (400 
MHz, CDCl3) 7.38-7.24 (5H, m, Ph), 4.62 (2H, s, PhCH2), 3.68 (3H, s, COOCH3), 2.89 
(2H, t, J 7.6, CH2), 2.63 (2H, t, J 7.6, CH2), 1.59 (6H, s, 2 × CH3); C (100 MHz, CDCl3) 
185.1, 172.4, 138.4, 128.4, 127.7, 127.6, 94.2, 82.9, 70.6, 67.0, 51.9, 40.1, 28.2, 27.6; m/z 
(EI-MS) 311.1 (M+Na)+. 
 
5-Oxo-7-phenyl-6-heptynoic acid, methyl ester 180. This compound is known and has 
been fully characterized.178 
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This compound was prepared following the general procedure above using 
phenylacetylene (326 mg, 3.2 mmol), n-BuLi (1.6 M in hexane, 1.9 cm3, 3.0 mmol), 
BF3·Et2O (454 mg, 0.4 cm
3, 3.2 mmol) and glutaric acid monomethyl ester chloride (526 
mg, 3.2 mmol). The product was isolated as a colourless oil (300 mg, 1.3 mmol, 43%). 
(found (ESI): M+ + Na, 253.0833. C14H14O3 requires M 253.0840); νmax 2952, 2199, 1733, 
1667, 1197, 1168, 758, 689 cm-1; H (400 MHz, CDCl3) 7.60-7.55 (2H, m, Ph), 7.49-7.43 
(1H, m, Ph), 7.41-7.35 (2H, m, Ph), 3.69-3.66 (3H, m, COOCH3), 2.82-2.73 (2H, m, 
COCH2), 2.44-2.35 (2H, m, CH2COO), 2.10-2.01 (2H, m, CH2); C (100 MHz, CDCl3) 
186.8, 173.3, 133.0, 130.8, 128.6, 119.8, 90.9, 87.7, 51.6, 43.3, 32.8, 19.1. m/z (EI-MS) 
253.1 (M+Na)+. 
 
General Procedure [2] Preparation by Using Alkynylzinc Reagents: 
 
To a solution of acetylene (8.6 mmol) in anhydrous THF (20 cm3) at -78 °C, n-BuLi (1.6 
M in hexane, 5.0 cm3, 8.0 mmol) was added in 3 min. The mixture was stirred at -78 °C 
for 1 h, anhydrous ZnCl2 (1.90 g in 8 cm
3 THF, 14.0 mmol) was added and the mixture 
was warmed to 0 °C for 30 min then glutaric acid monomethyl ester chloride (987 mg, 6.0 
mmol) was added in one portion. The reaction was stirred overnight and quenched by sat 
NH4Cl (10 cm
3), water (10 cm3), extracted with Et2O (2 × 30 cm
3) and dried over 
anhydrous MgSO4. After concentration under reduced pressure the crude product was 
purified by silica gel column chromatography (eluent hexane/EtOAc=15:1-8:1). 
      167 
 
 
4-Oxo-8-benzyloxy-5-octynoic acid, methyl ester 179. This compound is novel. 
 
This compound was prepared following the general procedure above using alkyne (674 
mg, 4.3 mmol), n-BuLi (1.6 M in hexane, 2.5 cm3, 4.0 mmol), anhydrous ZnCl2 (950 mg, 
7.0 mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (451 mg, 3.0 mmol). The 
product was isolated as a colourless oil (204.9 mg, 0.75 mmol, 25%). (found (ESI): M+ + 
Na, 297.1097. C16H18O4 requires M 297.1102); νmax 2952, 2864, 2213, 1734, 1674, 1208, 
1155, 1100, 738, 698 cm-1; H (400 MHz, CDCl3) 7.39-7.27 (5H, m, Ph), 4.56 (2H, s, 
PhCH2), 3.68 (3H, s, COOCH3), 3.64 (2H, t, J 6.8, BnOCH2), 2.89 (2H, t, J 6.8, COCH2), 
2.69 (2H, t, J 6.8, CH2C≡), 2.64 (2H, t, J 6.8, CH2COO); C (100 MHz, CDCl3) 185.4, 
172.6, 137.7, 128.5, 127.9, 127.7, 91.5, 81.0, 73.1, 67.1, 51.9, 40.0, 27.8, 20.5; m/z (EI-MS) 
275.1 (M+H)+. 
 
5-Oxo-6-undecynoic acid, methyl ester 181. This compound is known but not fully 
characterized.179 
 
This compound was prepared following the general procedure above using 1-hexyne (1.42 
g, 17.2 mmol), n-BuLi (1.6 M in hexane, 10.0 cm3, 16.0 mmol), anhydrous ZnCl2 (3.77 g, 
28 mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (1.97 g, 12.0 mmol). The 
product was isolated as a colourless oil (1.33 g, 6.3 mmol, 53%). (found (ESI): M+ + Na, 
233.1148. C12H18O3 requires M 233.1153); νmax 2958, 2210, 1736, 1671, 1196, 1161 cm-1; 
H (400 MHz, CDCl3) 3.60 (3H, s, COOCH3), 2.54 (2H, t, J 7.2, COCH2), 2.30 (2H, t, J 
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7.0, CH2C≡), 2.29 (2H, t, J 7.2, CH2), 1.94-1.86 (2H, m, CH2CH2COO), 1.53 (2H, m, 
CH2), 1.46 (2H, m, CH2), 0.86 (3H, t, J 7.3, CH3); C (100 MHz, CDCl3) 187.0, 173.3, 
94.6, 80.7, 51.5, 44.3, 32.8, 29.6, 21.9, 19.1, 18.5, 13.4. m/z (EI-MS) 233.1 (M+Na)+. 
 
5-Oxo-9-benzyloxy-6-nonynoic acid, methyl ester 183. This compound is novel. 
 
This compound was prepared following the general procedure above using acetylene (1.50 
g, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), anhydrous ZnCl2 (1.90 g, 
14.0 mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (987 mg, 6.0 mmol). The 
product was isolated as a colourless oil (1.274 g, 4.4 mmol, 73%). (found (ESI): M+ + Na, 
311.1254. C17H20O4 requires M 311.1259); νmax 2952, 2866, 2214, 1733, 1671, 1199, 1162, 
1099, 737, 698 cm-1; H (400 MHz, CDCl3) 7.38-7.26 (2H, m, Ph), 4.62 (2H, s, PhCH2O), 
3.66 (3H, s, COOCH3), 3.63 (2H, t, J 6.7, OCH2), 2.66 (2H, t, J 6.7, CH2C≡), 2.61 (2H, t, 
J 7.2, COCH2), 2.35 (2H, t, J 7.2, CH2COO), 2.00-1.92 (2H, m, CH2); C (100 MHz, 
CDCl3) 186.9, 173.3, 137.8, 128.5, 127.8, 127.7, 91.1, 81.3, 73.1, 67.2, 51.6, 44.3, 32.8, 
20.5, 19.0. m/z (EI-MS) 311.1 (M+Na)+. 
 
5-Oxo-8-benzyloxy-8-methyl-6-nonynoic acid, methyl ester 182. This compound is 
novel. 
 
This compound was prepared following the general procedure above using acetylene (1.50 
g, 8.6 mmol), n-BuLi (1.6 M in hexane, 5.0 cm3, 8.0 mmol), anhydrous ZnCl2 (1.90 g, 
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14.0 mmol) and 4-chloro-4-oxo-butanoic acid methyl ester (987 mg, 6.0 mmol). The 
product was isolated as a colourless oil (884 mg, 2.90 mmol, 48%). (found (ESI): M+ + Na, 
325.1410. C18H22O4 requires M 325.1415); νmax 2987, 2952, 2213, 1734, 1676, 1156, 1049, 
737, 697 cm-1; H (400 MHz, CDCl3) 7.38-7.24 (5H, m, Ph), 4.62 (2H, s, PhCH2O), 3.66 
(3H, s, COOCH3), 2.63 (2H, t, J 7.2, COCH2), 2.36 (2H, t, J 7.2, CH2COO), 2.00-1.93 
(2H, m, CH2), 1.60 (6H, s, 2 × CH3); C (100 MHz, CDCl3) 186.5, 173.2, 138.4, 128.4, 
127.63, 127.60, 93.8, 83.2, 70.6, 67.0, 51.7, 44.4, 32.7, 28.3, 19.0. m/z (EI-MS) 325.1 
(M+Na)+. 
 
3.11. Synthesis of 4-Pentyne-1,3-diones. 
General Procedure 
 
Aromatic ketone (0.37 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (0.38 mmol) 
and anhydrous MgBr2·OEt2 powder [or anhydrous Mg(ClO4)2 powder] (0.76 mmol) was 
added to a flask and laboratory grade CH2Cl2 (1.5 cm
3) was added via a syringe. The 
suspension was stirred at rt for 3 h then i-Pr2NEt (1.0 mmol) was added dropwise. A clean 
yellow solution was formed immediately and the solution was allowed to stir at rt for 5 h. 
Sat NH4Cl (3 cm
3) was added follow by aqueous HCl (10 %, 1 cm3) and stirring was 
continued for 5 min. After a clear solution has formed the aqueous layer was extracted 
with CH2Cl2 (2 x 5 cm
3) and the combined organic extract was dried over MgSO4. The 
solvent was evaporated under reduced pressure and the yellow solid product was dissolved 
in the minimum amount of CH2Cl2 and purified by silica gel column chromatography 
[eluent hexane/ CH2Cl2/EtOAc= 10:1:0-10:1: (0.2-0.4)]. 
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1,5-Diphenyl-4-pentyne-1,3-dione 192. This compound is known and has been fully 
characterized.134 
 
This compound was prepared following the general procedure above using acetophenone 
(873 mg, 7.4 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (1.84 g, 7.6 mmol), 
MgBr2·OEt2 (3.92 g, 15.2 mmol) and i-Pr2NEt (2.51 g, 20.0 mmol). The product was 
isolated as described above as light yellow crystals (1.49 g, 6.0 mmol, 81%); H (400 MHz, 
CDCl3) 7.71-7.68 (2H, m, Ph), 7.38-7.31 (3H, m, Ph), 7.27-7.13 (5H, m, Ph), 6.29 (1H, s, 
=CH); C (75 MHz, CDCl3) 184.7, 169.7, 133.9, 132.3, 132.1, 129.8, 128.3, 128.2, 128.0, 
126.7, 119.8, 100.7, 93.3, 85.5.  
 
1-(4-Methylphenyl)-5-phenyl-4-pentyne-1,3-dione 193. This compound is known and 
has been fully characterized.134 
 
This compound was prepared following the general procedure above using p-methyl 
acetophenone (45.0 mg, 0.34 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (94.0 
mg, 0.38 mmol), Mg(ClO4)2 (170.0 mg, 0.76 mmol) and i-Pr2NEt (129.0 mg, 1.0 mmol). 
The product was isolated as described above as yellow crystals (60 mg, 0.23 mmol, 66%); 
H (400 MHz, CDCl3) 15.87 (1H, br, OH), 7.90-7.81 (2H, m, Ar), 7.64-7.58 (2H, m, Ar), 
7.47-7.36 (3H, m, Ar), 7.31-7.25 (2H, m, Ar), 6.50 (1H, s, =CH), 2.42 (3H, s, CH3); C 
(75 MHz, CDCl3) 185.7, 169.7, 143.9, 132.7, 131.9, 130.4, 129.5, 128.6, 127.4, 120.6, 
101.1, 93.6, 86.2, 21.7. 
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1-(4-Methoxyphenyl)-5-phenyl-4-Pentyne-1,3-dione 194. This compound is known but 
not fully characterized.180 
 
This compound was prepared following the general procedure above using p-methoxyl 
acetophenone (25.5 mg, 0.17 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (47.0 
mg, 0.19 mmol), Mg(ClO4)2 (85.0 mg, 0.38 mmol) and i-Pr2NEt (64.0 mg, 0.50 mmol). 
The product was isolated as described above as yellow crystals (34 mg, 0.12 mmol, 72%); 
H (400 MHz, CDCl3) 15.97 (1H, br, OH), 7.94-7.90 (2H, m, p-MeOPh), 7.62-7.57 (2H, 
m, Ph), 7.47-7.36 (3H, m, Ph), 6.98-6.95 (2H, m, p-MeOPh), 6.47 (1H, s, =CH), 3.88 (3H, 
s, CH3); C (75 MHz, CDCl3) 185.9, 168.4, 163.7, 132.6, 130.3, 129.6, 128.6, 127.2, 120.6, 
114.1, 100.8, 93.5, 86.0, 55.5. 
 
1-(2-Furanyl)-5-phenyl-4-pentyne-1,3-dione 195. This compound is known but not fully 
characterized.181 
 
This compound was prepared following the general procedure above using 1-(2-
furyl)ethanone (374 mg, 3.40 mmol), 1-(3-phenyl-1-oxo-2-propynyl)-benzotriazole (940 
mg, 3.80 mmol), Mg(ClO4)2 (1.70 g, 7.6 mmol) and i-Pr2NEt (1.28 g, 10.0 mmol). The 
product was isolated as described above as yellow crystals (491 mg, 2.06 mmol, 61%); H 
(400 MHz, CDCl3) 15.10 (1H, br, OH), 7.64-7.57 (3H, m, Ar), 7.62-7.57 (3H, m, Ph and 
2-furyl), 7.47-7.36 (3H, m, Ph), 7.24 (1H, d, J 3.5, 2-furyl), 6.59 (1H, dd, J 3.5, 1.7, 2-
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furyl), 6.44 (1H, s, =CH); C (75 MHz, CDCl3) 177.4, 166.2, 150.4, 146.8, 132.6, 130.4. 
128.6, 120.5, 116.9, 112.9, 101.4, 94.5, 85.3. 
 
3.12. Synthesis of Propargylic 1,4-Diketones and 1,5-Diketones. 
General Procedure [1] from Diesters: 
 
To a solution of acetylene (7.5 mmol) in anhydrous THF (6 cm3) at -78 °C n-BuLi (1.6 M 
in hexane, 4.7 cm3, 7.5 mmol) was added in 3 min. The mixture was stirred at -78 °C for 1 
h and was added dropwise to a diester (2.5 mmol in 8 cm3 THF) and BF3·OEt2 (6.5 mmol) 
mixture at -78 °C. After 1 h, sat NH4Cl (10 cm
3) was added and the mixture was extracted 
with diethyl ether (3 × 30 cm3). The combined organic phase was washed with brine and 
dried over anhydrous MgSO4. The crude product was purified by silica gel column 
chromatography (eluent hexane/EtOAc=15:1). 
 
1,8-Diphenyl-1,7-octadiyne-3,6-dione 197. This compound is known and has been fully 
characterized.138 
 
This compound was prepared following the general procedure above using 
phenylacetylene (1.76 g, 17.2 mmol), n-BuLi (10.0 cm3, 16.0 mmol), dimethyl succinate 
(778 mg, 5.3 mmol) and BF3·OEt2 (1.73 cm
3, 13.8 mmol). The product was isolated as a 
white solid (394 mg, 1.38 mmol, 26%). H (400 MHz, CDCl3) 7.60-7.57 (4H, m, 2 × Ph), 
7.49-7.44 (2H, m, 2 × Ph), 7.41-7.37 (4H, m, 2 × Ph), 3.12 (4H, s, 2 × CH2); C (100 MHz, 
CDCl3) 185.1, 133.1, 130.9, 128.7, 119.8, 91.7, 87.5, 34.0. 
      173 
 
 
1,9-Diphenyl-1,8-nonadiyne-3,7-dione 198. This compound is known and has been fully 
characterized.138 
 
This compound was prepared following the general procedure above using 
phenylacetylene (0.88 g, 8.6 mmol), n-BuLi (5.0 cm3, 8.0 mmol), dimethyl glutarate (457 
mg, 2.86 mmol) and BF3·OEt2 (1.1 cm
3, 8.5 mmol). The product was isolated as white 
solid (148 mg, 0.49 mmol, 17%). H (400 MHz, CDCl3) 7.60-7.23 (10H, m, 2 × Ph), 2.71 
(4H, t, J 7.2, 2 × CH2CO), 2.12-2.05 (2H, m, CH2); C (100 MHz, CDCl3) 186.9, 133.1, 
130.8, 128.7, 119.8, 91.2, 87.7, 44.2, 18.3.   
 
General Procedure [2] from Weinreb Diamides: 
 
To a solution of acetylene (2.4 mmol) in anhydrous THF (10 cm3) at -78 °C n-BuLi (1.6 
M in hexane, 1.5 cm3, 2.4 mmol) was added in 3 min. The mixture was stirred at -78 °C 
for 1 h and a Weinreb diamide (204 mg in 3 cm3 THF, 1.0 mmol) solution was added 
dropwise. After 1h at -78 °C, the temperature was raised to  -10 °C during 2 h and sat 
NH4Cl (20 cm
3) and 2M HCl solution (5 cm3) was added at -10 °C. The mixture was 
extracted with diethyl ether (3 × 20 cm3) and combined organic phase was dried over 
anhydrous MgSO4. The crude product was purified by silica gel column chromatography 
(eluent hexane/EtOAc=12:1-8:1). 
 
1,8-Dibutyl-1,7-octadiyne-3,6-dione 201. This compound is novel. 
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This compound was prepared following the general procedure above using Weinreb 
diamide (326 mg, 1.6 mmol), n-BuLi (3.0 cm3, 4.8 mmol), 1-hexyne (417 mg,  2.4 mmol), 
and the product was isolated as described above as a colourless oil (361 mg, 1.47 mmol, 
92%). (found (ESI): M+ + Na, 269.1512. C16H22O2 requires M, 269.1517); νmax 2959, 2934, 
2872, 2219, 1670, 1192, 1150 cm-1; H (400 MHz, CDCl3) 2.89 (4H, s, 2 × CH2CO), 2.37 
(4H, t, J 7.3, 2 × CH2C≡), 1.61-1.53 (4H, m, 2 × CH2CH2C≡), 1.48-1.39 (4H, m, 2 × 
CH2CH3), 0.93 (6H, t, J 7.3, 2 × CH3); C (100 MHz, CDCl3) 185.4, 95.2, 80.5, 38.9, 29.6, 
21.9, 18.6, 13.5; m/z (EI-MS) 268.9 (M+Na)+. 
 
1,10-Dibenzyloxy-1,10-tetramethyl-2,8-octadiyne-4,7-dione 199. This compound is 
novel. 
 
This compound was prepared following the general procedure above using Weinreb 
diamide (204 mg, 1.0 mmol), n-BuLi (1.5 cm3, 2.4 mmol), alkyne (417 mg, 2.4 mmol), 
and the product was isolated as described above as a yellow oil (186 mg, 0.43 mmol, 43%). 
(found (ESI): M+ + Na, 453.2036. C28H30O4 requires M, 453.2041); νmax 2987, 2210, 1675, 
1235, 1157, 1113, 1047, 735, 696 cm-1; H (400 MHz, CDCl3) 7.38-7.24 (10H, m, 2 × Ph), 
4.62 (4H, s, 2 × CH2O), 2.91 (4H, m, 2 × CH2), 1.59 (12H, s, 4 × CH3); C (100 MHz, 
CDCl3) 184.6, 183.3, 128.4, 127.67, 127.64, 94.4, 82.9, 70.6, 67.1, 38.8, 28.2; m/z (EI-MS) 
453.1 (M+Na)+. 
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1,11-Dibenzyloxy-1,11-tetramethyl-2,9-nonadiyne-4,8-dione 200. This compound is 
novel. 
 
This compound was prepared following the general procedure above using Weinreb 
diamide (327 mg, 1.5 mmol), n-BuLi (3.0 cm3, 4.8 mmol), alkyne (870 mg, 5.0 mmol), 
and the product was isolated as described above as a yellow oil (527 mg, 1.19 mmol, 79%). 
(found (ESI): M+ + Na, 467.2193. C29H32O4 requires M, 467.2198); νmax 2982, 2937, 2211, 
1674, 1236, 1156, 1047, 735, 696 cm-1; H (400 MHz, CDCl3) 7.32-7.18 (10H, m, 2 × Ph), 
4.54 (4H, s, 2 × CH2O), 2.54 (4H, t, J 7.1, 2 × COCH2), 1.90 (2H, p, J 7.1, CH2), 1.52 
(12H, s, 4 × CH3); C (100 MHz, CDCl3) 186.4, 138.4, 128.4, 127.6, 93.9, 83.2, 70.6, 67.0, 
44.1, 28.3, 17.7; m/z (EI-MS) 467.1 (M+Na)+. 
 
3.13. Asymmetric Transfer Hydrogenation of Propargylic β-Keto Esters. 
General Procedure 
 
(R,R)-c2 (0.6 mg, 1.0 × 10-3 mmol) and HCO2H/Et3N 5:2 azeotropic mixture (168 mg) 
was added into a flask and freshly prepared β-keto ester (0.2 mmol) in degassed CH2Cl2 (1 
cm3) was injected under a nitrogen atmosphere. The mixture was stirred at rt until starting 
material was completely consumed (24-48 h). After quenched by sat NaHCO3 (5 cm
3) the 
mixture was extracted with CH2Cl2 (3 × 10 cm
3) and the combined organic extraction was 
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dried over MgSO4. Solvent was evaporated under reduced pressure and the crude product 
was purified by silica gel column chromatography (eluent hexane/EtOAc=10:1-5:1) to 
give the title products. 
 
(3R)-Hydroxy-5-phenyl-4-pentynoic acid, methyl ester R-167. This compound has 
been reported but not fully characterized.182 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3 mmol), ketone 143 (40.4 mg, 0.2 mmol), HCO2H/Et3N 5:2 (168 mg), 
CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (35.2 mg, 0.16 mmol, 
86%, 96% ee). [α]D31 +32.9 (c 0.8 in CHCl3) 96 % ee (R); (found (ESI): M+ + Na, 
227.0679. C12H12O3 requires M, 227.0684); νmax 3445, 2954, 1724, 1163, 11040, 756, 690 
cm-1; H (400 MHz, CDCl3) 7.44-7.40 (2H, m, Ph), 7.33-7.27 (3H, m, Ph), 5.01 (1H, t, J 
5.9, CHOH), 3.75 (3H, s, COOCH3), 3.23 (1H, br, OH), 2.86 (1H, d, J 5.9, HCH), 2.85 
(1H, s, HCH); C (100 MHz, CDCl3) 171.7, 131.8, 128.6, 128.3, 122.2, 88.0, 85.1, 59.2, 
52.1, 41.9; m/z (EI-MS) 227.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB 
column (250 mm × 4.6 mm), hexane:i-PrOH 95:5, 0.6 cm3/min, T = 30 °C. Retention 
times: (major - R) 20.1 min, (minor - S) 23.4 min. 
 
(3R)-Hydroxy-5-phenyl-4-pentynoic acid, ethyl ester R-171. This compound has been 
reported but not fully characterized.183 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3 mmol), ketone 144 (43.2 mg, 0.2 mmol), HCO2H/Et3N 5:2 (168 mg), 
CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (41.4 mg, 0.19 mmol, 
95%, 92% ee). [α]D26 +18.9 (c 0.6 in CHCl3) 92% ee (R); (found (ESI): M+ + Na, 
241.0835. C13H14O3 requires M, 241.0840); νmax 3429, 2982, 1717, 1159, 1025, 756, 690 
cm-1; H (400 MHz, CDCl3) 7.44-7.40 (2H, m, Ph), 7.35-7.27 (3H, m, Ph), 5.00 (1H, t, J 
6.0, CHOH), 4.23 (2H, q, J 7.1, COOCH2), 3.24 (1H, br, OH), 2.84 (2H, d, J 6.0, CH2), 
1.29 (3H, t, J 7.1, CH3); C (100 MHz, CDCl3) 171.3, 131.8, 128.6, 128.3, 122.3, 88.3, 
85.0, 61.1, 59.2, 42.2, 14.2; m/z (EI-MS) 241.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 95:5, 0.6 cm3/min, T = 
30 °C. Retention times: (major - R) 17.0 min, (minor - S) 20.6 min. 
 
(3R)-Hydroxy-4-nonynoic acid, methyl ester R-169. This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3  mmol), ketone 161 (41.0 mg, 0.22 mmol), HCO2H/Et3N 5:2 (168 mg), 
CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (38.0 mg, 20.6 mmol, 
92%, 97% ee). [α]D26 +27.1 (c 0.9 in CHCl3) 97% ee (R); (found (ESI): M+ + Na, 
207.0992. C10H16O3 requires M, 207.0997); νmax 3475, 2958, 1738, 1438, 1276, 1162, 
1022 cm-1; H (400 MHz, CDCl3) 4.71-4.65 (1H, m, CHOH), 3.66 (3H, s,COOCH3), 3.00 
(1H, d, J 5.7, OH), 2.66 (1H, d, J 1.6, HCHCOO), 2.65 (1H, s,  HCHCOO), 2.13 (2H, td, 
J 7.1, 2.0, CH2C≡), 1.45-1.26 (4H, m, CH2, CH2), 0.83 (3H, t, J 7.2, CH3); C (100 MHz, 
CDCl3) 171.8, 86.0, 79.3, 58.9, 51.9, 42.3, 30.5, 21.8, 18.3, 13.5; m/z (EI-MS) 207.1 
(M+Na)+. HPLC separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), 
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hexane:i-PrOH 96:4, 0.5 cm3/min, T = 30 °C. Retention times: (major - R) 17.8 min, 
(minor - S) 17.0 min. 
 
(3R)-Hydroxy-7-benzyloxy-4-heptynoic acid, methyl ester R-170. This compound is 
novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3  mmol), ketone 162 (52.0 mg, 0.20 mmol), HCO2H/Et3N 5:2 (168 mg), 
CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (48.3 mg, 0.18 mmol, 
92%, 97% ee). [α]D28 +17.6 (c 1.0 in CHCl3) 97 % ee (R); (found (ESI): M+ + Na, 
285.1097. C15H18O4 requires M, 285.1102); νmax 3427, 2865, 1735, 1163, 1096, 1062, 
1027, 737, 697 cm-1; H (400 MHz, CDCl3) 7.38-7.26 (5H, m, Ph), 4.78-4.72 (1H, m, 
CHOH), 4.54 (2H, s, PhCH2), 3.72 (3H, s,COOCH3), 3.57 (2H, t, J 7.0, BnOCH2), 2.94 
(1H, d, J 5.9, OH), 2.72 (2H, d, J 6.0, CH2COO), 2.52 (2H, td, J 7.0, 1.9, CH2C≡); C (100 
MHz, CDCl3) 171.7, 138.0, 128.4, 127.8, 127.7, 82.5, 80.5, 72.9, 68.2, 58.8, 51.9, 42.2, 
20.1; m/z (EI-MS) 285.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB 
column (250 mm × 4.6 mm), hexane:i-PrOH 96:4, 0.5 cm3/min, T = 30 °C. Retention 
times: (major - R) 55.3 min, (minor - S) 53.0 min. 
 
(3R)-Hydroxy-6-benzyloxy-6-methyl-4-heptynoic acid, methyl ester R-168. This 
compound is novel. 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3  mmol), ketone 160 (53.2 mg, 0.20 mmol), HCO2H/Et3N 5:2 (168 mg), 
CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (53.1 mg, 1.92 mmol, 
99%, 99% ee). [α]D28 +21.4 (c 0.8 in CHCl3) 99 % ee (R); (found (ESI): M+ + Na, 
299.1254. C16H20O4 requires M, 299.1259); νmax 3420, 2983, 1736, 1154, 1049, 735, 697 
cm-1; H (400 MHz, CDCl3) 7.35-7.15 (5H, m, Ph), 4.67-4.80 (1H, m, CHOH), 4.52 (2H, s, 
PhCH2), 3.61 (3H, s, COOCH3), 3.08 (1H, br, OH), 2.65 (2H, d, J 6.4, CH2COO), 1.45 
(6H, s, 2 × CH3); C (100 MHz, CDCl3) 171.6, 139.0, 128.3, 127.7, 127.4, 87.4, 83.5, 70.5, 
66.5, 58.8, 52.0, 42.0, 28.8; m/z (EI-MS) 299.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 96:4, 0.5 cm3/min, T = 
30 °C. Retention times: (major - R) 18.7 min, (minor - S) 18.1 min. 
 
3.14. Asymmetric Transfer Hydrogenation Dynamic Kinetic Resolution of 
α-Methyl-β-keto Esters. 
General Procedure 
 
(R,R)-c1 (4.2 mg, 6.7 × 10-3 mmol) or (R,R)-c2 (0.6 mg, 1.0 × 10-3 mmol) or catalyst c3 
(3.4 mg,  6.7 × 10-3 mmol), HCO2H/Et3N 5:2 azeotropic mixture was added into a flask 
and freshly prepared β-keto ester (0.2 mmol) in degassed CH2Cl2 was injected under a 
nitrogen atmosphere. The mixture was stirred at rt until starting material was completely 
consumed (48 h). After being quenched by sat NaHCO3 (5 cm
3) the mixture was extracted 
with CH2Cl2 (3 × 10 cm
3) and the combined organic extract was dried over MgSO4. 
Solvent was evaporated under reduced pressure and the crude product was purified by 
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silica gel column chromatography (eluent hexane/EtOAc=10:1-5:1) to give the title 
products. 
 
(2R)-Methyl-(3R)-hydroxy-5-phenyl-4-pentynoic acid, ethyl ester 172. This compound 
is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c1 
catalyst (1.7 mg, 2.7 × 10-3 mmol), ketone 163 (20.0 mg, 0.087 mmol), HCO2H/Et3N 5:2 
(84 mg), CH2Cl2 (0.5 cm
3) and the product was isolated as a colourless oil (20.0 mg, 0.086 
mmol, 99%, 98% ee, dr 24/1).[α]D23 +2.1 (c 0.3 in CHCl3) 98% ee (2R,3R), dr 24/1; 
(found (ESI): M+ + Na, 255.0992. C14H16O3 requires M, 255.0997); νmax 3450, 2982, 1717, 
1188, 1027, 755, 690 cm-1; H (400 MHz, CDCl3) 7.45-7.40 (2H, m, Ph), 7.34-7.27 (3H, 
m, Ph), 4.83 (1H, dd, J 6.9 4.1, CHOH), 4.22 (2H, q, J 6.7, COOCH2), 3.15 (1H, d, J 6.9, 
OH), 2.88-2.81 (1H, m, CH), 1.37 (3H, d, J 7.2, CH3), 1.29 (3H, t, J 6.7, COOCH2CH3); 
C (100 MHz, CDCl3) 174.2, 131.8, 128.6, 128.3, 122.4, 87.3, 85.7, 64.3 61.0, 45.5, 14.2, 
12.0; m/z (EI-MS) 255.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB 
column (250 mm × 4.6 mm), hexane:i-PrOH 96:4, 0.5 cm3/min, T = 30 °C. Retention 
times: (major - 2R, 3R) 17.7 min, (minor - 2S, 3S) 25.2 min. 94% yield, 13/1 dr, >99% ee 
were obtained when (R,R)-c2 (S/C=100/1) was used. 98% yield, 14/1 dr, >99% ee were 
obtained when (S,S)-c2 (S/C=200/1) was used. 88% yield, 11/1 dr, were obtained when 
catalyst c3 (S/C=30/1) was used. 
 
(2R)-Methyl-(3R)-hydroxy-4-nonynoic acid, ethyl ester 173. This compound is novel. 
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This compound was prepared following the general procedure above using (R,R)-c1 
catalyst (4.2 mg, 6.7 × 10-3 mmol), ketone 165 (41.0 mg, 0.20 mmol), HCO2H/Et3N 5:2 
(168 mg), CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (35.9 mg, 0.17 
mmol, 87%, 99% ee, dr 27/1). [α]D28 +4.7 (c 1.0 in CHCl3) 99% ee (2R,3R), dr 27/1; 
(found (ESI): M+ + Na, 235.1305. C12H20O3 requires M, 235.1310); νmax 3442, 2958, 2934, 
2874, 1732, 1251, 1184, 1025 cm-1; H (400 MHz, CDCl3) 4.61-4.57(1H, m, CHOH), 
4.19 (2H, q, J 7.1, COOCH2), 3.04 (1H, d, J 7.1, OH), 2.71 (1H, td, J 7.2 4.2, CHCH3), 
2.20 (2H, td, J 6.9 2.0, ≡CCH2), 1.52-1.35 (4H, m, CH2, CH2), 1.29 (3H, t, J 7.1, 
COOCH2CH3), 1.28 (3H, d, J 7.2, CHCH3), 0.90 (3H, t, J 7.2, CH2CH2CH3); C (100 
MHz, CDCl3) 174.3, 86.4, 78.5, 62.9, 60.8, 45.7, 30.6, 21.8, 18.3, 14.2, 13.5, 11.9; m/z 
(EI-MS) 235.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IC column (250 
mm × 4.6 mm), hexane:i-PrOH 96:4, 0.5 cm3/min, T = 30 °C. Retention times: (major - 
2R, 3R) 23.8 min, (minor - 2S, 3S) 21.4 min. 92% yield, 14/1 dr, >99% ee were obtained 
when (R,R)-c2 (S/C=200/1) was used; 21% yield, 13/1 dr, were obtained when catalyst c3 
(S/C=30/1) was used. 
 
(2R)-Methyl-(3R)-hydroxy-6-benzyloxy-6-methyl-4-heptynoic acid, ethyl ester 174. 
This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c1 
catalyst (4.2 mg, 6.7 × 10-3 mmol), ketone 164 (60.4 mg, 0.20 mmol), HCO2H/Et3N 5:2 
(168 mg), CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (54.9 mg, 0.18 
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mmol, 90%, 99% ee, dr 27/1). [α]D28 +5.4 (c 0.6 in CHCl3) 99% ee (2R,3R), dr 27/1; 
(found (ESI): M+ + Na, 327.1567. C18H24O4 requires M, 327.1572); νmax 3441, 2983, 1732, 
1244, 1186, 1156, 1041, 1028, 735, 696 cm-1; H (400 MHz, CDCl3) 7.37-7.22 (5H, m, 
Ph), 4.62 (1H, dd, J 7.1 4.3, CHOH), 4.60 (2H, s, PhCH2O), 4.16 (2H, q, J 7.1, COOCH2), 
3.12 (1H, d, J 7.1, OH), 2.78-2.71 (1H, m, CHCH3), 1.53 (6H, s, 2 × CH3), 1.30-1.24 (6H, 
m, CHCH3 and COOCH2CH3); C (100 MHz, CDCl3) 174.0, 139.0, 128.3, 127.7, 127.4, 
87.9, 82.8, 70.6, 66.6, 63.8, 61.0, 45.5, 28.9, 14.2, 12.1; m/z (EI-MS) 327.1 (M+Na)+. 
HPLC separation conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-
PrOH 96:4, 0.5 cm3/min, T = 30 °C. Retention times: (major - 2R, 3R) 16.6 min, (minor - 
2S, 3S) 18.5 min. 97% yield, 12/1 dr, >99% ee were obtained when (R,R)-c2 (S/C=200/1) 
was used. 
 
(2R)-Methyl-(3R)-hydroxy-7-benzyloxy-4-heptynoic acid, ethyl ester 175. This 
compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c1 
catalyst (4.2 mg, 6.7 × 10-3 mmol), ketone 166 (61.2 mg, 0.21 mmol), HCO2H/Et3N 5:2 
(168 mg), CH2Cl2 (1.0 cm
3) and the product was isolated as a colourless oil (46.5 mg, 0.16 
mmol, 76%, >98% ee, dr 31/1). [α]D28 +4.0 (c 0.7 in CHCl3) 98% ee (2R,3R), dr 31/1; 
(found (ESI): M+ + Na, 313.1410. C17H22O4 requires M, 313.1415); νmax 3446, 2981, 2939, 
1729, 1187, 1094, 1027, 736, 698 cm-1; H (400 MHz, CDCl3) 7.37-7.26 (5H, m, Ph), 
4.62-4.58 (1H, m, CHOH), 4.53 (2H, s, PhCH2O), 4.17 (2H, q, J 7.1, COOCH2), 3.57 (2H, 
t, J 7.1, BnOCH2), 3.02 (1H, d, J 6.9, OH), 2.70 (1H, qd, J 7.2 4.2, CHCH3), 2.52 (2H, td, 
J 7.2 2.0, CH2C≡), 1.28 (3H, d, J 7.2, CHCH3), 1.26 (3H, t, J 7.1, COOCH2CH3); C (100 
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MHz, CDCl3) 174.3, 138.0, 128.4, 127.71, 127.70, 83.1, 79.6, 73.0, 68.3, 63.9, 60.9, 45.4, 
20.1, 14.2, 11.8; m/z (EI-MS) 313.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 96:4, 0.8 cm3/min, T = 
30 °C. Retention times: (major - 2R, 3R) 39.9 min, (minor - 2S, 3S) 57.0 min. 92% yield, 
14/1 dr, >99% ee were obtained when (R,R)-c2 (S/C=200/1) was used. 
 
3.15. Asymmetric Transfer Hydrogenation of Propargylic γ and δ-Keto 
Esters. 
General Procedure 
 
(R,R)-c2 (0.6 mg, 1.0 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
and γ or δ-keto esters (0.5 mmol) in degassed CH2Cl2 was injected under nitrogen 
atmosphere. The mixture was stirred at rt until starting material was completely consumed 
(less than 72 h). After completion, the reaction was quenched by sat NaHCO3 (10 cm
3) the 
mixture was extracted with CH2Cl2 (3 × 20 cm
3) and the combined organic extraction was 
dried over MgSO4. Solvent was evaporated under reduced pressure and the crude product 
was purified by silica gel column chromatography (eluent hexane/EtOAc=10:1-5:1) to 
give the products. 
 
(4R)-Hydroxy-6-phenyl-5-hexynoic acid, methyl ester R-184. This compound is novel. 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3mmol), 4-oxo-6-phenyl-5-hexynoic acid methyl ester 176 (118.0 mg, 5.5 
mmol), HCO2H/Et3N 5:2 (105 mg) and CH2Cl2 (2.5 cm
3), and the product was isolated as 
a colourless oil (106.5 mg, 4.9 mmol, 89%, 94% ee). [α]D24+13.3 (c 0.7 in CHCl3) 94% ee 
(R); (found (ESI): M+ + Na, 241.0835. C13H14O3 requires M 241.0841); νmax 3414, 2952, 
1733, 1490, 1440, 1254, 1200, 1166, 1067, 756, 691 cm-1; H (400 MHz, CDCl3) 7.50-
7.27 (5H, m, Ph), 4.71 (1H, t, J 6.0, CHOH), 3.69 (3H, s, COOCH3), 2.70-2.54 (3H, m, 
CH2COO, CHOH), 2.19-2.10 (2H, m, CH2); C (100 MHz, CDCl3) 174.1, 131.7, 128.5, 
128.3, 122.4, 89.1, 85.4, 62.0, 51.8, 32.5, 29.8; m/z (EI-MS) 241.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-PrOH 
95:5, 0.8 cm3/min, T = 30 °C. Retention times: (major - R) 18.6 min, (minor - S) 49.1 min. 
 
(4R)-Hydroxy-5-decynoic acid, methyl ester R-185. This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3 mmol), ketone 177 (101 mg, 0.52 mmol), HCO2H/Et3N 5:2 (210 mg), 
CH2Cl2 (2.5 cm
3) and the product was isolated as a colourless oil ( 90.8 mg, 0.46 mmol, 
89%, 93% ee). (found (ESI): M+ + Na, 221.1148. C11H18O3 requires M 221.1153); νmax 
3435, 2957, 2934, 1737, 1437, 1167, 1061 cm-1; H (400 MHz, CDCl3) 7.50-7.27 (5H, m, 
Ph), 4.38 (1H, br, CHOH), 3.61 (3H, s, COOCH3), 2.64 (1H, br, CHOH), 2.53-2.39 (2H, 
m, CH2COO), 2.13 (2H, t, J 6.9, ≡CCH2), 1.98-1.90 (2H, m, CH2CH2COO), 1.44-1.28 
(4H, m, CH2, CH2), 0.84 (3H, t, J 7.2, CH3); C (100 MHz, CDCl3) 174.2, 85.9, 80.3, 61.5, 
51.7, 32.8, 30.6, 29.8, 21.9, 18.3, 13.5; m/z (EI-MS) 221.1 (M+Na)+.HPLC separation 
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conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 94:6, 0.8 
cm3/min, T = 30 °C. Retention times: (major - R) 50.8 min, (minor - S) 28.5 min. 
 
(4R)-Hydroxy-8-benzyloxy-5-octynoic acid, methyl ester R-187. This compound is 
novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.4 
mg, 6.7 × 10-4 mmol), ketone 179 (92.2 mg,  0.335 mmol), HCO2H/Et3N 5:2 (278 mg), 
CH2Cl2 (1.5 cm
3) and the product was isolated as a colourless oil (87.9 mg, 0.318 mmol, 
95%, 98% ee). [α]D34+ 8.3 (c 0.7 in CHCl3) 98% ee (R); (found (ESI): M+ + Na, 299.1254. 
C16H20O4  requires M 299.1259); νmax 3415, 2951, 2864, 1733, 1096, 1063, 737, 697 cm-1; 
H (400 MHz, CDCl3) 7.35-7.26 (5H, m, Ph), 4.54 (2H, s, PhCH2O), 4.43 (1H, tt, J 6.1 
2.0, CHOH), 3.67 (3H, s, COOCH3), 3.57 (2H, t, J 7.0, BnOCH2), 2.59-2.45 (5H, m, 
CH2COO, CH2C≡, OH), 1.99 (2H, td, J 7.2 7.1, CH2 CH2COO); C (100 MHz, CDCl3) 
174.1, 138.0, 128.4, 127.8, 127.7, 82.7, 81.5, 73.0, 68.3, 61.6, 51.8, 32.7, 29.8, 20.1; m/z 
(EI-MS) 299.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB column (250 
mm × 4.6 mm), hexane:i-PrOH 95:5, 0.7 cm3/min, T = 30 °C. Retention times: (major - R) 
26.4 min, (minor - S) 27.9 min. 
 
(4R)-Hydroxy-7-benzyloxy-7-methyl-5-octynoic acid, methyl ester R-186. This 
compound is novel. 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.4 
mg, 6.7 × 10-4 mmol), ketone 178 (104 mg,  0.36 mmol), HCO2H/Et3N 5:2 (277 mg), 
CH2Cl2 (1.6 cm
3) and the product was isolated as a colourless oil (80.2 mg, 0.28 mmol, 
77%, 99% ee). [α]D28 +5.4 (c 1.2 in CHCl3) 99% ee (R); (found (ESI): M+ + Na, 313.1410. 
C17H22O4 requires M 313.1415); νmax 3424, 2987, 2935, 1736, 1244, 1154, 1052, 1027, 
736, 697 cm-1; H (400 MHz, CDCl3) 4.37-4.23 (5H, m, Ph), 4.60 (2H, s, PhCH2O), 4.49 
(1H, t, J 6.1, CHOH), 3.67 (3H, s, COOCH3), 2.56-2.44 (2H, m, CH2COO), 2.44 (1H, br, 
CHOH), 2.03-1.98 (2H, m, CH2), 1.53 (6H, s, 2 × CH3); C (100 MHz, CDCl3) 174.0, 
139.0, 128.3, 127.6, 127.4, 87.6, 84.3, 70.6, 66.5, 61.4, 51.8, 32.5, 29.8, 29.0; m/z (EI-MS) 
313.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IC column (250 mm × 4.6 
mm), hexane:i-PrOH 94:6, 0.8 cm3/min, T = 30 °C. Retention times: (major - R) 20.4 min, 
(minor - S) 19.2 min. 
 
(5R)-Hydroxy-7-phenyl-6-heptynoic acid, methyl ester R-188. This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3 mmol), 5-oxo-7-phenyl-6-heptynoic acid methyl ester 180 (115 mg, 5.0 
mmol), HCO2H/Et3N 5:2 (105 mg), CH2Cl2 (2.5 cm
3) and the product was isolated as a 
colourless oil (104 mg, 0.45 mmol, 89%, 96% ee). [α]D24 + 0.5 (c 0.7 in CHCl3) 96% ee 
(R); (found (ESI): M+ + Na, 255.0992. C14H16O3 requires M 255.0997); νmax 3407, 2952, 
1733, 1097, 1053, 756, 691 cm-1; H (400 MHz, CDCl3) 7.36-7.34 (2H, m, Ph), 7.26-7.19 
(3H, m, Ph), 4.54 (1H, t, J 6.0, CHOH), 3.60 (3H, s, COOCH3), 2.35-2.32 (2H, m, 
CH2COO), 2.26 (1H, br, CHOH), 1.85-1.73 (4H, m, CH2CH2); C (100 MHz, CDCl3) 
174.0, 131.7, 128.4, 128.3, 122.5, 89.8, 85.1, 62.4, 51.6, 37.1, 33.6, 20.6. m/z (EI-MS) 
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255.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB column (250 mm × 4.6 
mm), hexane:i-PrOH 95:5, 0.8 cm3/min, T = 30 °C. Retention times: (major - R) 16.4 min, 
(minor - S) 68.5 min. 
 
(5R)-Hydroxy-6-undecynoic acid, methyl ester R-189. This compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.6 
mg, 1.0 × 10-3 mmol), ketone 181 (105 mg,  mmol), HCO2H/Et3N 5:2 (415 mg), CH2Cl2 
(2.0 cm3) and the product was isolated as colourless oil (85.6 mg, 4.0 mmol, 81%, 99% ee). 
[α]D34 + 4.1 (c 1.1 in CHCl3) 99% ee (R); (found (ESI): M+ + Na, 235.1305. C12H20O3 
requires M 235.1310); νmax 3441, 2955, 2933, 1732, 1236, 1196, 1161, 1028 cm-1; H (400 
MHz, CDCl3) 4.37 (1H, tt, J 6.4 1.9, CHOH), 3.68 (3H, s, COOCH3), 2.55 (1H, br, OH), 
2.37 (2H, t, J 7.5, CH2COO), 2.20 (2H, td, J 6.9 1.9, CH2C≡), 1.84-1.75 (2H, m, 
CH2CH2COO), 1.75-1.67 (2H, m, CH2), 1.53-1.44 (2H, m, CH2CH2CH3), 1.44-1.35 (2H, 
m, CH2CH2CH3), 0.91 (3H, t, J 7.2, CH2CH3); C (100 MHz, CDCl3) 174.0, 85.7, 80.8, 
62.1, 52.5, 37.4, 33.6, 30.7, 21.9, 20.6, 18.3, 13.6. m/z (EI-MS) 235.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IA column (250 mm × 4.6 mm), hexane:i-PrOH 
100:0, 0.8 cm3/min, T = 30 °C. Retention times: (major - R) 13.35 min, (minor - S) 13.02 
min. (chiral and racemic standard were analyzed by HPLC after conversion to the TBDPS 
ether) 
 
(5R)-Hydroxy-9-benzyloxy-6-nonynoic acid, methyl ester R-191. This compound is 
novel. 
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This compound was prepared following the general procedure above using (R,R)-c2 (0.4 
mg, 6.7 × 10-4 mmol), ketone 183 (101.2 mg, 3.51 mmol), HCO2H/Et3N 5:2 (277 mg), 
CH2Cl2 (1.6 cm
3) and the product was isolated as a colourless oil (101.1 mg, 3.48 mmol, 
99%, 99% ee). [α]D30 +5.5 (c 1.4 in CHCl3) 99% ee (R); (found (ESI): M+ + Na, 313.1410. 
C17H22O4 requires M 313.1415); νmax 3431, 2950, 2866, 1733, 1096, 1078, 1027, 737, 698 
cm-1; H (400 MHz, CDCl3) 7.37-7.25 (5H, m, Ph), 4.54 (2H, s, PhCH2O), 4.37-4.31 (1H, 
m, CHOH), 3.66 (3H, s, COOCH3), 3.57 (2H, t, J 7.0, BnOCH2), 2.55 (1H, br, OH), 2.51 
(2H, td, J 7.0, 2.0, CH2C≡), 2.35 (2H, t, J 7.1, CH2COO), 1.83-1.73 (2H, m, CH2CHOH), 
1.73-1.64 (2H, m, CH2); C (100 MHz, CDCl3) 174.0, 138.0, 128.4, 127.8, 127.7, 82.2, 
82.1, 72.9, 68.3, 62.0, 51.6, 37.2, 33.6, 20.6, 20.1. m/z (EI-MS) 313.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 
94:6, 1.0 cm3/min, T = 30 °C. Retention times: (major - R) 67.7 min, (minor - S) 66.2 min 
 
(5R)-Hydroxy-8-benzyloxy-8-methyl-6-nonynoic acid, methyl ester R-190. This 
compound is novel. 
 
This compound was prepared following the general procedure above using (R,R)-c2 (0.4 
mg, 6.7 × 10-4 mmol), ketone 182 (101.0 mg, 0.334 mmol), HCO2H/Et3N 5:2 (280 mg), 
CH2Cl2 (1.6 cm
3) and the product was isolated as a colourless oil (85.7 mg, 0.28 mmol, 
84%, 98% ee). [α]D28 +10.1 (c 1.2 in CHCl3) 98% ee (R); (found (ESI): M+ + Na, 
327.1567. C18H24O4 requires M 327.1572); νmax 3432, 2984, 1736, 1153, 1051, 1028, 736, 
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697 cm-1; H (400 MHz, CDCl3) 7.38-7.22 (5H, m, Ph), 4.61 (2H, s, PhCH2O), 4.39 (1H, t, 
J 6.2, CHOH), 3.65 (3H, s, COOCH3), 2.35 (2H, t, J 7.2, CH2COO), 2.24 (1H, br, 
CHOH), 1.83-1.74 (2H, m, CH2CH2COO), 1.74-1.65 (2H, m, CH2), 1.53 (6H, s, 2 × 
CH3); C (100 MHz, CDCl3) 173.9, 139.1, 128.3, 127.6, 127.4, 87.2, 85.1, 70.6, 66.5, 61.9, 
51.6, 37.1, 33.5, 29.0, 20.6. m/z (EI-MS) 327.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 94:6, 1.0 cm3/min, T = 
30 °C. Retention times: (major - R) 15.8 min, (minor - S) 19.1 min. 
 
3.16. Asymmetric Transfer Hydrogenation of Propargylic 1,4-Diketones 
and 1,5-Diketones. 
General Procedure 
 
(R,R)-c2 or (S,S)-c2 (0.6 mg, 1.0 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 
azeotropic mixture (372 mg) and diketones (0.2 mmol) in degassed CH2Cl2 (2.0 cm
3) was 
injected under nitrogen atmosphere. The mixture was stirred at rt until starting material 
was completely consumed (48 h). After the reaction was complete, sat NaHCO3 (4 cm
3) 
and water (4 cm3) was added and extracted with CH2Cl2 (3 × 15 cm
3). The combined 
organic extracts were concentrated and dried over anhydrous MgSO4 and purified by silica 
gel column chromatography (eluent hexane/EtOAc=6:1-3:1) to give the title products. In 
paper: The position of the meso compound in the chiral HPLC was established in each 
case by reducing a sample of ketone with a racemic sample of catalyst c1 under the 
general conditions above. 
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1,8-Diphenyl-1,7-octadiyne-(3R, 6R)-diol (R,R)-202. This compound is known but not 
fully characterized.184 
 
This compound was prepared following the general procedure above using both (R,R)-c2 
and (S,S)-c2 (0.6 mg, 1.0 × 10-3 mmol), HCO2H/Et3N 5:2 azeotropic mixture (84 mg), 
diketone 197 (57.2 mg, 0.2 mmol) and degassed CH2Cl2 (1 cm
3). The product was isolated 
as described above as white crystals (47.1 mg, 0.16 mmol, 81%, >99% ee, de 93% for 
R,R-diol), (45.0 mg, 0.15 mmol, 78%, >99% ee, de 96% for S,S-diol). [α]D28 +9.2 (c 0.9 in 
CHCl3 for R,R-diol); [α]D28 -8.5 (c 0.7 in CHCl3 for S,S-diol); MP 76 °C; (found (ESI): M+ 
+ Na, 313.1199. C20H18O2 requires M, 313.1204); νmax 3191, 1488, 1004, 750, 687 cm-1; 
H (400 MHz, CDCl3) 7.44-7.42 (4H, m, 2 × Ph), 7.37-7.26 (6H, m, 2 × Ph), 4.74 (2H, t, J 
5.7, 2 × CHOH), 2.81 (2H, s, 2 × OH), 2.16-2.01 (4H, m, 2 × CH2); C (100 MHz, CDCl3) 
185.1, 133.1, 130.9, 128.7, 119.8, 91.7, 87.5, 34.0; m/z (EI-MS) 313.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane: i-PrOH 
80:20, 0.8 cm3/min, T = 30 °C. Retention times, (R,R) 9.3 min, (meso) 24.8 min, (S,S) 51.2 
min. 
 
1,8-Dibutyl-1,7-octadiyne-(3R, 6R)-diol (R,R)-203. This compound is novel. 
 
This compound was prepared following the general procedure above using both (R,R)-c2 
and (S,S)-c2 (0.6 mg, 1.0 × 10-3 mmol), HCO2H/Et3N 5:2 azeotropic mixture (186 mg), 
diketone 201 (54.5 mg, 0.2 mmol) and degassed CH2Cl2 (2.0 cm
3). The product was 
isolated as described above as a colourless oil (48.1 mg, 0.19 mmol, 87%, >99% ee, de 95% 
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for R,R-diol), (45 mg, 0.18 mmol, 82%, >99% ee, de 93% for S,S-diol). [α]D30 +14.9 (c 0.8 
in CHCl3 for R,R-diol); [α]D30 -14.6 (c 0.7 in CHCl3 for S,S-diol); (found (ESI): M+ + Na, 
273.1825. C16H26O2 requires M, 273.1830); νmax 3329, 2957, 2931, 2862, 1456, 1328, 
1022 cm-1; H (400 MHz, CDCl3) 4.45 (2H, br, 2 × CHOH), 2.38-2.32 (2H, br, 2 × OH), 
2.20 (4H, td, J 6.8 1.8, 2 × CH2C≡), 1.94-1.82 (4H, m, 2 × CH2CHOH), 1.52-1.45 (4H, m, 
2 × CH2CH2C≡), 1.45-1.36 (4H, m, 2 × CH2CH3), 0.91 (6H, t, J 7.2, 2 × CH3); C (100 
MHz, CDCl3) 85.9, 80.8, 62.3, 33.7, 30.7, 21.9, 18.4, 13.6; m/z (EI-MS) 272.9 (M+Na)
+. 
HPLC separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane:i-
PrOH 90:10,0.6 cm3/min, T = 30 °C. Retention times, (R,R) 10.7 min, (meso) 12.5 min, 
(S,S) 11.1 min. 
 
1,10-Dibenzyloxy-1,10-tetramethyl-2,8-octadiyne-(4R,7R)-diol (R,R)-204. This 
compound is novel. 
 
This compound was prepared following the general procedure above using both (R,R)-c2 
and (S,S)-c2 (0.3 mg, 5.0 × 10-4 mmol), HCO2H/Et3N 5:2 azeotropic mixture (186 mg), 
diketone 199 (41 mg, 0.1 mmol) and degassed CH2Cl2 (1.0 cm
3). The product was isolated 
as described above as a colourless oil (34.5 mg, 0.079 mmol, 83%, >99% ee, de 96% for 
R,R-diol), (29.1 mg, 0.067 mmol, 70%, >99% ee, de 98% for S,S-diol). [α]D26 +13.5 (c 1.3 
in CHCl3 for R,R-diol); [α]D30 -13.0 (c 1.5 in CHCl3 for S,S-diol); (found (ESI): M+ + Na, 
457.2349. C28H34O4 requires M, 457.2354); νmax 3395, 2983, 1244, 1152, 1048, 1027, 734, 
695 cm-1; H (400 MHz, CDCl3) 7.39-7.22 (10H, m, 2 × Ph), 4.60 (4H, s, 2 × CH2O), 4.45 
(2H, br, 2 × CHOH), 2.62 (2H, s, 2 × OH), 1.96-1.77 (4H, m, 2 × CH2), 1.52 (12H, s, 4 × 
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CH3); C (100 MHz, CDCl3) 139.0, 128.4, 127.7, 127.4, 87.4, 84.9, 70.7, 66.5, 61.8, 33.3, 
29.0; m/z (EI-MS) 457.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IB 
column (250 mm × 4.6 mm), hexane: i-PrOH 95:5, 0.6 cm3/min, T = 30 °C. Retention 
times, (R,R) 17.7 min, (meso) 21.0 min, (S,S) 19.6 min. 
 
1,8-Nonadiyne-1,9-diphenyl-(3R,7R)-diol (R,R)-205. This compound is known but not 
fully characterized.138 
 
This compound was prepared following the general procedure above using both (R,R)-c2 
and (S,S)-c2 (0.2 mg, 3.3 × 10-4 mmol), HCO2H/Et3N 5:2 azeotropic mixture (56 mg), 
diketone 198 (19.9 mg, 0.067 mmol) and degassed CH2Cl2 (0.5 cm
3).The product was 
isolated as described above as white crystals (19.4 mg, 0.064 mmol, 96%, >99% ee, 97% 
de for R,R-diol), (16.3 mg, 0.054 mmol, 81%, >99% ee, 97% de for S,S-diol). [α]D23-26.2 
(c 0.4 in CHCl3) >99% ee (S,S), 97% de; [α]D23 +30.9(c 0.2 in CHCl3) >99% ee (R,R), 97% 
de; MP 102 °C; (found (ESI): M+ + Na, 327.1356. C21H20O2 requires M, 327.1361); νmax 
3348, 2949, 2915, 1489, 1416, 1107, 1068, 914, 758, 689 cm-1; H (400 MHz, CDCl3) 
7.43-7.37 (4H, m, 2 × Ph), 7.32-7.23 (6H, m, 2 × Ph), 4.64 (2H, t, J 6.4, 2 × CHOH), 2.24 
(2H, s, 2 × OH), 1.93-1.84 (4H, m, 2 × CH2), 1.83-1.74 (2H, m, CH2); C (100 MHz, 
CDCl3) 131.7, 128.4, 128.3, 122.6, 89.9, 85.1, 62.8, 37.4, 21.1; m/z (EI-MS) 327.1 
(M+Na)+. HPLC separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), 
hexane: i-PrOH 80:20, 0.8 cm3/min, T = 30 °C. Retention times, (R,R) 9.9 min, (meso) 
31.1 min, (S,S) 47.2 min. 
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1,11-Dibenzyloxy-1,11-tetramethyl-2,9-octadiyne-(4R, 8R)-diol (R,R)-206. This 
compound is novel. 
 
This compound was prepared following the general procedure above using both (R,R)-c2 
and (S,S)-c2 (0.3 mg, 5.0 × 10-4 mmol), HCO2H/Et3N 5:2 azeotropic mixture (186 mg), 
diketone 200 (45.0 mg, 0.1 mmol) and degassed CH2Cl2 (1.0 cm
3). The product was 
isolated as described above as a colourless oil (38.9 mg, 0.8 mmol, 86%, >99% ee, de 97% 
for R,R-diol), (43.6 mg, 0.1 mmol, 97%, >99% ee, de >98% for S,S-diol). [α]D28 + 0.29 (c 
0.9 in CHCl3 for R,R-diol); [α]D28-0.23 (c 0.6 in CHCl3 for S,S-diol); (found (ESI): M+ + 
Na, 471.2506. C29H36O4 requires M, 471.2511); νmax 3380, 2984, 2934, 1243, 1152, 1049, 
1027, 734, 695 cm-1; H (400 MHz, CDCl3) 7.38-7.22 (10H, m, 2 × Ph), 4.60 (4H, s, 2 × 
CH2O), 4.37 (2H, t, J 6.1, 2 × CHOH), 1.86 (2H, s, 2 × OH), 1.78-1.66 (4H, m, 2 × CH2), 
1.66-1.58 (2H, m, CH2), 1.53 (12H, s, 4 × CH3); C (100 MHz, CDCl3) 139.1, 128.3, 127.6, 
127.4, 87.2, 85.3, 70.6, 66.5, 62.2, 37.4, 29.0, 21.0; m/z (EI-MS) 471.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IB column (250 mm × 4.6 mm), hexane: i-PrOH 
95:5, 0.5 cm3/min, T = 30 °C. Retention times, (R,R) 28.6 min, (meso) 31.8 min, (S,S) 33.2 
min. 
 
3.17. Total Synthesis of (-)-Yashabushidiol B. 
 
Ethyl (3S)-hydroxy-5-phenylpentanoate. This compound is known and has been fully 
characterized.185 
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Alcohol R-171 (306 mg, 1.40 mmol, 92% ee) was stirred vigorously with Pd(OH)2/C (129 
mg, 20% Pd(OH)2) under 1 atm H2 atmosphere at rt in degassed MeOH (10 cm
3). After 1h 
the catalyst was removed by filtration and washed with more MeOH. The eluent was 
concentrated and the product was used without purification. H (400 MHz, CDCl3) 7.31-
7.24 (2H, m, Ph), 7.22-7.15 (3H, m, Ph), 4.16 (2H, s, J 7.2, COOCH2), 4.06-3.98 (1H, m, 
CHOH), 2.86-2.78 (1H, d, J 2.8, PhHCH), 2.74-2.66 (1H, s, PhHCH), 2.51 (1H, dd, J 12.4, 
3.4, HCHCOO), 2.44 (1H, dd, J 12.4, 8.6, HCHCOO), 1.90-1.69 (2H, m, CH2CHOH), 
1.27 (3H, t, J 7.2,CH3); C (100 MHz, CDCl3) 173.0, 141.7, 128.5, 128.4, 125.9, 76.2, 60.8, 
41.3, 38.1, 31.8, 14.2. 
 
(3S)-Hydroxy-N-methoxy-N-methyl-benzenepentanamide 210. This compound is 
known and has been fully characterized.186 
 
To a solution of N,O-dimethylhydroxylaminehydro chloride (549 mg, 5.6 mmol) in THF 
(8cm3) n-BuLi (1.6 M in hexane, 6.9 cm3, 11.0 mmol) was added dropwise at -78 °C. 
After stirring at room temperature for 10 min, the mixture was cooled to -78 °C, and a 
solution of the crude ethyl (3S)-hydroxy-5-phenylpentanoate (1.40 mmol) in THF (2.0 
cm3) was added. The reaction mixture was stirred at -78 °C for 4 h, then quenched with sat 
NH4Cl (6 cm
3) and extracted with EtOAc (3× 20 cm3). The combined organic layers were 
dried over MgSO4 and concentrated. The crude product was purified by silica gel column 
chromatography (eluent hexane/EtOAc=4:1-1:1) to afford the Weinreb amide 210 (288.1 
mg, 1.28 mmol, 90% over two steps). [α]D22+ 34.5 (c 0.5 in CHCl3); H (400 MHz, CDCl3) 
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7.30-7.16 (5H, m, Ph), 4.08-4.01 (1H, m, CHOH), 3.88 (1H, d, J 2.9, OH), 3.67 (3H, s, 
OCH3), 3.19 (3H, s, NCH3), 2.86 (1H, ddd, J 13.8, 10.0, 5.4, HCHCON), 2.76-2.64 (2H, 
m, HCHCON and PhHCH), 2.48 (1H, dd, J 16.8, 9.5, PhHCH), 1.94-1.84 (1H, m, 
HCHCHOH),1.78-1.70 (1H, m, HCHCHOH); C(100 MHz, CDCl3) 173.8, 142.0, 128.5, 
128.4, 125.8, 67.2, 61.3, 38.2 (2C), 31.9 (2C); m/z (ESI-MS) 238.1 (M+H)+. Lit34 (S)-
Weinreb amide []D25 +28.6 (c=1.08, CHCl3, >99% ee). 
 
Ethyl hydroxy-5-phenylpentanoate. This compound is known and has been fully 
characterized. 185 
 
To a solution of diisopropylamine (3.23 g, 32 mmol) in THF (40 cm3) at -78 °C was added 
n-BuLi (1.6 M in hexane, 20.0 cm3, 32 mmol) dropwise over 20 min then a solution of 
ethylacetate (2.45 g, 27.8 mmol) in THF (10 cm3) was added dropwise over 20 min. After 
stirring for 1.5 h, 3-phenylpropionaldehyde (3.16 g, 23.5 mmol in 10 cm3 THF) was added 
in one portion. The resulting mixture was stirred at -78 °C for 2 h and sat NH4Cl (50 cm
3) 
was added. The mixture was extracted with ethyl acetate (3 × 50 cm3) and the combined 
organic phase was washed with brine (15 cm3), and dried over anhydrous MgSO4. The 
crude product was purified by silica gel column chromatography (eluent 
hexane/EtOAc=8:1) to afford the racemic compound as a colourless oil (4.5 g, 20.2 mmol, 
86%). H (400 MHz, CDCl3) 7.31-7.24 (2H, m, Ph), 7.22-7.15 (3H, m, Ph), 4.16 (2H, s, J 
7.2, COOCH2), 4.06-3.98 (1H, m, CHOH), 2.86-2.78 (1H, d, J 2.8, PhHCH), 2.74-2.66 
(1H, s, PhHCH), 2.51 (1H, dd, J 12.4, 3.4, HCHCOO), 2.44 (1H, dd, J 12.4, 8.6, 
HCHCOO), 1.90-1.69 (2H, m, CH2CHOH), 1.27 (3H, t, J 7.2,CH3). 
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(5S)-Hydroxy-1,7-diphenylhept-1-yn-3-one 212. This compound is known and has been 
fully characterized.187 
 
To a solution of phenylacetylene (146 mg, 1.45 mmol) in anhydrous THF (6 cm3) at -
78 °C, n-BuLi (1.6 M in hexane, 0.79 cm3, 1.26 mmol) was added in 3 min. The mixture 
was stirred at -78 °C for 1 h and Weinreb amide 210 (81.1 mg in 0.5 cm3 THF, 0.36 mmol) 
solution was added dropwise. After 30 min at -78 °C, temperature was raised to -10 °C for 
2 h and sat NH4Cl (5 cm
3) was added at -10 °C and the mixture was extracted with EtOAc 
(3 × 20 cm3) and the combined organic phase was dried over anhydrous MgSO4.The crude 
product was purified by silica gel column chromatography (eluent hexane/EtOAc=8:1-5-1) 
to afford ketone 212 as a light yellow solid (86.0 mg, 0.30 mmol, 85%). MP 43-44 °C; 
[α]D26 + 27.6 (c 0.5 in CHCl3); H (400 MHz, CDCl3) 7.60-7.54 (2H, m, Ph), 7.50-7.45 
(1H, m, Ph), 7.42-7.37 (2H, m, Ph), 7.32-7.27 (2H, m, Ph), 7.24-7.17 (3H, m, Ph), 4.24-
4.17 (1H, m, CHOH), 2.91-2.80 (3H, m, CH2CO and OH), 2.77-2.69 (2H, m, CH2Ph), 
1.93-1.73 (2H, m, CH2CH2Ph); 
13C NMR(100 MHz, CDCl3) 186.3, 140.6, 132.1, 130.0, 
127.6, 127.4 (2C), 124.9, 118.6, 90.9, 86.8, 65.9, 51.3, 37.0, 30.7; m/z (ESI-MS)  279.1 
(M+H)+. Lit187 MP 45-50 °C; S enantiomer []D +17.7 (c 1.0 in CHCl3, 96% ee). 
 
(-)-Yashabushidiol B 213. This compound is known and has been fully characterized.139-
141 
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(R,R)-c2 (0.3 mg, 5 × 10-4 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture 
(60 mg) and ketone 212 (13.2 mg, 0.047 mmol) in degassed CH2Cl2 (0.5 cm
3) was 
injected under nitrogen atmosphere. The mixture was stirred at rt until the starting material 
was completely consumed then the reaction was quenched by sat NaHCO3 (0.5 cm
3), 
extracted with EtOAc (3 × 5 cm3) and the combined organic phase was dried over 
anhydrous MgSO4. After concentration, Pd(OH)2/C (5 mg, 20% Pd(OH)2) and MeOH 
(2.0 cm3) was added. The solution was degassed once and stirred vigorously under a1 atm 
H2 atmosphere for 1 h. The catalyst was removed by filtration and washed by MeOH. The 
product solution were concentrated and purified by silica gel column chromatography 
(eluent hexane/EtOAc=6:1-2:1) to afford (-)-yashabushidiol B as white needles (13.2 mg, 
0.047 mmol, 98%, >99 ee, dr > 20/1 (determined by 1H NMR), dr = 75/1 (determined by 
HPLC)). MP 87 °C; [α]D22 - 5.0(c 0.5 in CHCl3); H (400 MHz, CDCl3) 7.31-7.24 (4H, m, 
2 × Ph), 7.22-7.16 (6H, m, 2 × Ph), 4.03-3.94 (2H, m, 2 × CHOH), 2.78 (2H, ddd, J 13.7 
8.9 5.8, 2 × HCHPh), 2.66 (2H, ddd, J 13.7 8.4 6.5, 2 × HCHPh), 2.34 (2H, br, 2 × OH), 
1.91-1.82 (2H, m, 2 × HCHCH2Ph), 1.82-1.71 (2H, m, 2 × HCHCH2Ph), 1.67 (2H, t, J 6.2, 
CHCH2CH); C (100 MHz, CDCl3) 141.9, 128.5, 128.4, 125.9, 68.9, 42.6, 39.1, 32.2. m/z 
(ESI-MS) 285.1 (M+H)+. HPLC separation conditions: CHIRALPAK IC column (250 
mm x 4.6 mm), hexane: i-PrOH 92:8, 0.8 cm3/min, T = 30 °C. Retention times, (R,R) 16.0 
min, (S,S) 17.7 min, (meso) 21.6 min. Lit140 MP 91-92 °C; ([]D -7.3 (c=1, CHCl3).  
 
Racemic+meso Yashabushidiol B. 
 
      198 
 
Racemic catalyst c1 (6 mg, 0.01 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic 
mixture (84 mg) and ketone ±212 (60 mg, 0.21 mmol) in degassed CH2Cl2 (1.5 cm
3) was 
injected under a nitrogen atmosphere. The mixture was stirred at rt until the starting 
material was completely consumed and the reaction was quenched by sat NaHCO3 (1 
cm3), extracted with CH2Cl2 (3 × 5 cm
3) and the combined organic phase was dried over 
anhydrous MgSO4. After concentration, Pd(OH)2/C (30 mg, 20% Pd(OH)2) and MeOH 
(10 cm3) was added. The solution was degassed once and stirred vigorously under 1 atm 
H2 atmosphere for 1.5 h. The catalyst was removed by filtration and washed with MeOH. 
The solution was concentrated and purified by silica gel column chromatography (eluent 
hexane/EtOAc=6:1-2:1) to afforded yashabushidiol B as a white solid (dr 5/1). H (400 
MHz, CDCl3) 7.31-7.24 (4H, m, 2 × Ph), 7.22-7.16 (6H, m, 2 × Ph), 4.03-3.94 (2H, m, 2 × 
CHOH), 2.78 (2H, ddd, J 13.7 8.9 5.8, 2 × HCHPh), 2.66 (2H, ddd, J 13.7 8.4 6.5, 2 × 
HCHPh), 2.34 (2H, br, 2 × OH), 1.91-1.82 (2H, m, 2 × HCHCH2Ph), 1.82-1.71 (2H, m, 2 
× HCHCH2Ph), 1.67 (2H, t, J 6.2, CHCH2CH). (racemic and meso diols were unable to be 
differentiated by 1H NMR ) 
Racemic reduction catalyst c1 was prepared by combining equal masses of each 
enantiomerically-pure catalyst. Due to weighing errors on the small scale required, the 
product exhibits a small residual enantiomeric excess (see HPLC in supporting 
information).  
 
3.18. Synthesis of Racemic Diynols. 
General Procedure 
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CuCl powder (6 mg, 2 mol%, 0.06 mmol) was added to a solution of degassed n-
BuNH2(30%)/H2O (7.5 cm
3) at 0 °C. The blue colour was quenched by the addition of a 
spatula’s tip of NH2OH·HCl. An alkyne solution (3.3 mmol, 1.1 equiv in THF 1 cm3) was 
added and the reaction mixture was stirred for 5 min then bromoalkyne (3.0 mmol, 1.0 
equiv in THF 1 cm3) was added. Every few minutes a spatula’s tip of NH2OH·HCl (0.66 
equiv in total) was added to the reaction mixture. After starting material was completely 
consumed (monitored by TLC 30 min to 2 h) the mixture was warmed to rt, quenched 
with sat NH4Cl (10 cm
3) and extracted with CH2Cl2 (3 × 30 cm
3). The organic extracts 
were combined and dried with sodium sulfate, filtered, concentrated and purified by 
column chromatography (hexane:EtOAc ratios are dependent on the polarity of products) 
to afford pure products.  Full characterisation data is given for the asymmetric products. 
 
6-Phenyl-3,5-hexadiyne-2-ol 215. This compound is known but not fully 
characterized.188 
This compound was prepared following the general procedure above using CuCl (20 mg, 
0.2 mmol), NH2OH·HCl (690 mg, 6.0 mmol), 3-butyn-2-ol (770 mg, 11.0 mmol), 
(bromoethynyl)benzene (1.82 g, 10.0 mmol) and n-BuNH2(30%)/H2O solution (26 cm
3). 
The product was isolated as a white solid (1.53 g, 9.0 mmol, 90%).  
 
7-Benzyloxy-7-methyl-3,5-octadiyne-2-ol 216. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (11 mg, 
0.11 mmol), NH2OH·HCl (235 mg, 3.36 mmol), 4-bromo-3-butyn-2-ol (998 mg, 6.76 
mmol), [[(1,1-dimethyl-2-propyn-1-yl)oxy]methyl]-benzene (978 mg, 5.6 mmol) and n-
BuNH2(30%)/H2O solution (14.0 cm
3). The product was isolated as colourless oil (1.10 g, 
4.5 mmol, 79%). 
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3,5-Decadiyne-2-ol 217. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (6.0 mg, 
0.06 mmol), NH2OH·HCl (126 mg, 1.8 mmol), 3-butyn-2-ol (234 mg, 3.3 mmol), 1-
bromohex-1-yne (486 mg, 3.0 mmol) and n-BuNH2(30%)/H2O solution (7.5 cm
3).The 
product was isolated as colourless oil (309 mg, 2.1 mmol, 69%).  
 
5,7-Dodecadiyne-4-ol 218. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (6.0 mg, 
0.06 mmol), NH2OH·HCl (126 mg, 1.8 mmol), 1-hexyn-3-ol (323 mg, 3.3 mmol), 1-
bromohex-1-yne (485 mg, 3.0 mmol) and n-BuNH2(30%)/H2O solution (7.5 cm
3). The 
product was isolated as colourless oil (471 mg, 2.6 mmol, 88%). 
 
5,7-Decadiyne-1,9-diol 219. This compound is known but not fully characterized.189 
This compound was prepared following the general procedure above using CuCl (21 mg, 
0.2 mmol), NH2OH·HCl (421 mg, 6.06 mmol), 4-bromo-3-butyn-2-ol (1.80 g, 12.2 
mmol), 5-hexyn-1-ol (996 mg, 10.1 mmol) and n-BuNH2(30%)/H2O solution (26 cm
3). 
The product was isolated as colourless oil (1.65 g, 9.9 mmol, 98%). 
 
1-Phenyl-3,5-decadiyne-2-ol 220. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (6.0 mg, 
0.06 mmol), NH2OH·HCl (128 mg, 1.68 mmol), 1-phenylbut-3-yn-2-ol (438 mg, 3.0 
mmol), 1-bromohex-1-yne (660 mg, 3.3 mmol) and n-BuNH2(30%)/H2O solution (7.0 
cm3). The product was isolated as colourless oil (488 mg, 2.2 mmol, 72%). 
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5-(1’-Benzyoxyl-cyclohexanyl)-3,5-hexadiyn-2-ol 221. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (6.0 mg, 
0.06 mmol), NH2OH·HCl (117 mg, 1.68 mmol), 4-bromo-3-butyn-2-ol (488 mg, 3.3 
mmol), [[(1-ethynylcyclohexyl)oxy]methyl]-benzene (642 mg, 3.0 mmol) and n-
BuNH2(30%)/H2O solution (7.0 cm
3). The product was isolated as colourless oil (820 mg, 
2.9 mmol, 97%). 
 
2,8-Dimethyl-2-benzyloxy-3,5-nonadiyne-7-ol 222. This compound is novel. 
This compound was prepared following the general procedure above using CuCl (6 
mg, 0.06 mmol), NH2OH·HCl (128 mg, 1.68 mmol), 1-bromo-4-methyl-1-pentyn-3-
ol (532 mg, 3.0 mmol), [[(1,1-dimethyl-2-propyn-1-yl)oxy]methyl]-benzene (574 
mg, 3.3 mmol) and n-BuNH2(30%)/H2O solution (7.0 cm
3). The product was isolated 
as colourless oil (589 mg, 2.2 mmol, 73%). 
 
3.19. Synthesis of Diynones. 
General Procedure 
 
Alcohol (1.0 mmol) was dissolved in CH2Cl2 (8 cm
3) and activated MnO2 power (2.0-2.3 
g) was added. After stirringat rt for 30 min to 1 h; MnO2 was filtered and washed with 
CH2Cl2. The filtratrate was concentrated and purified by silica gel column 
chromatography (pure CH2Cl2) to afford the pure products. 
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6-Phenyl-3,5-hexadiyn-2-one 223. This compound is known and has been fully 
characterized.190 
 
This compound was prepared following the general procedure above using alcohol 215 
(22.5 mg, 0.132 mmol) and MnO2 (150 mg, 1.7 mmol). The product was isolated as a 
yellow solid (21.7 mg, 0.129 mmol, 98%). νmax 2207, 1657, 1185, 753, 682 cm-1;H (400 
MHz, CDCl3) 7.57-7.52 (2H, m, Ph), 7.47-7.42 (1H, m, Ph), 7.39-7.34 (2H, m, Ph), 
2.41(3H, s, CH3); C (100 MHz, CDCl3) 183.4, 133.0, 130.5, 128.7, 120.2, 86.5, 78.6, 75.1, 
72.1, 32.6. 
 
7-Benzyloxy-7-methyl-3,5-octadiyn-2-one 224. This compound is novel. 
 
This compound was prepared following the general procedure above using alcohol 216 
(242 mg, 1.0 mmol) and MnO2 (2.3 g, 27 mmol). The product was isolated as a colourless 
oil (203 mg, 0.85 mmol, 85%). (found (ESI): M+ + Na, 263.1043; C16H16O2 requires M, 
263.1042); νmax 2987, 2231, 2139, 1674, 1202, 1183, 1155, 1048, 732, 695 cm-1; H (400 
MHz, CDCl3) 7.38-7.25 (5H, m, Ph), 4.61 (2H, s, CH2Ph), 2.37 (3H, s, CH3CO), 1.59 (6H, 
s, 2 × CH3C); C (100 MHz, CDCl3) 182.3, 138.2, 128.4, 127.73, 127.69, 90.4, 75.8, 74.2, 
71.2, 67.4, 67.2, 32.6, 28.3;  m/z (ESI-MS) 263.1 (M+Na)+. 
 
3,5-Decadiyn-2-one 225. This compound is known and has been fully characterized.191 
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This compound was prepared following the general procedure above using alcohol 217 
(179 mg, 1.2 mmol) and MnO2 (2.7 g, 31 mmol). The product was isolated as a 
ketone/CH2Cl2 4/1 mixture and was used directly after purification. H (400 MHz, CDCl3) 
2.38 (2H, t, J 7.0, ≡CCH2), 2.35 (3H, s, CH3CO), 1.61-1.52 (2H, m, ≡CCH2CH2), 1.48-
1.38 (2H, m, CH2CH3), 0.93 (3H, t, J 7.3, CH3). 
 
5,7-Dodecadiyn-4-one 226. This compound is novel. 
 
This compound was prepared following the general procedure above using alcohol 218 
(178 mg, 1.0 mmol) and MnO2 (2.0 g, 23 mmol). The product was isolated as a colourless 
oil (145 mg, 0.82 mmol, 82%). (found (ESI): M+ + H, 177.1274; C12H16O requires M, 
177.1274); νmax 2961, 2934, 2230, 2145, 1667, 1269, 1230 cm-1; H (400 MHz, CDCl3) 
2.54 (2H, t, J 7.3, CH2CO), 2.38 (2H, t, J 7.0, ≡CCH2), 1.75-1.65 (2H, m, 
CH3CH2CH2CO), 1.60-1.52 (2H, m, ≡CCH2CH2), 1.49-1.38 (2H, m, ≡CCH2CH2 CH2), 
0.95 (3H, t, J 7.5, CH3), 0.93 (3H, t,J 7.4, CH3); C (100 MHz, CDCl3) 187.2, 90.6, 76.1, 
72.2, 63.8, 47.3, 29.8, 21.9, 19.3, 17.5, 13.4 (2 C); m/z (ESI-MS) 199.1 (M+Na)+. 
 
1-Hydroxyl-5,7-decadiyn-9-one 227. This compound is novel. 
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This compound was prepared following the general procedure above using alcohol 219 
(168 mg, 1.0 mmol) and MnO2 (2.3 g, 27 mmol). The product was isolated as a colourless 
oil (150 mg, 0.9 mmol, 90%). (found (ESI): M+ + Na, 187.0730; C10H12O2 requires M 
187.0729); νmax 3325, 2938, 2226, 2145, 1668, 1262, 1133, 619 cm-1;H (400 MHz, 
CDCl3) 3.72-3.64 (2H, m, CH2OH), 2.40-2.47 (2H, m, ≡CCH2), 2.36 (2H, s, CH3CO), 
1.73-1.65 (4H, m, CH2CH2CH2OH), 1.44 (1H, br, OH); C (100 MHz, CDCl3) 183.7, 90.5, 
75.9, 72.7, 64.1, 62.1, 32.6, 31.6, 24.2, 19.5;  m/z (ESI-MS) 187.1 (M+Na)+. 
 
5-(1’-Benzyoxyl-cyclohexanyl)-3,5-hexadiyn-2-one 229. This compound is novel. 
 
This compound was prepared following the general procedure above using alcohol 221 
(282 mg, 1.0 mmol) and MnO2 (2.3 g, 27 mmol). The product was isolated as a colourless 
oil (200 mg, 0.7 mmol, 71%). (found (ESI): M+ + Na, 303.1356; C19H20O2 requires M, 
303.1356); νmax 2935, 2868, 2228, 2137, 1673, 1237, 1132, 1087, 1067, 735, 695 cm-1; H 
(400 MHz, CDCl3) 7.38-7.25 (5H, m, Ph), 4.62 (2H, s, CH2Ph), 2.38 (2H, s, CH3CO), 
2.06-1.97 (2H, m, cycle hexanyl), 1.82-1.67 (4H, m, cycle hexanyl), 1.60-1.48 (3H, m, 
cycle hexanyl), 1.40-1.28 (1H, m, cycle hexanyl); C (100 MHz, CDCl3) 183.4, 138.5, 
128.4, 127.7, 127.6, 90.3, 75.6, 74.4, 69.0, 66.1, 36.8, 32.6, 25.2, 22.6; m/z (ESI-MS) 
303.1 (M+Na)+. 
 
1-Phenyl-3,5-decadiyn-2-one 228. This compound is novel. 
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This compound was prepared following the general procedure above using alcohol 220 
(226 mg, 1.0 mmol) and MnO2 (2.3 g, 27 mmol). The product was isolated as yellow oil 
(56 mg, 0.25 mmol, 25%). (found (ESI): M+ + H, 225.1274; C16H16O requires M, 
225.1274); νmax 2959, 2933, 2228, 2144, 1665, 1310, 701 cm-1; H (400 MHz, CDCl3) 
7.38-7.21 (5H, m, Ph), 3.84 (2H, s, CH2Ph), 2.35 (2H, t, J 7.0, ≡CCH2), 1.59-1.49 (2H, m, 
≡CCH2CH2), 1.46-1.36 (2H, m, CH2CH3), 0.91 (3H, t, J 7.3, CH3); C (100 MHz, CDCl3) 
184.1, 132.5, 129.8, 128.8, 127.5, 91.5, 77.9, 72.1, 63.8, 52.1, 29.7, 21.9, 19.4, 13.5; m/z 
(ESI-MS) 247.1 (M+Na)+. 
 
2,8-Dimethyl-2-benzyloxy-3,5-nonadiyn-7-one 230. This compound is novel. 
 
This compound was prepared following the general procedure above using alcohol 222 
(134 mg, 0.5 mmol) and MnO2 (1.20 g, 14 mmol). The product was isolated as a 
colourless oil (131 mg, 0.5 mmol, 98%). (found (ESI): M + H+, 269.1536; C18H20O2 
requires M, 269.1536); νmax 3032, 2229, 2136, 1183, 1050, 1001, 733, 696 cm-1; H (400 
MHz, CDCl3) 7.39-7.26 (5H, m, Ph), 4.62 (2H, s, CH2Ph), 2.73-2.62 (1H, m, CH), 1.59 
(6H, s, 2 × CH3C), 1.21 (6H, d, J 7.0, 2 × CH3CH); C (100 MHz, CDCl3) 190.9, 138.3, 
128.4, 127.7, 127.6, 89.9, 75.2, 74.8, 71.2, 67.6, 67.1, 43.1, 28.4, 17.7; m/z (ESI-MS) 
291.1 (M+Na)+. 
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3.20. Asymmetric Transfer Hydrogenation of Diynones. 
General Procedure 
 
(S,S)-c2/(S,S)-c1 (3.0 mg, 5.0 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic 
mixture (84 mg) and diynone (0.05 mmol) in degassed CH2Cl2 (0.5 cm
3) was injected. The 
mixture was stirred at rt until starting material was completely consumed (1-3 h). The 
reaction mixture was quenched by sat NH4Cl (4 cm
3) and extracted with dichloromethane 
(3 × 10 cm3). The combined organic phase was dried over anhydrous MgSO4, 
concentrated and purified by silica gel column chromatography (eluent hexane/EtOAc). 
 
6-Phenyl-3,5-hexadiyn-(2S)-ol S-215. This compound is known but not fully 
characterized.188 
 
This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 mg) and ketone 223 (8.4 mg, 0.05 mmol). 
The product was isolated as a white solid (2.1 mg, 0.013 mmol, 25 %, 94 % ee). [α]D24 -
58.4 (c 0.1 in CHCl3) 94% ee (S); MP 29 °C; νmax 3312, 2982, 2236, 1126, 1067, 751, 684 
cm-1;H (400 MHz, CDCl3) 7.50-7.47 (2H, m, Ph), 7.38-7.28 (3H, m, Ph), 4.66 (1H, q, J 
6.6, CH), 2.17 (1H, br, OH), 1.52 (3H, d, J 6.6, CH3); C (00 MHz, CDCl3) 132.6, 129.3, 
128.4, 121.5, 84.0, 77.8, 73.2, 68.9, 58.9, 24.0; m/z (ESI-MS) 193.0 (M+Na)+. HPLC 
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separation conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 
95:05, 0.8 cm3/min, T = 30 °C. Retention times: (major - S) 13.4 min, (minor - R) 15.6 
min. 
 
7-Benzyloxy-7-methyl-3,5-octadiyne-(2S)-ol S-216. This compound is novel. 
 
This compound was prepared following the general procedure above using both (S,S)-c1 
(3.0 mg, 5.0 × 10-3 mmol) and (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 
mg) and ketone 224 (12.0 mg, 0.05 mmol). The product was isolated as a colourless oil 
(10.4 mg, 0.043 mmol, 86%, ee 94% for non-tethered catalyst) and (9.9 mg, 0.041 mmol, 
82 %, ee 93% for tethered catalyst). [α]D22 -30.5 (c 0.3 in CHCl3) 93% ee (S);found (ESI): 
M+ + Na, 265.1199; C16H18O2 requires M, 265.1199); νmax 3384, 2984, 1264, 1147, 1084, 
1046, 1026, 735, 696 cm-1; H (400 MHz, CDCl3) 7.38-7.25 (5H, m, Ph), 4.61 (2H, s, 
CH2Ph), 4.61-4.52 (1H, m, CH), 2.05 (1H, br, OH), 1.55 (6H, s, 2 × CH3C), 1.47 (3H, d, J 
6.6, CH3); C (100 MHz, CDCl3) 138.6, 128.4, 127.8, 127.5, 82.1, 81.0, 71.1, 68.4, 68.2, 
66.9, 58.7, 28.7, 23.9; m/z (ESI-MS) 265.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 96:04, 0.8 cm3/min, T = 
30 °C. Retention times: (major - S) 10.3 min, (minor - R) 10.8 min. 
 
3,5-Decadiyne-(2S)-ol S-217. This compound is novel. 
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This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 mg) and 
ketone 225 (7.4 mg, 0.05 mmol). The product was isolated as a colourless oil (7.0 mg, 
0.047 mmol, 94 %, ee 97% for non-tethered catalyst) and (5.6 mg, 0.037 mmol, 75 %, ee 
97% for tethered catalyst). [α]D22 -20.6 (c 0.7 in CHCl3) 97% ee (S); (found (ESI): M+ + 
Na, 173.0937; C10H14O requires M, 173.0937); νmax 3329, 2959, 2933, 2257, 1097, 1074, 
1027 cm-1; H (400 MHz, CDCl3) 4.57 (1H, m, CH), 2.28 (2H, t, J 6.9, CH2C≡), 1.99 (1H, 
d, J 5.3, OH), 1.55-1.37 (4H, m, CH3CH2CH2), 1.46 (3H, d, J 6.7, CH3), 0.91 (3H, t, J 7.3, 
CH3); C (100 MHz, CDCl3) 81.9, 77.1, 69.2, 64.3, 58.7, 30.2, 24.1, 21.9, 18.9, 13.5; m/z 
(ESI-MS) 173.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IC column (250 
mm × 4.6 mm), hexane:i-PrOH 96:04, 0.8 cm3/min, T = 30 °C. Retention times: (major - S) 
10.6 min, (minor - R) 12.1 min.  
 
3,5-Decadiyne-(4S)-ol S-218. This compound is novel. 
 
This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol),  HCO2H/TEA 5:2 (83 mg) 
and ketone 226 (8.8 mg, 0.05 mmol). The product was isolated as a colourless oil (8.1 mg, 
0.046 mmol, 91%, ee 97% for non-tethered catalyst) and (8.4 mg, 0.047 mmol, 95%, ee 
98% for tethered catalyst). [α]D22 -0.3 (c 0.6 in CHCl3) 98% ee (S); (found (ESI): M+ + Na, 
201.1250; C12H18O requires M 201.1249); νmax 3317, 2959, 2933, 2872, 2254, 1464, 1113 
cm-1; H (400 MHz, CDCl3) 4.42 (1H, t, J 5.5, CHOH), 2.29 (2H, t, J 6.8, CH2C≡), 1.91-
1.62 (3H, m, CH2CHOH), 1.57-1.36 (6H, m, CH2CH3 and CH2CH2CH3), 0.99-.088 (6H, 
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m, 2 × CH3); C (100 MHz, CDCl3) 81.7, 76.5, 69.9, 64.4, 62.7, 39.7, 30.2, 21.9, 19.0, 
18.4, 13.7, 13.5; m/z (ESI-MS) 201.1 (M+Na)+. HPLC separation conditions: 
CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 97:03, 0.6 cm3/min, T = 
30 °C. Retention times: (major - S) 10.4 min, (minor - R) 11.2 min. (this compound was 
protected as the p-MeOC6H4CO ester and used for HPLC) 
 
5,7-Decadiyne-1,(9S)-diol S-219. This compound is known but not fully characterized. 
 
This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 mg) and 
ketone 227 (8.3 mg, 0.05 mmol). The product was isolated as a colourless oil (7.5 mg, 
0.045 mmol, 89 %, ee >90% for non-tethered catalyst) and (8.0 mg, 0.047 mmol, 96 %, 
ee >90% for tethered catalyst). [α]D24 -8.6 (c 0.4 in CHCl3) >90% ee (S); (found (ESI): M+ 
+ Na, 189.0886; C10H14O2 requires M 189.0886); νmax 3321, 2935, 2254, 1322, 1098, 
1060, 1030 cm-1; H (400 MHz, CDCl3) 4.59-4.53 (1H, m, CHOH), 3.67 (2H, t, J 5.8, 
CH2OH), 2.46 (1H, d, J 5.1, CHOH), 2.34 (2H, t, J 6.8, CH2C≡), 1.76-1.59 (5H, m, 
CH2CH2CH2OH), 1.46 (3H, d, J 6.6, CH3); C (100 MHz, CDCl3) 81.3, 77.5, 69.0, 64.7, 
66.2, 58.6, 31.7, 24.5, 24.1, 19.1; m/z (ESI-MS) 189.1 (M+Na)+. HPLC separation 
conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 100:0, 0.6 
cm3/min, T = 30 °C. Retention times: (major - S) 11.8 min, (minor - R) 12.3 min. (this diol 
was protected by TBDPS and used for HPLC) 
 
5-(1’-Benzyoxyl-cyclohexanyl)-3,5-hexadiyn-(2S)-ol S-221. This compound is novel. 
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This compound was prepared following the general procedure above using (S,S)-c1(3.1 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol),  HCO2H/TEA 5:2 (83 mg) 
and ketone 229 (14.0 mg, 0.05 mmol). The product was isolated as a colourless oil (11.9 
mg, 0.042 mmol, 85%, ee 95% for non-tethered catalyst) and (10.6 mg, 0.038 mmol, 76%, 
ee 90% for tethered catalyst). [α]D22 +7.9 (c 0.4 in CHCl3) 95% ee (S); (found (ESI): M+ + 
Na, 305.1512; C19H22O2 requires M, 305.1512); νmax 3362, 2933, 2857, 1087, 1066, 934, 
733, 696 cm-1; H (400 MHz, CDCl3) 7.39-7.30 (4H, m, Ph), 7.23-7.29 (1H, m, Ph), 4.63 
(2H, s, CH2Ph), 4.59-4.52 (1H, m, CH), 2.19-2.15 (1H, br, OH), 2.03-1.93 (2H, m, 
cyclohexyl), 1.75-1.66 (4H, m, cyclohexyl), 1.61-1.47 (3H, m, cyclohexyl), 1.46 (3H, d, J 
6.7, CH3), 1.38-1.25 (1H, m, cyclohexyl); C (100 MHz, CDCl3) 138.3, 128.4, 127.8, 
127.5, 81.7, 80.7, 74.7, 70.0, 68.4, 65.9, 58.7, 37.1, 25.3, 24.0, 22.7; m/z (ESI-MS) 305.1 
(M+Na)+. HPLC separation conditions: CHIRALPAK IC column (250 mm × 4.6 mm), 
hexane:i-PrOH 97:3, 0.8 cm3/min, T = 30 °C. Retention times: (major - S) 13.0 min, 
(minor - R) 13.9 min.  
 
1-Phenyl-3,5-decadiyne-(2S)-ol S-220. This compound is novel. 
 
This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 mg) and 
ketone 228 (11.2 mg, 0.05 mmol). The product was isolated as a colourless oil (10.2 mg, 
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0.045 mmol, 90 %, ee 97% for non-tethered catalyst) and (10.5 mg, 0.046 mmol, 92 %, ee 
98% for tethered catalyst). [α]D22 -22.0 (c 0.8 in CHCl3) 97% ee (S); (found (ESI): M+ + 
Na, 249.1250; C16H18O requires M, 249.1250); νmax 3332, 2957, 2930, 2253, 1454, 1029, 
747, 698 cm-1; H (400 MHz, CDCl3) 7.35-7.23 (5H, m, Ph), 4.61(1H, q, J 6.1, ≡CCH), 
3.03 (1H, dd, J 13.4 6.1, HCHPh), 2.98 (1H, dd, J 13.4 6.1, HCHPh), 2.28 (2H, t, J 7.4, 
≡CCH2), 1.93 (1H, d, J 6.1, OH), 1.55-1.47 (2H, m, ≡CCH2CH2), 1.46-1.36 (2H, m, CH2 
CH3), 0.91 (3H, t, J 7.3, CH3); C (100 MHz, CDCl3) 136.2, 129.8, 128.5, 127.0, 82.1, 
75.6, 70.9, 64.3, 63.6, 43.9, 30.2, 21.9, 19.0, 13.5; m/z (ESI-MS) 249.1 (M+Na)+. HPLC 
separation conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 
97:3, 0.8 cm3/min, T = 30 °C. Retention times: (major - S) 15.9 min, (minor - R) 19.7 min. 
 
2,8-Dimethyl-2-benzyloxy-3,5-nonadiyne-(7S)-ol S-222. This compound is novel. 
 
This compound was prepared following the general procedure above using (S,S)-c1 (3.0 
mg, 5.0 × 10-3 mmol) or (S,S)-c2 (3.0 mg, 5.0 × 10-3 mmol), HCO2H/TEA 5:2 (83 mg) and 
ketone 230 (13.3 mg, 0.05 mmol). The product was isolated as a colourless oil (10.6 mg, 
0.039 mmol, 79 %, ee 96% for non-tethered catalyst) and (12.7 mg, 0.048 mmol, 95%, ee 
99% for tethered catalyst). [α]D24 +4.9 (c 0.5 in CHCl3) 99% ee (S); (found (ESI): M+ + Na, 
293.1512; C18H22O2 requires M, 293.1512); νmax 3374, 2963, 2933, 1147, 1027, 735, 696 
cm-1; H (400 MHz, CDCl3) 7.39-7.24 (5H, m, Ph), 4.62 (2H, s, CH2Ph), 4.23 (1H, t, J 5.7, 
CHOH), 1.98 (1H, br, OH, ), 1.94-1.86 (1H, m, CH(CH3)2), 1.56 (6H, s, 2 × CH3C), 1.02 
(3H, d, J 6.8, CHCH3), 1.01 (3H, d, J 6.8, CHCH3); C (100 MHz, CDCl3) 138.6, 128.4, 
127.8, 127.5, 81.6, 79.4, 71.1, 69.6, 68.6, 68.3, 66.9, 34.6, 28.7, 18.1, 17.5; m/z (ESI-MS) 
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293.1 (M+Na)+. HPLC separation conditions: CHIRALPAK IC column (250 mm × 4.6 
mm), hexane:i-PrOH 97:3, 0.8 cm3/min, T = 30 °C. Retention times: (major - S) 8.9 min, 
(minor - R) 10.7 min. 
 
3.21. Total Synthesis of Panaxjapyne A. 
1-Iodo-2-decyne 236. This compound is novel. 
 
I2 (1.448 g, 5.7 mmol) was added to a vigorouslystirred solution of imidazole (2.135 g, 6.4 
mmol) and PPh3 (1.573 g, 6.0 mmol) in dry CH2Cl2 (13 cm
3). The resulting solution was 
stirred for 10 min then a solution of 2-decyn-1-ol 231 (655 mg, 4.25 mmol) in dry CH2Cl2 
(5 cm3) was added via syringe. The mixture was stirred for 30 min and the solid residue 
was removed by filtration and rinsed with hexane (100 cm3). The solution was 
concentrated and purified by column chromatography (pure hexane) to give the product 
236 as a colourless oil (1.02 g, 3.9 mmol,91%). νmax 2924, 2854, 1463, 1170, 1142, 557 
cm-1; H (400 MHz, CDCl3) 3.71 (2H, t, J 2.4, CH2I), 2.21-2.16 (2H, m, ≡CCH2), 1.53-
1.46 (2H, m, ≡CCH2CH2), 1.40-1.24 (8H, m, CH2CH2CH2CH2CH3), 0.89 (3H, t, J 6.9, 
CH3); C (100 MHz, CDCl3) 86.9, 77.0, 31.7, 29.1, 28.8, 28.4, 22.6, 19.1, 14.1, -16.6. No 
response was found from ether ESI-MS or HRMS. 
 
Trimethyl-1,4-dodecadiynylsilane 237. This compound is novel. 
 
Ground K2CO3 power (370 mg, 2.7 mmol) and CuI (231 mg, 1.2 mmol) powder were 
dried at 140 °C undervacuum for 30 min. After cooled to rt, anhydrous DMF (9.5 cm3) 
was injected followed by ethynyltrimethylsilane (1.33 cm3, 9.5 mmol). The suspension 
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was stirred for 10 min then a solution of 1-iodo-2-decyne 236 (500 mg, 1.9 mmol) in 
DMF (3 cm3) was added and stirring was continued for 24 h. Sat NH4Cl (20 cm
3) and 
water (20 cm3) were added and the mixture was extracted with hexane/Et2O 4/1 mixture (2 
× 40 cm3), and the organic extracts were dried over anhydrous MgSO4. After 
concentration the crude product was purified by column chromatography (pure hexane) to 
afford product 237 as yellow oil (329 mg, 1.4 mmol, 74 %). (found (ESI): M+ + H, 
235.1877. C15H26Si requires M, 235.1876); νmax 2957, 2928, 2856, 2183, 1249, 1012, 840 
cm-1; H (400 MHz, CDCl3) 3.03 (2H, t, J 2.4, ≡CCH2CH≡), 1.99 (2H, tt, J 7.0, 2.4, 
≡CCH2), 1.36-1.27 (2H, m, ≡CCH2CH2), 1.25-1.06 (8H, m, CH2CH2CH2CH2CH3), 0.72 
(3H, t, J 7.0, CH3), -0.25 (9H, s, Si(CH3)3); C (100 MHz, CDCl3) 100.9, 84.7, 81.2, 73.4, 
31.8, 28.9, 28,8, 28.7, 22.7, 18.8, 14.1, 11.0, 0.03; m/z (ESI-MS) 257.1 (M+Na)+. 
 
(4Z)-4-Dodecen-1-ynyltrimethylsilane 234. This compound is known but not fully 
characterized.192 
 
Ni(OAc)2·4H2O (46.0 mg, 0.185 mmol) was dissolved in EtOH (4.0 cm
3) and treated with 
a suspension of NaBH4 (6.8 mg, 0.185 mmol) in EtOH (3.0 cm
3) under hydrogen. After 
stirringfor 15 min., ethylenediamine (27.8 mg, 0.46 mmol) in EtOH (2.0 cm3) was added. 
After stirring for 1.5 h, a solution of freshly prepared diyne (213 mg, 0.91 mmol) in EtOH 
(2.0 cm3) was added and the mixture was stirred vigorously for 55 min (longer reaction 
time cause yield decrease). The EtOH was removed and the residue was purified by 
column chromatography (pure hexane) to afford product 234 as acolourless oil (190 mg, 
0.81 mmol, 88%, Z/E 23/1). (found (ESI): M+ + Na, 259.1852. C15H28Si requires M, 
259.1852); νmax 2957, 2924, 2855, 2176, 1249, 839, 759 cm-1; H (400 MHz, CDCl3) 5.36-
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5.23 (2H, m, CH=CH), 2.83 (2H, d, J 6.0, ≡CCH2CH=), 1.88 (2H, q, J 6.8, =CHCH2), 
1.26-1.07 (10H, m, (CH2)5CH3), 0.74 (3H, t, J 7.0, CH3), -0.25 (9H, s, Si(CH3)3); C (100 
MHz, CDCl3) 131.9, 123.6, 105.4, 83.9, 31.7, 29.2, 29.11, 29.08, 27.1, 22.5, 18.3, 14.0, 
0.0; m/z (ESI-MS) 473.4 (2M+H)+. 
 
1-Bromo-(4Z)-dodecen-1-yne 238. This compound is novel. 
 
To a solution of 234 (77 mg, 0.33 mmol) in acetonitrile (3.5 cm3) was added NBS (70 mg, 
0.39 mmol) and AgF (49.5 mg, 0.39 mmol). After the reaction had completed (30 min), 
the mixture was diluted with water (10 cm3), extracted with hexane (3 × 20 cm3) and dried 
over anhydrous MgSO4. After concentration, the crude product was purified by a short 
column (pure hexane) to afford product 238 as colourless oil (73.3 mg,0.30 mmol, 93%). 
νmax 2955, 2924, 2854, 1464, 723 cm-1; H (400 MHz, CDCl3) 5.54-5.45 (1H, m, CH=CH), 
5.44-5.35 (1H, m, CH=CH), 2.95 (2H, d, J 6.8, ≡CCH2CH=), 2.02 (2H, q, J 7.2, =CCH2), 
1.40-1.20 (10H, m, CH2CH2CH2CH2CH2CH3), 0.88 (3H, t, J 7.0, CH3); C (100 MHz, 
CDCl3) 132.5, 122.9, 78.6, 37.8, 31.9, 29.3, 29.20, 29.18, 27.2, 22.7, 18.0, 14.1. No 
response was found from ether ESI-MS or HRMS. 
 
(±)-Panaxjapyne A ±239. This compound is known and has been fully characterized. 
 
CuCl power (2.1 mg, 0.022 mmol, 3 mol%) was added to a solution of degassed n-
BuNH2(30%)/H2O (1.6 cm
3) at 0 °C. The blue colour was quenched by the addition of a 
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spatula’s tip of NH2OH·HCl. 1-Pentyn-3-ol (89 mg, 1.05 mmol, 1.5 equiv in THF) was 
added and the reaction mixture was stirred for 1 min then freshly prepared 1-bromo-(4Z)-
dodecen-1-yne (170 mg, 0.69 mmol in THF) was added. Every few minutes a spatula’s tip 
of NH2OH·HCl (31.3 mg, 0.45 mmol as total amount) was added to the mixture. After the 
starting material had been completely consumed (about 30 min, monitored by TLC) the 
mixture was quenched usingsat NH4Cl (4 cm
3), warmed to rt and extracted with CH2Cl2 (3 
× 20 cm3). The organic extracts were dried over anhydrous MgSO4, concentrated and 
purified by column chromatography (hexane:EtOAc 20/1-10/1) to afford (±)-panaxjapyne 
A as a colourless oil (155.1 mg, 0.63 mmol, 90%).  
 
Panaxjapynone A. This compound is novel. 
 
Alcohol ±239 (154.5 mg, 0.63 mmol) in CH2Cl2 (4.5 cm
3) was treated with activated 
MnO2 (2.0 g). After strirring at rt for 1.5 h, the MnO2 was filtered and the solid residue 
was rinsed with CH2Cl2 (30 cm
3). The organic filterate was concentrated and purified by a 
short silica gel column (hexane:EtOAc 20/1) to afford pure panaxjapynone A as light 
yellow oil (112.2 mg, 0.46 mmol, 73%). (found (ESI): M+ + H, 245.1900. C17H24O 
requires M, 245.1900); νmax 2920, 2855, 2233, 2145, 1673, 1235, 1101, 1037 cm-1; H 
(400 MHz, CDCl3) 5.60-5.52 (1H, m, CH=CH), 5.42-5.33 (1H, m, CH=CH), 3.11 (2H, d, 
J 6.9, ≡CCH2CH=), 2.58 (2H, q, J 7.3, COCH2), 2.03 (2H, q, J 7.3, =CHCH2), 1.42-1.22 
(10H, m, CH2CH2CH2CH2CH2CH3), 1.14 (3H, t, J 7.4, COCH2CH3), 0.88 (3H, t, J 7.1, 
CH3); C (100 MHz, CDCl3) 187.6, 133.9, 120.8, 88.2, 76.0, 72.4, 63.5, 38.8, 31.8, 29.2 (3 
C), 27.3, 22.6, 18.0, 14.1, 7.9; m/z (ESI-MS) 267.1 (M+Na)+. 
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Panaxjapyne A 239. This compound is known and has been fully characterized.99 
 
(S,S)-c2 (6.0 mg, 0.01 mmol) was dissolved in HCO2H/Et3N 5:2 azeotropic mixture (166 
mg) and ketone panaxjapynone A (24.2 mg, 0.1 mmol) in degassed CH2Cl2(1.0 cm
3) was 
injected under a nitrogen atmosphere. The mixture was stirred at rt for 1 h then quenched 
using sat NH4Cl (3 cm
3), extracted with CH2Cl2 (3 × 15 cm
3) and the combined organic 
phase was dried over anhydrous MgSO4, concentrated and purified by column 
chromatography (hexane:EtOAc 20/1-10/1) to afford panaxjapyne A 239 as a yellow oil 
(20.3 mg, 0.083 mmol, 85%, 96% ee by HPLC (analyze of panaxjapyne A 4-
methoxybenzonate); ee determined by modified Mosher ester method was >90% ee 
however a more accurate value was obtained by chiral HPLC analysis). [α]D28 +11.0 (c 0.1 
in CH3OH) 96% ee (S); Lit
99 [α]D+50.0 (c 0.02 in CH3OH) (S); (found (ESI): M+ + Na, 
269.1876. C17H26O requires M, 269.1876); νmax 3330, 2958, 2854, 2256, 1460, 1012, 967, 
903 cm-1; H (400 MHz, CDCl3) 5.55-5.47 (1H, m, CH=CH), 5.42-5.34 (1H, m, CH=CH), 
4.38-4.33 (1H, m, J 6.1, CHOH), 3.03 (2H, d, J 6.9, =HCCH2C≡), 2.02 (2H, q, J 7.1, 
=CHCH2), 1.79-1.69 (3H, m, CHOHCH2 and OH), 1.40-1.22 (10H, m, 
CH2CH2CH2CH2CH2CH3), 1.01 (3H, t, J 7.4, CHOHCH2CH3), 0.88 (3H, t, J 7.0, CH3); 
C (100 MHz, CDCl3) 133.0, 122.0, 79.6, 76.7, 69.9, 64.1 (2C), 31.8, 30.7, 29.25, 29.20, 
29.17, 27.2, 22.7, 17.7, 14.1, 9.3; m/z (ESI-MS) 269.1 (M+Na)+. HPLC separation 
conditions: CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 97:03, 0.6 
cm3/min, T = 30 °C. Retention times: (major - S) 10.9 min, (minor - R) 13.7 min. Ee was 
determined to be 96% by analysis of racemic panaxjapyne A and panaxjapyne A 4-
methoxybenzonate. 
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(Z)-Dec-2-ene-1-ol 232. This compound is known and has been fully characterized.147a 
 
A mixture of quinoline (152 mg, 1.18 mmol,) and Lindlar’s catalyst (108 mg, 10% w/w) 
in EtOAc (30 cm3) was stirred at rt for 1 h. A solution of 2-decyn-1-ol (1.07 g, 7.0 mmol) 
in EtOAc (10 cm3) was injected. After the mixture had beendegassed once, a H2 balloon 
was attached and then the mixture was stirred vigorously for 9 h. The reaction mixture was 
then filtered through a plug of Celite, concentrated and purifiedby column 
chromatography (hexane/EtOAc=3:1) to afforded the alkene 232 as a colourless oil (1.08 
g, 7.0 mmol, 99%, Z/E=14/1). H (400 MHz, CDCl3) 5.63-5.51 (2H, m, CH=CH), 4.19 
(2H, d, J 6.1, CH2OH), 2.07 (2H, q, J 7.0, =CHCH2), 1.60 (1H, br, OH), 1.40-1.20 (10H, 
br, (CH2)5CH3), 0.88 (3H, t, J 7.0, CH3). 
 
(Z)-1-Bromodec-2-ene 233. This compound is known and has been fully 
characterized.147a 
At 0 °C, under a N2 atmosphere, a solution of (Z)-dec-2-ene-1-ol 232(1.08 g, 7.0 mmol,) 
and Ph3P (2.20 g, 8.1 mmol) in dry CH2Cl2 (28 cm
3) was treated with CBr4 (2.82 g, 8.5 
mmol, in 10 cm3 CH2Cl2) solution dropwise. After the addition was complete, the mixture 
waswarmed to room temperature and stirred for 1.5 h. Solvent was evaporated under 
reduced pressure and the crude product was purified by flash column chromatography 
(pure hexane) to afforded pure bromide 233 as a colourless oil (1.20 g, 5.5 mmol, 78%). 
H (400 MHz, CDCl3) 5.78-5.69 (1H, m, =CHCH2OH), 5.63-5.57 (1H, m, =CH), 4.00 
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(2H, d, J 8.2, CH2OH), 2.13 (2H, qd, J 7.4 1.4, =CHCH2), 1.43-1.23 (10H, br, (CH2)5CH3), 
0.86 (3H, t, J 6.5, CH3). 
 
3.22. Synthesis of Chiral 1-(2’-Naphthyl)ethyl-(4-phenylbenzoate). 
Chiral 1-(2’-Naphthyl)ethanol 241. This compound is known and has been fully 
characterized. 
 
(R,R)-c2 or (S,S)-c2 (0.6 mg, 1.0 × 10-3 mmol) was dissolved in HCO2H/Et3N 5:2 
azeotropic mixture (840 mg, 0.59 cm3) and 2-acetonaphthone 240 (340 mg, 2.0 mmol) in 
degassed CH2Cl2 (2.0 cm
3)was injected under a nitrogen atmosphere. The mixture was 
stirred at 35 °C for 48 h then saturated aqueous NaHCO3 (10 cm
3) was added. The 
reaction mixture was extracted with CH2Cl2 (3 × 20 cm
3), dried over anhydrous MgSO4, 
concentrated and purified by silica gel column chromatography (eluent 
hexane/EtOAc=5:1) to give chiral 1-(2’-naphthyl)ethanol 241 as a white solid (334.4 mg, 
1.94 mmol, 97%, 93% ee for R-241), (331.4 mg, 1.93 mmol, 96%, 93% ee for S-241). 
[α]D24 + 37.8 (c 0.5 in EtOH), 93% ee (R). (Lit155a [α]D25 + 41.2 (c 0.50 in EtOH), 95% ee 
(R); Lit155b [α]D25 + 36.3 (c 0.58 in EtOH), 85% ee (R), H (400 MHz, CDCl3) 7.84-7.80 
(4H, m, Ar), 7.51-7.44 (3H, m, Ar), 5.06 (1H, qd, J 6.5, 3.6, CH), 1.93 (1H, brs, OH), 1.57 
(3H, d, J 6.5 CH3). HPLC separation conditions: CHIRALPAK IB column (250 mm x 4.6 
mm) hexane:i-PrOH 96:4, 0.7 cm3/min, T = 30 °C. Retention times, (S) 18.1 min, (R) 19.2 
min. GC condition: Chrompaccyclodextrin-β-236M-19 50m, Carrier = hydrogen, T = 
155 °C, P = 15 psi, Retention time for R isomer 60.8 min., Retention times for S isomer 
62.4 min. 
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Chiral 1-(2’-naphthyl)ethyl-(4-phenylbenzoate) 243. This compound is novel. 
 
To a solution of chiral 1-(2’-naphthyl)ethan-1-ol 241 (294 mg, 1.71 mmol) and 4-
phenylbenzoyl chloride (555 mg, 2.56 mmol) in CH2Cl2 (40 cm
3), DMAP (catalytic 
amount, 5 mg) and triethylamine (518 mg , 5.13 mmol) in CH2Cl2 (15 cm
3) wereadded 
dropwise at 0 °C. The reaction mixture was allowed to warm up to room temperature 
overnight and sat NaHCO3 (30 cm
3) was added. After stirring for 2 h, the organic phase 
was separated and further extracted with CH2Cl2 (2 × 40 cm
3). The combined organic 
phase was washed with brine (10 cm3), dried over anhydrous MgSO4,concentrated and 
purified by silica gel column chromatography (eluent hexane/CH2Cl2/EtOAc=10:1:0.4) to 
give 1-(2’-naphthyl)ethyl-(4-phenylbenzoate) 243 as a white solid (501 mg, 1.42 mmol, 
82 % for R, 480 mg, 1.36 mmol, 80 % for S). [α]D32 - 170.5 (c 0.5 in CHCl3) >99% ee (R). 
[α]D32 + 169.0 (c 0.6 in CHCl3) >99% ee (S). Recrystallized samples were used for optical 
rotation measurements. MP 110 °C; (found (ESI): M+ + Na, 375.1356. C25H20O2 requires 
M, 375.1355); νmax 1704, 1283, 1275, 745 cm-1; H (400 MHz, CDCl3) 8.18-8.15 (2H, m, 
Ar), 7.90-7.81 (4H, m, Ar), 7.67-7.58 (5H, m, Ar), 7.50-7.37 (5H, m, Ar), 6.32 (1H, d, J 
6.6, CH), 1.77 (3H, q, J 6.6, CH3); C (100 MHz, CDCl3) 165.8, 145.7, 140.1, 139.2, 133.3, 
133.1, 130.2, 129.3, 129.0, 128.5, 128.2, 128.1, 127.7, 127.3, 127.1, 126.3, 125.1, 125.1, 
124.1, 73.1, 22.4. HPLC separation conditions: CHIRALPAK IB column (250 mm x 4.6 
mm) hexane:i-PrOH 98:2, 0.6 cm3/min, T = 30 °C. Retention times, (R) 12.8 min and (S) 
23.1 min. A sample of the racemic alcohol was prepared by NaBH4 reduction of 2-
acetonaphthone and conversion to the ester for HPLC analysis. 
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5. Appendix: Selected Experimental Data 
5.1. X-ray Crystallography Data of Yashabushitriol 
 
Crystal data: C19H24O3, M = 300.38, Monoclinic, space group P2(1) a=9.32711(10), b = 
5.70755(6), c = 15.13134(16) A, = 90 deg., = 91.5550(10) deg., = 90 deg., U 
=805.220(15) Å3 (by least squares refinement on 5461 reflection positions), T =150(2)K, 
lambda = 1.54184 Å, Z = 2, D(cal) = 1.239 Mg/m3, F(000)=324. Mu(MoK-) = 0.655 
mm-1. Crystal character: colourless block. Crystal dimensions 0.45 x 0.20 x 0.12 mm. 
 
5.2. HPLC Results of Typical Compounds 
HPLC separation conditions for compound R-114: CHIRALPAK IB column (250 mm × 
4.6 mm), hexane:i-PrOH 90:10, 1.0 cm3/min, T = 30 °C. Retention times: (major - R) 14.9 
min, (minor - S) 17.3 min. 
Racemic 114 
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Chiral R-114, S/C=1000/1 
 
Chiral R-114, S/C=5000/1 
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HPLC separation conditions for compound R-171: CHIRALPAK IB column (250 mm × 
4.6 mm), hexane:i-PrOH 95:5, 0.6 cm3/min, T = 30 °C, 254 nm UV. 
Racemic 171. 
 
Chiral R-171. 
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HPLC separation conditions for compound 172: CHIRALPAK IB column (250 mm × 4.6 
mm), hexane:i-PrOH 96:4, 0.5 cm3/min, T = 30 °C, 254 nm UV. 
Chiral (2R, 3R)-172 prepared by using catalyst (R,R)-c1. 
 
Chiral (2S, 3S)-172 prepared by using catalyst (S,S)-c2 
 
Chiral (2R, 3R)-172 prepared by using catalyst (R,R)-c2. 
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HPLC separation conditions for compound R-184: CHIRALPAK IB column (250 mm × 
4.6 mm), hexane:i-PrOH 95:5, 0.8 cm3/min, T = 30 °C, 254 nm UV. 
Racemic 184. 
 
Chiral R-184. 
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HPLC separation conditions for compound R-188: CHIRALPAK IB column (250 mm × 
4.6 mm), hexane:i-PrOH 95:5, 0.8 cm3/min, T = 30 °C, 254 nm UV. 
Racemic 188. 
 
Chiral R-188. 
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HPLC separation conditions for compound 202: CHIRALPAK IB column (250 mm × 4.6 
mm), hexane: i-PrOH 80:20, 0.8 cm3/min, T = 30 °C, 254 nm UV. 
Racemic + meso 202. 
 
Chiral S,S-202. 
 
Chiral R,R-202. 
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HPLC separation conditions for compound 205: CHIRALPAK IB column (250 mm × 4.6 
mm), hexane: i-PrOH 80:20, 0.8 cm3/min, T = 30 °C, 254 nm UV. 
Racemic + meso 205 
 
Chiral R,R-205. 
 
Chiral S,S-205. 
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HPLC separation conditions for compound S-215: CHIRALPAK IC column (250 mm × 
4.6 mm), hexane:i-PrOH 96:04, 0.8 cm3/min, T = 30 °C, 210 nm UV. 
Racemic 215. 
 
Chiral S-215. 
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HPLC separation conditions for compound panaxjapyne A 4-methoxybenzonate (reduced 
by (S,S)-c2) : CHIRALPAK IC column (250 mm × 4.6 mm), hexane:i-PrOH 97:03, 0.6 
cm3/min, T = 30 °C, 210 nm UV. 
Racemic 
 
Chiral 
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(-)-Yashabushidiol B 213; CHIRALPAK IC column (250 mm x 4.6 mm), hexane:i-PrOH 
92:8, 0.8 cm3/min, T = 30 °C, 210 nm UV. 
Racemic 213 (from 1H NMR the racemic anti-diol sample contain 15 % of meso-diol) 
 
(-)-Yashabushidiol B 213. 
 
 
 
 
 
 
S,S 
meso 
R,R 
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Racemic 243; HPLC separation conditions: CHIRALPAK IB column (250 mm x 4.6 mm) 
hexane:i-PrOH 98:2, 0.6 cm3/min, T = 30 °C. Retention times, (R) 12.8 min and (S) 23.1 
min. 
 
Chiral R-243. 
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5.3. 1H and 13C NMR Spectra of Typical Compounds 
1H NMR of R-114. 
 
13C NMR of R-114. 
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1H NMR of R-171. 
 
13C NMR of R-171. 
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1H NMR of (2R, 3R)-172. 
 
13C NMR of (2R, 3R)-172. 
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1H NMR of R-184. 
 
13C NMR of R-184. 
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1H NMR of R-188. 
 
13C NMR of R-188. 
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1H NMR of R,R-202. 
 
13C NMR of R,R-202. 
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1H NMR of R,R-205. 
 
13C NMR of R,R-205. 
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1H NMR of (-)-yashabushidiol B 219. 
 
13C NMR of (-)-yashabushidiol B 219. 
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1H NMR of yashabushitriol 129. 
 
13C NMR of yashabushitriol 129. 
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1H NMR of 5-epi-yashabushitriol 5-epi-129. 
 
 
13C NMR of 5-epi-Yashabushitriol 5-epi-129. 
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1H NMR of S-215. 
13C NMR of S-215. 
 
 
 
 
 
 
 
      258 
 
1H NMR of panaxjapyne A 239. 
 
13C NMR of panaxjapyne A 239. 
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1H-1H Cosy of panaxjapyne A 239. 
 
1H NMR of Racrmic panaxjapyne A-(S)-MTPA ester 
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1H NMR of panaxjapyne A-(S)-MTPA ester 
 
1H NMR of R-243. 
 
13C NMR of R-243. 
 
